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Abstract 
Neurofibromatosis type 1 (NF1) is a common genetic disorder that predisposes to the 
development of heterogeneous tumours of Schwann cell origin, termed neurofibromas. 
Neurofibromas are thought to arise from a combination of genetic events – loss of the 
Ras-GAP neurofibromin in the Schwann cell lineage – and microenvironmental cues. 
Schwann cells are specialised cells that ensheath and myelinate the axons in the 
peripheral nervous system (PNS). In the adult they are present in a quiescent state, 
however following damage to the PNS they have a remarkable ability to regenerate. 
Distal to the site of injury, Schwann cells dedifferentiate to a progenitor-like state, in 
which they contribute to nerve repair by recruiting a robust inflammatory response 
and helping axons return to their targets. Work from our laboratory has shown that 
activation of the Ras/Raf/ERK pathway plays a central role in driving the switch in 
Schwann cell state from a fully differentiated to a proliferating, “progenitor-like” cell. 
Crucially, neurofibromas resemble injured nerves in that they are composed of a 
mixture of inflammatory cells and Schwann cells that are found dedifferentiated and 
dissociated from axons, suggesting that deregulation of Ras/ERK may trigger 
tumourigenic events.  
In this thesis I present work on how the Ras/Raf/ERK pathway may be regulated in 
Schwann cells. I show that the phosphatase MKP3 may be involved in controlling the 
levels of ERK activity in Schwann cells during differentiation and following nerve injury. 
I also describe a new model for neurofibroma formation. Using transgenic mice I show 
that Nf1 loss in adult, myelinating Schwann cells has no effect on peripheral nerves and 
does not induce tumourigenesis. However, when coupled with an injury, the mice 
developed tumours at a high frequency. Furthermore, I show that in the absence of 
Nf1, ERK signalling is deregulated upon injury, implicating this pathway in the tumour 
formation. This may have therapeutic relevance, which is currently being tested in our 
animal model. In addition, we observed that tumours only arise at the wound site, 
despite Schwann cells dedifferentiating along the length of the nerve. This strongly 
implies that the microenvironment is a crucial player in the outcome of Nf1 loss and 
reveals this new animal model as a promising system to further dissect molecular 
events involved in tumourigenesis. 
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Chapter 1: Introduction  
1.1 General Introduction 
The identification of the original cell that gives rise to tumours has crucial implications 
for understanding the biology of cancer. In particular, the rigorous investigation of the 
early cellular events of tumourigenesis is dependent on the knowledge of the specific 
initiating-cell that acquires the initial genetic mutations (Alcantara Llaguno et al., 2009). 
Furthermore, the identification of the cell of origin of specific tumours may allow the 
development of unique treatment targets and strategies. In principle, any cell with a 
proliferative capacity may be a target for oncogenic transformation. Stem cells have 
become the most popular candidate given their inherent capacity to self-renew and 
longevity that would allow the sequential accumulation of the genetic or epigenetic 
modifications required for tumourigenesis. In mouse models of intestinal and prostate 
cancer, for example, it seems clear that the cancers originate in a bona fide stem cell 
that is capable of self-renewal and multilineage differentiation (Visvader, 2011). 
Nevertheless, it has also become clear that at least in some specific tumours, more 
differentiated cell populations, such as progenitors or even fully differentiated cells, 
may be the culprits. That certainly seems to be the case in neurofibromas, benign 
tumours of the peripheral nerve sheath that arise mainly in the context of the tumour 
predisposition syndrome, NF1 (Dirks, 2008). Neurofibromas, despite their mixed cell 
composition have been shown to originate from Schwann cells (SCs) that have lost 
neurofibromin, a negative regulator of Ras signalling. Importantly, differentiated SCs 
themselves, rather than a stem cell population, are the source for new cells in the 
adult, making it plausible that mature, fully differentiated cells may be prone to become 
transformed to neoplastic cells. Indeed, neurofibromas provide a powerful model to 
gain new insight into tumour biology: first because the initial genetic lesion driving the 
tumour is well defined and secondly because the developmental steps of the SC lineage 
are well characterized. Furthermore, given the complex interaction between neoplastic 
SCs and the non-neoplastic elements of the tumour, neurofibromas are also excellent 
models to study the role of tumour microenvironment and how its modulation may 
alter the susceptibility of specific cells to become tumour-initiating cells. Before 
presenting work aimed at testing the issues raised above, I shall introduce the biology 
of Schwann cells, reviewing the most relevant literature on SC development and 
differentiation. I will also characterize the events that follow injury to the peripheral 
nervous system (PNS), with a special focus on how Schwann cells and their inherent 
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plasticity play a central role in the regeneration of peripheral nerves. Finally, I will 
introduce Neurofibromatosis type I, the genetics behind the disease, and conclude by 
discussing the major findings, regarding the biology of neurofibroma formation. 
 
1.2 Glial cells of the Peripheral Nervous System  
Glial cells mediate key functions in the nervous system. In the PNS, the glial 
components can be divided into three major categories: the Schwann cells (SCs) 
surrounding the peripheral nerves, the satellite cells - associated with neuronal cells 
bodies in peripheral ganglia - and the enteric glia (Corfas et al., 2004; Jessen, 2004). 
Schwann cells form the majority of the glial population and based on their morphology, 
biochemical signature and type of neuron (or area of their axons) with which they 
associate can be divided into three classes: myelinating Schwann cells (mSCs), non-
myelinating SCs (nmSCs) and perisynaptic SCs (also known as teloglia or terminal SCs) 
(Figure 1-1). The latter reside at neuro-muscular junctions (NMJ) where they cover, 
without completely wrapping around, the presynaptic terminal of motor axons and 
have active roles in the formation, function, maintenance and repair of the NMJ (Feng 
and Ko, 2008). Interestingly, they share markers expressed by both myelinating and 
non-myelinating SCs, including the small calcium binding protein S100, the glial fibrillary 
associated protein (GFAP) and the myelin protein P0, but the signals determining their 
differentiation remain poorly understood. Despite the crucial functions that these cells 
play at the NMJ, a detailed discussion of their biology is outside the scope of this 
thesis. The myelinating and non-myelinating Schwann cells are the most abundant glia 
in the PNS; mSCs associate with and myelinate single large calibre axons of all motor 
and some sensory neurons, whilst nmSCs ensheath multiple smaller axons emanating 
from many sensory and all post-ganglionic sympathetic neurons (Figure 1-1). Schwann 
cells play indispensable roles in supporting peripheral axons: during development they 
provide trophic support to the growing axons; in the adult, their main function is to 
ensheath and myelinate axons, protecting against axonal damage and enabling rapid 
conduction of nerve impulses (Taveggia et al., 2010). In addition they contribute to 
immune surveillance and ionic homeostasis in peripheral nerves (Brill et al., 2011). The 
role of Schwann cells may not be restricted to their interaction with peripheral axons- 
non-myelinating SCs present in the bone marrow have recently been implicated in the 
regulation of hematopoietic stem cell hibernation (Yamazaki et al., 2011). Moreover, 
SCs are behind the astonishing regenerative capabilities of the PNS in response to 
wounding. 
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Figure 1-1: Schematic representation of a peripheral nerve and 
associated glial cells. A spinal nerve, emanating from the spinal cord is depicted. The 
cell bodies of sensory neurons reside in the PNS at the dorsal root ganglion (DRG), whereas 
motor neurons cell bodies reside in the CNS. Sensory axons, coming from the dorsal roots, 
meet motor neurons, coming from the ventral roots, to produce mixed spinal nerves. The 
image also shows the location of satellite cells, terminal SCs and myelinating and non-
myelinating SCs. 
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Critical for their role in nerve repair is Schwann cells plasticity: following nerve injury, 
quiescent, fully differentiated cells revert to a “progenitor-like” phenotype that in many 
ways resembles the early stages of SC development. This striking feature is essential to 
provide a favourable environment for axonal regrowth. 
Before discussing how Schwann cell plasticity underlies nerve regeneration and how it 
may be involved in the formation of peripheral nerve tumours, I will first discuss the 
process of SC development. 
 
1.3 The Schwann cell lineage 
1.3.1 The origin of Schwann cells 
The course of Schwann cell development has been intensively studied (Figure 1-2). The 
majority of myelinating and non-myelinating SCs from spinal nerves derive from neural 
crest stem cells (NCSCs), a subset of neural crest cells (NCCs) characterized by the 
ability to self-renew and to undergo multilineage differentiation into myofibroblasts, 
glia and neurons (Morrison et al., 1999; Stemple and Anderson, 1992). Neural crest 
cells, that also give rise to other major cell types including satellite cells, boundary cap 
cells, melanocytes, craniofacial bones and cartilage and endocrine cells (Dupin et al., 
2003; Maro et al., 2004), delaminate from the neural tube around embryonic day 8.5 
(E8.5) in the mouse, and undergo extensive proliferation and migration along distinct 
pathways. To delaminate from the neural plate NCCs go through an epithelial-to-
mesenchymal transition that appears to involve interplay between Noggin and bone 
morphogenetic protein-4 (BMP4) (Sela-Donenfeld and Kalcheim, 1999). The 
subpopulation of NCSCs can be identidified at this stage by the expression of several 
markers including the low affinity neurotrophin receptor p75, the neural adhesion 
protein L1, the intermediate filament nestin and the brain lipid-binding protein (BLBP). 
Importantly, NCSCs differentiate terminally by late gestation and cannot be detected 
postnatally in the PNS. An exception occurs in the gut, where NCSCs persist 
throughout adult life (Kruger et al., 2002).  
Schwann cells in dorsal and ventral roots and satellite cells within the ganglion also 
originate, in part, via early cell pools other than NCSCs such as boundary cap cells 
(BCCs) (Maro et al., 2004). Boundary cap cells are neural crest derived multipotent 
cells, which can be identified in the embryo around day 10 (E10) by the expression of 
the transcription factor Krox-20  (as detailed below this gene will also be expressed in 
pro-myelinating SCs, but later in development). It is thought that BCCs differentiate 
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shortly after birth, however due to the lack of specific markers it remains possible that 
some BCCs persist in the adult, where they may constitute a reservoir of multipotent 
neural cells in the PNS. The processes by which BCCs give rise to different cell 
populations remain largely unknown, therefore I will focus my attention on the 
development of SCs in the spinal nerve trunks innervating the limbs, that originate 
from migrating neural crest stem cells that differentiate into Schwann cell precursors 
(SCPs). 
Upon migration into peripheral nerves, NCSCs associate with outgrowing naked axons 
and commit to the SC lineage through a stepwise process, characterized by a strong 
dependence on axonal signals and involving three main transitions: the engagement of 
neural crest cells into the SC lineage, which leads to the formation of Schwann cell 
precursors (SCPs), the maturation of these precursors into immature Schwann cells 
(ISCs) and lastly, occurring around birth, the cell-cycle exit and differentiation into 
either the myelinating or the non-myelinating phenotypes (Figure 1-2). Importantly, 
this last step in SC development is reversible, as injury signals induce mature SCs to 
revert to a dedifferentiated state (discussed in section 1.7). 
 
1.3.2 NCSC to SCP transition 
Schwann cell precursors are the glial cells found in the limb nerves of the mouse 
embryo at E12/13 and represent the earliest well-defined stage of PNS glial 
development. Schwann cell precursors are highly migratory and proliferative cells, 
which are first found associated with outgrowing axons before starting to extend 
sheet-like processes that communally envelope axons in large bundles. SCPs, while 
sharing with NCSCs the expression of markers such as p75, L1 and the intermediate 
filament nestin (Jessen et al., 1994), can be distinguished by the expression of lineage 
specific markers such as Desert hedgehog (DHH), the growth associated protein-43 
(GAP43), F-spondin and low levels of myelin protein zero (P0) and proteolipid protein 
(PLP) (Curtis et al., 1992; Dong et al., 1999; Jessen et al., 1994; Jessen and Mirsky, 
1999). At this stage, SCPs depend strictly on axonal signals for survival and 
proliferation and, reciprocally, play a pivotal role in promoting axonal survival (Jessen 
and Mirsky, 2005). It is still unclear what drives NCSCs to commit to the glial lineage. 
Glial specification is blocked in mice lacking Sox-10,  however Sox-10 expression is 
detected in all migrating neural crest cells indicating that Sox-10 expression alone is 
not sufficient to promote gliogenesis (Britsch et al., 2001). Sox-10 may exert at least 
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part of its functions by controlling the expression of ErbB3 receptors in NCSCs 
(Britsch et al., 2001). 
 
 
 
Figure 1-2: The Schwann cell lineage. Diagrammatic representation of the major 
transitions and signalling pathways involved in Schwann cell differentiation. The formation of 
fully differentiated myelinating and non-myelinating SCs begins around birth and is reversible 
(dashed lines) (adapted from Jessen and Mirsky, 2005). On the right, EM micrographs of a 
myelinating (top) and a non-myelinating SC ensheathing a group of axons (Remak bundle) 
(bottom), are shown. 
 
 
Neuregulin-1 (NRG1)/ErbB signalling may also be involved in SC specification, since in 
vitro, the axonal derived factor NRG1 is able to block neuronal specification (Shah et 
al., 1994), which might lead indirectly to increased gliogenesis. Nevertheless, in the 
same cultures SCs develop readily with or without NRG1, indicating that NRG1 
signalling is not required for glial specification. Instead, at this stage of development 
NRG1 signalling is critical for the proper migration of the neural crest cells (Britsch et 
al., 1998). Given the critical role that NRG1 and their receptors play in SC behaviour, 
a brief description of the main isoforms present in the PNS will follow. 
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The NRG1 gene encodes more than 15 transmembrane and secreted protein isoforms, 
generated by alternative promoter usage and mRNA splicing. In the axonal membrane 
of peripheral axons, three major types of neuregulin-1 proteins can be found  (I, II and 
III), all sharing an epidermal growth factor (EGF)-like domain and differing in their N-
terminal sequences (Figure 1-3). Neuregulin-1 isoforms Type I (also known as 
heregulin or Neu) and II (also known as glial growth factor [GGF]) have N-terminal 
immunoglobulin-like domains that following proteolytic cleavage can be shed and 
released as soluble proteins from the neuronal surface. Two main isoforms of NRG1 
Type III have been described in the PNS, β1a and β3 (Ho et al., 1995; Meyer et al., 
1997), both defined by the presence of a cystein-rich domain (CRD). In the case of 
NRG1 Type III β1a, the CRD domain functions as a second transmembrane domain in 
that the mature form remains tethered to the axonal membrane after cleavage. The 
second type of NRG1 Type III present in the PNS, the β3 isoform (also known as 
sensory and motor neuron-derived factor- SMDF) lacks the transmembrane-domain 
C-terminal of the EGF-like domain and remains less studied. Consequently, NRG1 
Type III can only function in a juxtracrine fashion, signalling only to cells that it is 
directly in contact with (Brinkmann et al., 2008). Neuregulin-1 isoforms mediate their 
effects in Schwann cells by binding the ErbB3 receptor (they can also bind to ErbB4, 
but this is only minimally expressed in SCs). Upon ligand binding, ErbB3, which lacks an 
active kinase, heterodimerizes with ErbB2 (that is unable to bind NRG1 but has an 
active kinase) leading to receptor co-phosphorylation, recruitment of adaptor proteins 
and activation of downstream pathways (specified below). 
Neuregulin-induced signals are not only involved at this early stage of SC development, 
but have emerged as key regulators of axon-SC interactions at each stage of the 
Schwann cell lineage (Adlkofer and Lai, 2000). These include the survival and 
proliferation of SCPs: transgenic animals lacking NRG1 Type III isoforms or the 
ErbB2/3 receptors show a near complete absence of SCPs in developing nerve trunks, 
without affecting the formation of satellite glia within the dorsal root ganglia (DRG) 
(Dong et al., 1995; Erickson et al., 1997; Garratt et al., 2000a; Garratt et al., 2000b; 
Lee et al., 1995; Riethmacher et al., 1997; Wolpowitz et al., 2000). Importantly, these 
mice exhibited abnormal neuronal death, underscoring the importance of SC-neuron 
interactions in the support of neuronal survival (Wolpowitz et al., 2000). In contrast, 
deletion of the Type I and II neuregulin-1 isoforms did not affect the generation or 
survival of Schwann cells, indicating that different neuregulin isoforms perform distinct 
   
  22 
functions in Schwann cells (Meyer et al., 1997). Figure 1-3 describes some of the 
specific biological functions that have been attributed to each of the NRG1 isoforms. 
 
 
Figure 1-3: Neuregulin-1 isoforms expressed in the PNS and potential 
isoform-specific roles. Schematic representation of the three major isoforms of NRG1 
expressed in peripheral axons, before and after proteolytic cleavage (adapted from Mei and 
Xiong, 2008).  A brief description of the biological impact of each isoform is also shown.  
(Figures removed due to copyright restrictions). 
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It seems likely that, at this stage, the effects of the NRG1/ErbB signalling in Schwann 
cell proliferation/survival, are mediated, at least in part, through the ERK pathway, as a 
similar phenotype has been recently described in mice with selective inactivation of 
ERK1 and ERK2 kinases, suggesting that the ERK pathway is necessary to transduce 
NRG1/ErbB signals during the development of the Schwann cell lineage (Newbern et 
al., 2011). Moreover, NRG1 Type III may also act as an endogenous guidance cue 
controlling Schwann cell migration. Studies in zebrafish have shown that ectopic pan-
neuronal expression of human NRG1 Type III in the spinal cord is sufficient to induce 
Schwann cells to trespass within the central nervous system (CNS), indicating that this 
signal promotes Schwann cell motility and attraction to ectopic locations (Perlin et al., 
2011).  
Interestingly, there is an emerging concept that SCPs can act as multipotent 
progenitors in the developing nervous system (Doetsch, 2003). This concept was 
fuelled by a fate-mapping study that demonstrated that the small number of fibroblasts 
present in the postnatal nerve originate from cells that are neural crest derived and 
express desert hedgehog (DHH) and are, therefore, presumably SCPs. In addition, 
SCPs have also been identified as a cellular origin of skin melanocytes (Adameyko et 
al., 2009). This idea is consistent with previous observations that P0 positive cells from 
early nerves or DRG in the rat have the potential to generate both neurons and 
fibroblasts (Hagedorn et al., 1999; Morrison et al., 1999).  
Importantly, all SCPs differentiate during embryogenesis and are not found in adult 
peripheral nerves. 
 
1.3.3 SCP to immature SC progression 
As development proceeds, SCPs start to form basal lamina, proliferate and ensheath 
fasciculating axons and become immature Schwann cells (ISCs). The molecular 
mechanisms controlling this transition remain largely unknown. Again, neuregulin-1 
might be involved because in vitro, the NRG1 Type I isoform has been shown to 
accelerate the conversion of SCPs to the immature phenotype (Dong et al., 1995). 
Nevertheless, Schwann cell development in transgenic mice lacking all Type 1 and Type 
II NRG1 isoforms occurs normally, indicating that probably in vivo, Type I and Type II 
isoforms are not involved in regulating the progression of SCP to immature Schwann 
cells (Meyer et al., 1997).  
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Recent studies have implicated Notch signalling at this developmental stage; 
inactivation of the major transcriptional mediator of canonical Notch (RBJP) delayed 
the transition from SCPs to the immature Schwann cell fate and, conversely, 
constitutive activation of the pathway resulted in premature Schwann cell generation 
(Woodhoo et al., 2009).  
This transition occurs between E13-15 in mice and involves coordinated changes in 
molecular expression, regulation of survival and response to mitogenic signals. 
Contrary to SCPs that rely entirely on axonal-derived survival signals (in particular 
NRG1), immature SCs are able to maintain their own survival by setting in motion 
autocrine survival circuits. Importantly, these same autocrine signals likely maintain the 
survival of SCs after axonal degeneration, which is crucial for nerve regeneration. 
Major components of the autocrine loop have been identified and include insulin 
growth factor-2 (IGF-2), platelet-derived growth factor-β (PDGFβ), neurotrophin-3 
(NT3), leukemia inhibitor factor (LIF) and lysophosphatidic acid (LPA). Also laminin, 
one of the major components of SC basal lamina, acts in concert with these 
components to promote longer-term survival (Lobsiger et al., 2000; Meier et al., 1999). 
The transition of SCP to ISC coincides with major changes in the architecture of the 
developing peripheral nerves: they become vascularised and a distinct layer of the 
developing epineurium appears at the nerve surface. A more detailed description of 
the structure of the peripheral nerve will be given in section 1.6. 
 
1.3.4 Preparation for differentiation – radial sorting and proliferation 
 Immature Schwann cells, which can be identified by the expression a number of 
differentiation markers such S100, GFAP, and the sulfated O4 (Corfas et al., 2004; 
Jessen and Mirsky, 2005), are initially found arrayed around the edges of large axon 
bundles. At this point the fate of immature SCs begins to diverge to form myelinating 
or non-myelinating Schwann cells. The decision to commit to one of the two possible 
differentiated forms is not SC autonomous, but instead depends on the diameter of 
the axons SCs randomly associate with. Through a process termed radial sorting, 
Schwann cells extend radial extensions (lamellipodia) into the axons bundles and sort 
them into smaller fascicles. Then, immature Schwann cells contacting large-diameter 
axons pluck out one axon to ensheath establishing a 1:1 relationship, wrap their 
membrane around the axon (see Figure 1-5) and start expressing stage-specific factors, 
including Oct-6 - such cells have reached the pro-myelinating state.  A large number of 
small unmyelinated axons are also radially sorted and achieve a 1:1 relationship with 
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non-myelinating SCs, indicating that this process, although required for myelination is 
not part of a myelin-specific program. The remaining small-calibre axons, destined to 
become non-myelinating, become surrounded and segregated by the cytoplasm of SCs 
in groups termed Remak bundles (Figure 1-1). To ensure that all the axons are 
ensheathed at the completion of radial sorting, SCs must adjust their numbers by 
controlling survival and proliferation and by coordinating the extension and 
stabilization of their processes (Raphael et al., 2011; Webster et al., 1973). The latter is 
known to involve interactions between β1-integrin in the SC membrane and laminin-γ1 
present in their basal lamina, as transgenic mice lacking either laminin or integrin fail to 
extend cytoplasmic processes and therefore exhibit impaired radial sorting and 
myelination (Chen and Strickland, 2003; Feltri et al., 2002). Activation of this pathway 
mediates its effects, at least partially, through downstream activation of the Rho family 
GTPase Rac1 (Benninger et al., 2007; Nodari et al., 2007).  
The importance of the burst in SC number at this stage was demonstrated by studies 
in a mouse model with conditional deletion of the focal adhesion kinase (FAK) in 
Schwann cells. FAK mutant Schwann cells are able to associate normally with axon 
bundles and extend lamellipodia but exhibit impaired proliferation, which in turn 
results in inefficient axonal sorting (Grove et al., 2007). Importantly, FAK is known to 
be activated by the presence of laminin and has also been shown to interact with ErbB 
receptors upon NRG binding (Fernandez-Valle et al., 1998; Vartanian et al., 2000), 
suggesting that it may represent a point of crosstalk between the ECM and axonal 
signals.  In fact, axonal neuregulin-1 signalling through ErbB is again key to this process, 
as shown by studies in zebrafish where pharmacological or genetic disruption of ErbB 
signalling generates defects in radial sorting and myelination due to impaired 
lamellipodia extension and reduced SC proliferation (Lyons et al., 2005; Raphael et al., 
2011).   
 
1.3.5 Threshold levels of NRG1 type III dictate Schwann cell fate 
Following birth, when the process of axonal sorting is mostly completed, Schwann 
cells, in response to environmental signals that may include ATP released from 
electrically active axons (Stevens and Fields, 2000; Stevens et al., 2004), cease to 
proliferate and become ready to complete their final engagement into one of the two 
mature differentiated cells. The Schwann cells associated with large diameter axons will 
engage into the complex program of myelination. An instruction to myelinate comes 
from the NRG1 Type III β1a expressed on the axonal membrane (Taveggia et al., 
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2005). This was elegantly elucidated by in vitro studies using superior cervical ganglion 
neurons, which normally have small-calibre axons associated with non-myelinating 
Schwann cells. When NRG1 Type IIIβ1a was ectopically expressed in these neurons, 
SCs were instructed to change their fate and myelinate. Expression also rescued 
myelination in sensory neurons from NRG1 Type III-deficient mice that otherwise 
failed to myelinate (Taveggia et al., 2005). Furthermore, the levels of axonal NRG1 
type III signalling through ErbB determines the myelin thickness. Mice heterozygous for 
NRG1 Type III exhibit severe hypomyelination in the PNS, while neuronal 
overexpression of NRGI Type III has the converse effect and leads to hypermyelination 
(Michailov et al., 2004; Taveggia et al., 2005). Importantly, the ensheathment and 
segregation of smaller calibre axons by the cytoplasm of non-myelinating SCs in Remak 
bundles is also controlled by Type III isoforms (Taveggia et al., 2005). Together, these 
studies provided compelling evidence that a threshold of NRG1 Type III signalling 
determines the binary choice between myelination and ensheathment: smaller axons 
that express low levels of membrane NRG1 Type III instruct SCs to become non-
myelinating whereas larger axons express higher levels of this ligand and thereby 
induce SCs to myelinate (Michailov et al., 2004; Nave and Salzer, 2006; Taveggia et al., 
2005). Proteolytic cleavage of NRG1 Type III regulates the levels of active neuregulin 
at the axon surface and hence plays a crucial role in the control of myelination. Two 
major metalloproteases that cleave NRG1 at different cleavage sites, the secretase β-
amyloid converting enzyme-1 (BACE-1) and the tumour-necrosis factor-α-converting 
enzyme (TACE) have been shown to play opposing roles. BACE-/- mice show a 
phenotype similar to that seen in mice with mutations in NRG1 Type III or SC-specific 
ErbB2 knockouts, implicating BACE-1 in NRG1 processing and activation (Figure 1-3) 
(Hu et al., 2006; Willem et al., 2006). In contrast, processing by neuronal TACE (also 
known as ADAM19) appears to exert a negative effect in myelination, as reducing its 
activity rescues hypomyelination in NRG1 Type III haploinsufficient mice (La Marca et 
al., 2011).  
In accordance to the pivotal role that NRG1 plays in SC differentiation, transgenic 
mice with targeted deletion of the ErbB2 gene at the pro-myelinating stage or 
expressing a dominant-negative form of the ErbB receptors in SCs display striking 
myelination defects (Chen et al., 2003; Garratt et al., 2000b). The levels of ErbB 
receptors at the Schwann cell membrane are also critical, as demonstrated by a study 
using erbin knock out mice. Erbin is an adaptor protein that stabilizes ErbB receptors; 
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its ablation leads to a reduction of ErbB2 levels in SCs, which resulted in aberrant 
axonal segregation and marked hypomyelination (Tao et al., 2009).  
 
 
1.3.6 Differentiation into non-myelinating SCs 
Not much is known about the molecular cues that drive SCs to become non-
myelinating. Few molecular changes are likely to be involved in this transition given the 
similarities between immature and non-myelinating SCs. Both share identical molecular 
phenotypes, at least in morphology and expression of antigenic markers, exhibiting cell 
surface molecules that are not found on myelinating SCs such as the cell adhesion 
molecules L1, neural cell adhesion molecule (NCAM) and the neurotrophin receptor 
p75 (Jessen and Mirsky, 2002). Nevertheless, non-myelinating Schwann cells can be 
distinguished by the expression of the markers GalC, sGalC and integrins α1β1 and 
α7β1 (Jessen et al., 1985; Previtali et al., 2003a; Previtali et al., 2003b; Stewart et al., 
1997). These cell surface molecules, however, are also expressed by mature 
myelinating Schwann cells, indicating that further study is needed to identify molecular 
changes restricted to this transition. Differentiation markers such as P0 are also 
downregulated during this transition and become undetectable in intact adult nmSC, 
probably as a result of inhibitory axonal signalling (Lee et al., 1997). 
As mentioned, evidence exists that NRG1 may also be required for the differentiation 
into non-myelinating Schwann cells. Remak bundles in NRG1 Type III deficient mice 
contained abnormal number of axons and were incompletely segregated by the 
cytoplasm of non-myelinating SCs (Taveggia et al., 2005). Moreover, genetic 
inactivation of this NRG isoform using Nav1.8-Cre mice also resulted in aberrant 
Remak bundles (Fricker et al., 2009). Additionally, deposition of basal lamina also 
appears to be required for the proper formation of non-myelinating SCs, as mice with 
targeted ablation of laminin at the immature stage failed to form non-myelinating cells 
(Yu et al., 2009). However, it is difficult to conclude if such effects are direct 
consequences of defective differentiation of nmSCs or if it is a consequence of 
abnormal radial sorting.  
 
1.3.7 Differentiation into myelinating SCs 
The transition to myelinating Schwann cells involves far more complex morphological 
and genetic changes. Most of the antigens associated with immature SCs, such as the 
neurotrophin receptor p75, are downregulated and there is strong upregulation of a 
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number of genes associated with the control of myelination and formation of the 
myelin sheath such as Oct-6, Krox-20, myelin protein zero (P0), myelin-associated 
glycoprotein (MAG), peripheral myelin protein 22 (PMP22), myelin basic protein (MBP) 
and periaxin (Jessen and Mirsky, 2002).  
In this part of my thesis, I shall begin by reviewing the initial events of myelination, 
during which SCs engage in multiple interactions with axons and basal lamina and 
establish a highly polarized organization. Next, I will discuss the major signalling 
pathways that appear to be involved in the process and will finish with a brief summary 
of the transcriptional networks implicated in the control of SC differentiation state.  
 
1.3.8 Signals mediating early events of myelination: Schwann cell-
axon interaction  
Myelination involves an intimate interaction between axons and Schwann cells that 
results in dynamic morphological changes and the subsequent unidirectional wrapping 
of multiple layers of membrane concentrically around axons (Figure 1-5). 
Ensheathment and wrapping are initiated at the site of the SC-axon interface and 
require specific molecular mediators for recognition, adhesion and induction of the 
process. These mediators include the adhesion molecule N-cadherin, which is found 
enriched at the pre-myelinating SC-axon interface.  Depletion of N-cadherin (N-cad) 
from SCs in co-cultures systems results in defective process extension and alignment 
with axons, despite normal deposition of basal lamina (Wanner and Wood, 2002). 
However, transgenic mice with targeted ablation of N-cadherin in SCs only exhibit a 
minor delay in myelination and myelin sheaths formed without any detectable defects, 
suggesting that N-cad, although likely playing a role in establishing the timely initiation 
of myelination is a nonessential component for the formation and maturation of the 
myelin sheath (Lewallen et al., 2011). Other adhesion molecules, the nectin-like 
proteins (Necl), have been implicated as critical mediators of SC-axonal adhesion and 
myelination. Nectin-like protein 4 is expressed by SCs and binds to Necl1 present 
along the axons and disruption of this specific interaction inhibits the initiation of 
myelination (Maurel et al., 2007; Spiegel et al., 2007). 
Following the initial contact with axons, Schwann cells require the establishment of a 
radial organization in order to initiate the subsequent events of myelination. The 
establishment of this polarized organization is achieved at least in part due to the 
asymmetrical distribution of the Partitioning defective-3 (Par-3) protein at the sites of 
contact between SCs and axons.  Using Par-3 transgenic mice Chan and co-workers 
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showed that this asymmetrical distribution is critical for myelination to proceed, as 
disruption of Par-3 localization lead to a block in myelination, despite the initial SC-
axon adhesion and alignment not being affected (Chan et al., 2006). 
The neurotrophins, a family of growth factors that include nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and NT 4/5, 
represent, together with NRG1 Type III, major signals controlling myelination. 
Neurotrophins mediate their effect through two different classes of receptors, the low 
affinity receptor p75 that binds all known neurotrophins and the more selective Trk 
family of tyrosine kinase receptors. Neurotrophins play distinct effects on SC 
myelination. Notably, depletion of BDNF or functional inactivation of p75 inhibits 
myelin sheath formation (Chan et al., 2001; Cosgaya et al., 2002). Once activated by 
BDNF, p75 interacts with Par-3, which results in the relocalization of the receptor to 
the sites of SC-axon contact where it mediates its promyelinating effects (Chan et al., 
2006). What lies downstream of this interaction and exactly how it mediates 
myelination remains elusive. In contrast, NT-3, via Trk receptors, acts as an inhibitory 
regulator of myelination (Chan et al., 2001). 
 
1.3.9 Signals and pathways mediating myelination  
Given what has been discussed up to this point, it is clear that the coordination of 
diverse signals is required for the proper initiation of myelination. Once SCs have 
established the right organization around the axon, multiple pathways are activated and 
culminate in the promotion of a transcriptional network that ultimately drives the 
formation of the myelin sheath. In Schwann cells, most signals that promote 
myelination act through the transcription factors, Oct-6, Krox-20 and Sox-10. As 
emphasized earlier, NRG1 Type III plays a dramatic effect in the control of many 
aspects of neural development, in particular, in SC myelination. The binding of NRG1 
to ErbB receptors in SCs results in the activation of a variety of downstream 
intracellular signalling pathways such as phosphatidylinositol 3 kinase (PI3K)/Akt, 
Ras/ERK and Calcineurin-NFAT (Newbern and Birchmeier, 2010). Evidence exist that 
all of these signalling pathways are required for myelination. Disruption of the PI3K 
pathway results in inhibition of axonal-mediated SC proliferation and myelination 
(Maurel and Salzer, 2000; Ogata et al., 2004). Conversely, overexpression of PI3K or 
activated AKT promotes myelin protein expression (Ogata et al., 2004). Interestingly, 
the extent of PI3K activation is directly graded by the amount of NRG1 present at the 
axonal surface. This was elegantly demonstrated using in vitro cultures of SCs treated 
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with membrane fractions isolated from different neurons. Treatment of SCs with 
axonal membranes from NRG1 wild-type (wt) neurons produced robust AKT 
phosphorylation, whilst no activation was observed when membranes from NRG1-/- 
neurons were used instead. An intermediary grade of AKT activation was achieved 
when membranes from NRG1 heterozygous neurons were used (Taveggia et al., 
2005). Together, these studies suggest that the amount of myelin produced is a direct 
measure of the extent of PI3K/AKT activation. 
Until recently, the ERK pathway was thought to exert opposing functions on 
myelination, since strong and sustained activation of ERK inhibits myelin gene 
expression and myelination in vitro (Harrisingh et al., 2004; Ogata et al., 2004; Syed et 
al., 2010) and in vivo (Napoli et al, 2012). However, a more complex involvement of 
the ERK pathway in Schwann cell development has emerged by recent findings. 
Selective deletion of ERK kinases in the Schwann cell lineage at approximately E13 
using a Dhh-Cre recombinase resulted in a marked downregulation of Krox-20 and 
severe hypomyelination, suggesting that signalling through ERK is required for Krox-20 
induction and consequently, myelination (Newbern et al., 2011). Supporting this 
notion, conditional ablation of the nonreceptor tyrosine phosphatase Shp2 (that acts 
to promote sustained signalling through the ERK pathway) at the onset of myelination 
using the Krox-20 promoter also resulted in marked hypomyelination (Grossmann et 
al., 2009).  
Another mechanism by which NRG1 signalling is likely to positively regulate 
myelination is by increasing the Ca2+ levels in SCs through induction of the 
phospholipase C-γ. This activates the phosphatase calcineurin, which dephosphorylates 
and subsequently activates the nuclear factor of activated T cells-3 (NFATc3) and c4 
resulting in their translocation into the nucleus. Conditional deletion of calcineurin β1 
in SCs results in defects in radial sorting and severely disrupted peripheral myelination 
(Kao et al., 2009).  
It has long been known that cAMP elevation in vitro induces SCs to express myelin 
markers, suggesting that cAMP is part of the signalling system that promotes 
myelination. cAMP exerts at least part of its pro-differentiative effects through 
activation of protein kinase A (PKA) that in turn phosphorylates and activates nuclear 
factor kappa-B (NF-κB), required for myelination (see below) (Howe and McCarthy, 
2000; Nickols et al., 2003; Yoon et al., 2008). Two recent papers from the Talbot 
laboratory have finally demonstrated that cAMP signalling is also required for 
myelination in vivo and provided important insights of how this might be happening. 
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Using zebrafish and rodent models, the authors found that activation of the G-protein 
coupled receptor Gpr126 by an as yet unknown axonal ligand results in increased 
levels of cAMP, which is critical for myelination. Accordingly, deletion of the receptor 
induced arrest at the promyelinating state, which could be rescued by treatment with 
the adenylate cyclase activator, forskolin (Monk et al., 2009; Monk et al., 2011). This 
mechanism was independent of NRG1, given that the levels of NRG and SC receptors 
ErbB2/3 remained normal. Nevertheless, both pathways are likely to crosstalk and in 
fact, cAMP appears to switch NRG1 from a proliferative signal to a differentiation one 
(Arthur-Farraj et al., 2011).  
Additional evidence for the interaction between both pathways come from studies 
showing that NRG1 Type III and cAMP-dependent activation of PKA act cooperatively 
to increase the activity of NF-κB (Limpert and Carter, 2010). In Figure 1-4, a summary 
of the main signalling pathways involved in SC myelination is represented. 
 
1.3.10 Transcriptional control of SC differentiation 
Myelination signals and their downstream signalling pathways converge on a number of 
transcription factors that initiate a genetic program to drive the transition of immature 
promyelinating proliferative cells to myelinating ones. The myelination process involves 
a coordinated balance between two opposing transcriptional programmes: negative 
regulators that act as myelination breaks, and positive regulators that lie downstream 
of myelination signals such as NRG and cAMP. Coordination between both programs 
ensures the timely onset and termination of myelination during development. Negative 
regulators may include the c-Jun-amino (N)-terminal kinase (JNK) and Notch: both 
pathways are active in immature SC, where they seem to be required for NRG1-
signalling, and are then inactivated by Krox-20 dependent signalling when SCs start 
myelinating (Jessen and Mirsky, 2008; Woodhoo et al., 2009). If this is prevented and 
the JNK or the Notch pathway remain active, myelination is blocked (Jessen and 
Mirsky, 2005; Woodhoo et al., 2009). Other candidate transcription factors that might 
be involved in the negative regulation of myelination include Sox-2 and Id2 and Id4 (Le 
et al., 2005; Svaren and Meijer, 2008).  
The positive regulation of myelination, however, has been much more extensively 
studied. The backbone of the positive circuit driving the transition from 
promyelination to myelination comprises the transcription factors Oct-6 (also known 
as SCIP), Brn-2, Sox-10 and the zinc-finger transcription factor Krox-20 (Svaren and 
Meijer 2008). In addition, other transcription factors, such as YY1 (Yin yang-1), NFκB 
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(nuclear factor of κ-light polypeptide gene enhancer in B cells) and NFAT also appear 
to be crucial for myelination.  
The POU homeo-domain transcription factors Oct-6/SCIP and its close relative Brn-2 
are first seen expressed in Schwann cells following initial axonal contact and its 
expression peaks when the 1:1 relationship with axons has been established (Arroyo 
et al., 1998; Blanchard et al., 1996; Lemke et al., 1991; Scherer et al., 1994). Deletion 
of Oct-6 and Brn-2 in mice results in a delayed onset of myelination, with pro-
myelinating Schwann cells persisting into adulthood (Bermingham et al., 1996; Jaegle et 
al., 2003), indicating that both factors are important for regulating the timing of 
transition to the myelinated state. Importantly, the subsequent downregulation of Oct-
6 and Brn-2 (both proteins becoming undetectable by two postnatal weeks) is critical 
for the later events of myelination (Scherer et al., 1994). Indeed, the forced expression 
of Oct-6 beyond the early myelinating stages, results in hypomelination and axonal loss 
(Ryu et al., 2007). Oct-6 has been shown to repress myelin genes such as P0 and MBP, 
which may indicate that Oct-6 downregulation if required for the de-repression of 
myelin associated gene expression in differentiating Schwann cells (Monuki et al., 1993; 
Monuki et al., 1990).  
In contrast to the dynamic and transient pattern of expression of Oct-6/Brn-2, the 
specification factor Sox-10 is expressed throughout the Schwann cell lineage (Britsch 
et al., 2001; Schreiner et al., 2007). As mentioned before, peripheral glia are absent in 
Sox-10 deficient mice (Britsch et al., 2001), indicating that this factor is absolutely 
required for specification. Furthermore, selective loss of Sox-10 in immature SCs 
prevents Oct-6 and Krox-20 expression and consequently lineage progression (Finzsch 
et al., 2010). Ablation of Sox-10 in adult Schwann cells is sufficient to induce 
demyelination and axonal degeneration, revealing that its expression in the adult is also 
required for maintenance of a myelinating phenotype (Bremer et al., 2011). Sox-10 
interacts synergistically with Oct-6 to activate Krox-20 in myelinating SCs. In addition 
to activating Oct-6 and Krox-20 expression, combinatorial interactions between Krox-
20 and Sox-10 have been implicated in the regulation of a number of Krox-20 target 
genes (Ghislain and Charnay, 2006; Jones et al., 2007; Schreiner et al., 2007). 
As mentioned, a major transcriptional target of Oct-6/Sox-10 regulation is the 
immediate early gene Krox-20/Egr2 (Chavrier et al., 1990; Ghislain and Charnay, 2006; 
Ghislain et al., 2002). Basal levels of Krox-20 are first detected during embryonic 
development in the boundary cap and then later upon transition of SCPs to the 
immature Schwann cell state (Golding and Cohen, 1997; Murphy et al., 1996; 
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Niederlander and Lumsden, 1996; Schneider-Maunoury et al., 1993; Wilkinson et al., 
1989). Following birth, Krox-20 expression is downregulated in non-myelinating cells, 
whilst being robustly upregulated in pro-myelinating Schwann cells (Blanchard et al., 
1996; Zorick et al., 1996a).  
The transcription factor Krox-20 controls major myelin genes such as P0, MBP, PMP22, 
Connexin32 (Cx32) and MAG and is therefore referred to as the master regulator of 
PNS myelination. Consistent with this designation, deletion of Krox-20 results in a 
differentiation arrest with SCs stalling at the pro-myelinating state and a failure of 
myelin formation. Moreover, despite being able to establish a 1:1 relationship with 
axons, pro-myelinating Schwann cells continue to proliferate in the absence of Krox-20 
(Topilko et al., 1994) indicating that Krox-20 expression is required to promote the 
onset of myelination coupled to cell cycle withdrawal. Furthermore, continuous 
expression of Krox-20 throughout adulthood is required for the maintenance of 
myelination, as its ablation in adult Schwann cells results in progressive demyelination 
in the PNS characterized by Schwann cell dedifferentiation and degeneration of myelin 
sheaths (Decker et al., 2006).  
Other transcription factors have been shown to be involved in the positive regulation 
of myelination. In particular, NFATc4 (as said, activated downstream of 
NRG/Calcineurin) complexes with and enhances Sox10 activity at the P0 and Krox-20 
promoters (Ghislain and Charnay, 2006; Nagarajan et al., 2001; Schreiner et al., 2007; 
Topilko et al., 1994). In addition, NF-κB binding appears to stimulate both Oct-6 and 
Sox-10 activity (Jacob et al., 2011; Yoon et al., 2008). A simplified view of the 
transcriptional machinery involved in SC differentiation is depicted in Figure 1-4. 
A flurry of recent studies has directed attention to the involvement of epigenetics in 
the regulation of the transcriptional machinery that control SC differentiation. Histone 
deacetylases (HDACs) in particular have been implicated in SC myelination, as 
HDAC1/2 double null Schwann cells arrest at the immature or the pro-myelinating 
stages. HDACs were shown to interact with and activate Sox-10 and the master 
regulator Krox-20. An independent study showed that both HDACs also interact with 
and deacetylate NF-κB, inducing binding of this complex to the Sox10 promoter and 
thereby increasing its activity (Chen et al., 2011; Jacob et al., 2011). 
Finally, another level of transcriptional control has recently been unravelled. 
Conditional ablation of Dicer, the ribonuclease responsible for the generation of 
mature micro-RNAs, induced marked downregulation of positive regulators of the 
myelination program, including Krox-20 and upregulation of myelination inhibitors such 
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as Sox-2 and Notch. Consequently, SCs arrested at the promyelinating stage and failed 
to form myelin. Schwann cell gene expression is therefore critically regulated by 
mature miRNAs (Pereira et al., 2010). 
 
Figure 1-4:  Major signalling pathways and transcriptional networks 
involved in SC differentiation. A) Signalling through ErbB, gpr126 and integrin 
receptors have been shown to activate various signalling pathways key to SC differentiation.  
B) Positive regulators are in green and negative regulators shown in red. 
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1.4 Myelin structure and function 
Given the extraordinary relevance and complexity that the myelinated fibre represents 
I shall, in this part of the introduction, focus on the composition and organization of 
myelin mentioning, when appropriate, peripheral neuropathies associated with 
defective myelin production. 
Myelination results in a dramatic increase in the velocity of impulse propagation and is 
critical for axon health and stability. The myelin sheath is a lipid-rich, specialised 
membrane that wraps around axons (typically larger than 1 µm in diameter) in a 
multilamellar spiralling manner (Figure 1-5A). The myelinating SC and its associated 
axons are organized into distinct molecular, structural and functional domains. These 
domains include the internodal region, juxtaparanode, paranodal junctions and Nodes 
of Ranvier (Nave, 2010; Poliak and Peles, 2003) (Figure 1-5B and C). The importance 
of myelin organization and integrity is emphasized in various demyelinating diseases 
where the disruption of these domains results in conduction block and axonal 
degeneration (Scherer and Wrabetz, 2008). Key to the function of myelinated fibres 
are the Nodes of Ranvier. They consist of discontinuous, small (1 micron wide) 
intermittent interruptions of exposed axons to which the voltage-gated sodium (Na+) 
channels localize. It is this focal concentration of Na+ channels, together with the 
increased resistance and reduced capacitance of the myelinate regions of the axons 
that allows for the rapid saltatory conduction of myelinated axons. The molecular 
composition of the node has been extensive characterized. Briefly, Nodes of Ranvier 
are highly enriched in neural adhesion molecules such as NrCAM and neurofascin, 
which bind glial matrix components like gliomedin (Eshed et al., 2005).  
In the PNS, the nodes are filled with SC microvilli that emanate from the outer ends of 
the cell (Figure 1-5D). The microvilli, which express a specific matrix enriched in ezrin, 
radixin and moesin, play an important role in node formation and function. Flanking the 
nodes, Schwann cell membranes form loops that are connected to the axolemma by 
specialized axo-glial junctions (Figure 1-6A). These paranodal junctions, composed of a 
complex of axonal contactin and contactin-associated protein (Capsr) and glial 
neurofascin, promote tight attachment between axons and glia and are thought to 
provide a barrier to the lateral diffusion of proteins in order to maintain the 
composition of the nodes (Charles et al., 2002; Eshed et al., 2005; Poliak and Peles, 
2003; Rios et al., 2000; Rios et al., 2003). The axon is further organized into the 
juxtaparanodes that are enriched in potassium channels, but which function remains 
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Figure 1-5: Diagrams of the structural regions of myelinated fibres. A) 
Schwann cells form myelin by enwrapping their membrane several times around the axon 
(Adapted from Lodish, 5th edition); B) Myelin covers the axons leaving regions of naked axons, 
the nodes of Ranvier; C) Schematic longitudinal view of a myelinated fibre showing the 
different domains; D) Detail showing the SC microvilli and basal lamina (Adapted from Poliak 
and Peles, 2005). (Figures removed due to copyright restrictions). 
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unknown (Salzer et al., 2008). The remaining domain in the myelinated fibre comprises 
the internode that can reach up to 1mm in length in the adult PNS (Abe et al., 2004) 
Along the internode the inner SC membrane (adaxonal), uniformly separated from the 
axon by a periaxonal space of 15nm, interacts with the axon through a set of adhesion 
molecules that include the nectin-like (Necl) cell adhesion molecules, a family of Ig-like 
CAM (also known as cell adhesion molecules Cadm) and the synaptic cell adhesion 
molecules (SynCAMs). A simplified view of a myelinated fibre is shown in Figures 1-5 
and 1-6. 
 
1.4.1 Myelin composition 
The myelin membrane is organized into two structurally and biochemically distinct 
areas: compact, which is found at the internodes and results from the apposition of 
adjacent layers of SC membrane and exclusion of the cytoplasm, and regions of non- 
non-compact myelin. Compact myelin in the PNS is largely composed of lipids, mainly 
cholesterol and sphingolipids, including galactocerebroside (GalC) and sulfatide (Snipes 
and Suter, 1995). The main myelin proteins are protein zero (P0), peripheral myelin 
protein 22 kDa (PMP22), myelin basic protein (MBP) and proteolipid protein (PLP) 
(Figure 1-6B).  
As mentioned before, P0 is first expressed at low levels in SCPs, becoming strongly 
upregulated at the onset of myelination in mSCs (Baron et al., 1994). In the myelin 
sheath, P0 accounts for more than half of the PNS myelin protein and plays a key role 
in mediating the stabilization and compaction of consecutive layers of myelin 
(Kirschner and Ganser, 1980). P0 is a 28kDa glycoprotein containing an extracellular 
Ig-like domain, a hydrophobic transmembrane region, and a small, basic intracellular 
domain (Lemke et al., 1988). The extracellular domain mediates homotypic 
interactions across the extracellular space, in that way keeping together opposing 
myelin membranes (Filbin et al., 1990; Shapiro et al., 1996) (Figure 1-6B). The 
intracellular domain forms heterotypic interaction with lipids and promotes the close 
apposition of intracellular membranes. In humans, mutations in the P0 gene are 
associated with demyelinating diseases such as Charcot-Marie Tooth 1B (CMT1B), 
Dejerine-Sottas syndrome (DSS) and congenital hypomyelination (CH) (Hayasaka et al., 
1993a; Hayasaka et al., 1993b; Warner et al., 1996). The phenotypes of these diseases 
resemble those that develop in transgenic mice expressing targeted mutations in P0. In 
P0-null mice Schwann cells form a multilamellar spiral of membrane around axons, but 
the myelin does not compact (Giese et al., 1992). 
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Figure 1-6: Myelinated axons and areas of compact and non-compact 
myelin. A) Schematic representation of a myelinated axon; Compact myelin is shown in 
pale blue; Non-compacted myelin is shown in dark blue. The Schmidt-Lanterman incisures 
(SLIs) correspond to areas of non-compacted myelin that spiral around the axon (adapted 
from Nave, 2010); B) major components of compact myelin; C) major components of non-
compact myelin. (Figures removed to copyright restrictions). 
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P0 heterozygous mice also develop a late-onset demyelinating neuropathy, indicating 
that even a modest reduction in the amount of P0 causes instability of compact myelin 
(Martini et al., 1995; Shy et al., 1997; Zielasek et al., 1996). Thus, a single allele of P0 is 
sufficient for the normal compaction of the myelin, but both are required for its long-
term maintenance. Other protein elements of the myelin sheath have also been 
implicated in human disease. PMP22, for example, is a hydrophobic membrane protein 
(Figure 1-6B) whose levels appear to be crucial for the maintenance of the myelin 
sheath (although its function remains unknown). Accordingly, three copies of the 
PMP22 gene lead to CMT1A disease, probably owing to a modest increase of PMP22 
protein in the compact myelin (Hanemann and Muller, 1998; Vallat et al., 1996). 
The role of lipids in myelin composition has been much harder to study. Nevertheless, 
targeted disruption of the UDP-galactose-ceramide galactosyltransferase gene (cgt) 
provided an unprecedented opportunity to perturb the lipid components of myelin 
(Bosio et al., 1998; Dupree et al., 1998). CGT is necessary for the synthesis of 
galactocerebroside and sulfatide, therefore, these glycolipids are completely absent in 
cgt-/- mice. Cgt-/- mice develop neurological signs with the onset of myelination, and 
most die between 18 and 30 days. Surprisingly, despite the normal ultrastructure 
appearance of most PNS myelin sheaths, axonal conduction velocity is dramatically 
slowed, which may be related to abnormal paranodes (Bosio et al., 1998; Dupree et al., 
1998). Collectively, these observations highlight the importance of the stoichiometric 
organization of the myelin sheath, as perturbations in any one component can alter the 
entire structure.  
In myelinating SCs, regions of non-compact myelin are found at the paranodal loops, 
the Schmidt-Lanterman incisures (SLI), nodal microvilli and the inner and outer edges 
of the myelin sheath (Figure 1-5 and 1-6). Non-compact myelin contains a significant 
amount of cytoplasm and its components include periaxin, myelin-associated 
glycoprotein MAG, E-cadherin and the integrins α6β1 and α6β4 which interact with 
the basal lamina and connexin 32 (Figure 1-6C). The specialized Schmidt-Lanterman 
incisures are inclusions of cytoplasm present in each layer of myelin connecting the 
Schwann cell nucleus to the consecutive layers of myelin membranes (Figure 1-6A) 
(Salzer, 2003; Scherer, 1999). 
 
1.5 Schwann cell basal lamina 
SCs typically form a basal lamina around their abaxonal cytoplasmic membrane that 
separates the cell from the mesenchymal endoneurial space of the peripheral nerve. In 
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longitudinal sections, SC basal lamina forms a continuous tube that even bridges the 
nodal gaps. The SC basal lamina is a complex and organized network of secreted 
proteins rich in extracellular matrix (ECM) components such as laminin heterodimers 
(composed of α2/merosin, β1, and γ1 laminin chains), collagens I and IV, fibronectin, 
entactin/nidogen and proteoglycans (perlecan, N-syndecan and bamacan) (Bunge, 1993; 
Chernousov and Carey, 2000; Court et al., 2006). The ECM proteins provide the 
substrate on which SCs reside. In this way, they play not only a supportive role, 
providing strength and structure to Schwann cells, but may also regulate key aspects of 
SCs behaviour through sequestration and local release of growth factors. Indeed, as 
discussed before, interactions between laminin in the basal lamina and integrin 
receptors at SC membranes trigger many different intracellular signals required to 
control SC proliferation and differentiation (reviewed in (Yu et al., 2007)). In addition, 
some ECM components of the basal lamina may play an important role in the process 
of nerve regeneration by providing a guidance structure that promotes axonal 
regrowth (Stoll and Muller, 1999; Zhang et al., 1995). In the next sections of this 
thesis, I shall briefly describe the anatomy of the peripheral nerves, and then proceed 
to discuss, in more detail, the events that follow injury to the PNS and how SCs and 
their associated basal lamina are critical mediators of nerve regeneration. 
 
1.6 The anatomy of peripheral nerves 
To understand the biology of Schwann cells in the context of nerve regeneration and 
tumourigenesis it is relevant to first consider some basic concepts of the anatomy of 
peripheral nerves. From the central nervous system (CNS) emerge multiple branches 
of two different categories of peripheral nerves- cranial and spinal, whose terminals 
reach all body districts. Although nerve trunks located in distinct parts of the organism 
may differ with respect to the fibre-type composition and number of fascicles, the 
morphology of these nerves trunks is remarkably similar (with the olfactory and optic 
nerves being exceptions) (Sunderland, 1990; Sunderland and Bradley, 1949). In this 
thesis, most of the experiments were performed on one of the largest spinal nerves 
present in both human and rodent organisms, the sciatic nerve. The sciatic nerve, as all 
the spinal nerves, contains mixed axons, i.e., sensory and motor, and is therefore 
composed of a mixture of myelinated and unmyelinated nerve fibres (Williams, 1999). 
A schematic representation of a peripheral nerve is shown is Figure 1-7. 
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Figure 1-7: Schematic representation of peripheral nerves. The sciatic 
nerve and other spinal nerves are represented. Schwann cells in the nerve trunks (nerves that 
innervate the limbs) are derived from SCPs; Schwann cells in the nerve roots (ventral and 
dorsal) and satellite cells in the DRG, originate from distinct progenitors, the boundary cap 
cells. A cross-section of a nerve trunk composed by 3 fascicles is also shown, together with 
the major contributing cell types. 
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Classically, two types of layers can be distinguished in the nerve trunks: the 
epineurium, which is an outer layer that encloses the entire nerve whether this is uni- 
or multifascicular and the more internal, multilayered perineurium that surrounds 
individual fascicles (Figure 1-7). The epineurium is composed of a supporting and 
protective connective tissue, which includes a collagen tissue sheath and a plexus of 
blood vessels that pass across the perineurium to communicate with the network of 
arterioles and venules within the endoneurium. In addition, it may also contain 
fibroblasts, some resident macrophages and mast cells and variable amounts of adipose 
tissue (Geuna et al., 2009). 
Within the epineurium, fascicles of nerve fibres are individually ensheathed by the 
perineurium, a dense and mechanically strong, yet flexible cellular sheath that consists 
of alternating layers of collagen and uninterrupted, concentric rings of flattened, 
specialized, fibroblast-like cells that are connected by tight junctions (Akert et al., 1976; 
Key and Retzius 1876). Such cells, termed perineurial cells, contain a patchy basal 
lamina and numerous pinocytic vesicles and often, bundles of microfilaments.  
The perineurial sheath serves as a metabolically active barrier, protecting axons from 
ionic flux, toxins and infection (Kristensson and Olsson, 1971; Olsson, 1990). Despite 
the essential function that the perineurial cells play in the peripheral nerve function, 
their origin is not fully clarified. Previous studies have suggested that during 
development the perineurium appears to form by a series of steps in which nearby 
mesenchymal or fibroblasts cells first assemble as a loosely organized tube around the 
nerve and then mature to create a multilayered barrier (Du Plessis et al., 1996; 
Thomas and Jones, 1967). In support of this idea, fibroblasts cultured in the presence 
of neurons and Schwann cells form “perineurial-like” structures (Bunge et al., 1989). 
However other characteristics, such as association of perineurial cells with basal 
lamina, are quite different from fibroblasts. Studies in zebrafish have suggested that in 
these animals, the perineurium develops from glial cells that originate in the CNS 
(Kucenas et al., 2008). Whether there is similar origin in mammals remains to be 
demonstrated. Regardless of their origin, it is known that the final maturation step 
requires the signalling molecule desert hedgehog (DHH), which is expressed by 
Schwann cells. In the absence of DHH, the perineurium is disorganized and is 
permeable to macromolecules and inflammatory cells (Parmantier et al., 1999).  
The compartment within the perineurium, the endoneurium, represents a loose, soft, 
connective tissue that embeds and protects the fascicles during movement and 
external trauma (Lundborg 2005). It contains the SC-axon units (often referred as the 
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nerve fibres) embedded in a collagenous matrix that also supports a capillary network, 
a population of resident macrophages and a variable, but generally reduced, number of 
fibroblasts (Thomas, 1993). Schwann cells represent the majority of the cell population 
within the endoneurium, followed by endothelial cells and resident macrophages (2-
9%), while fibroblasts represent less than 4% of the total (Causey and Barton, 1959; 
Mueller et al., 2003). 
 
1.7 Wallerian degeneration and PNS repair 
In contrast to the CNS, peripheral nerves have a remarkable ability to regenerate 
following an injury. Underlying the success of this process is the plasticity of Schwann 
cells that respond to the injury by reverting from a seemingly stable, specialised cell 
state to a proliferating precursor-like cell (Parrinello et al., 2010; Scherer and Salzer, 
2001; Zochodne, 2008).  
Traumatic injury to the PNS produces abrupt tissue damage at the lesion site where 
the physical impact occurred. Additionally, the nerve stump distal to the wound site 
and a small reactive zone at the end of the proximal stump, despite not having 
encountered the physical trauma directly, also undergo a series of well-characterized 
molecular and cellular events collectively known as Wallerian Degeneration (WD). 
During Wallerian degeneration, axons downstream of the injury site, degenerate 
leaving behind SCs that dedifferentiate and divide inside the basal lamina tubes that 
surrounded the original nerve fibres, organizing themselves into columns termed Bands 
of Bungner (Figure 1-8). Meanwhile, SCs together with resident and infiltrating 
macrophages clear the axonal and myelin debris, thereby generating a conducive 
environment for newly formed axons, that can then associate with the SC columns and 
re-grow distally until reaching their targets. Following axonal regeneration, Schwann 
cells then re-differentiate to give rise to a fully repaired and functional nerve 
(Fernandez-Valle et al., 1995; Shamash et al., 2002; Stoll et al., 1989; Zhang et al., 
2000). The same process is triggered in both crushed and transected nerves, although 
the success of repair may vary depending on the type of injury. Most strikingly, the 
maintenance of an intact basal lamina that occurs during a crush, but not in a 
transection, is thought to improve the success of regeneration by preserving the 
integrity of the original axonal paths and allowing accurate reinnervation (Nguyen et 
al., 2002). More severe injuries, such as nerve transections, involve more complex 
tissue remodelling. Upon cut, the nerve stumps on either side of the cut retract, 
generating a gap, which must be bridged by new tissue; moreover, the regrowing 
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axons from the proximal stump must travel through this newly formed tissue - the 
nerve bridge - to reach the distal stump and their targets (McDonald et al., 2006) 
(Figure 1-8). 
 
Figure 1-8: Wallerian Degeneration in the PNS. Schematic representation of the 
events that follow an injury: A) nerve transection leaves a gap separating both stumps of the 
nerve; B) axonal degeneration, SC dedifferentiation and infiltration of inflammatory cells; C) 
regenerating nerve with axons sprouting from the proximal stump and growing towards target 
tissue along the SC cords (in the nerve bridge) and the bands of Bungner (in the distal stump); 
D) a repaired and functional nerve. 
 
1.7.1 Axonal degeneration 
Within 24-48 hours of physical injury, the axolemma and cytoskeleton of the axons 
downstream of the lesion begin to degenerate. Evidence that axonal degeneration 
results from an active process rather than from mere axonal starvation secondary to 
the lack of cell body derived signals came from the discovery of the naturally occurring 
Wallerian Degeneration Slow (Wlds) mutant mice whose axons survive for as long as a 
month after transection (Brown et al., 1994; Lunn et al., 1989; Tsao et al., 1994). It is 
now thought that axonal degeneration is a caspase-independent process, mediated by 
the rapid activation of calcium-dependent axonal proteases, such as calpain (Glass et 
al., 2002). Moreover, the ubiquitin-proteasome system (UPS) is also involved, since 
blockage of proteasome activity has been shown to delay axon degeneration from 
injury both in vivo (Ehlers, 2004; Hoopfer et al., 2006; MacInnis and Campenot, 2005; 
Zhai et al., 2003) and in vitro (Gerdts et al., 2011). The genetic mutation underlying the 
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Wlds mice was found to result in the formation of an abnormal fusion protein 
consisting of the N-terminal 70 amino acids (N70) of the multi-ubiquitination factor 
Ube4b (the 70 amino acid portion, however, was found not to influence ubiquitination) 
and the full-length NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyl 
transferase 1 (Nmnat1), separated by a short linker sequence (Mack et al., 2001). A 
recent study has shown that expression of both Nmnat-1 and the first 16 base pairs of 
N70 is required to protect axons from degeneration (Conforti et al., 2009). Exactly 
how they act to protect axonal integrity, however, remains to be elucidated. One 
plausible explanation suggests that as Nmnat1 shares with Nmnat2 (a known axonal 
survival signal), the same enzymatic domain for NAD+ synthesis (Jia et al., 2007; Yan et 
al., 2010), the WldS protein may exert its protective effect by augmenting or 
substituting for Nmnat2 to maintain sufficient levels of Nmnat enzyme activity in the 
distal axons after injury (Gilley and Coleman, 2010; Wang et al., 2012).  
 
1.7.2 Schwann cell response: dedifferentiation and demyelination 
As a prompt response to degenerating axons, SCs in the distal stump rapidly convert 
from a mitotically quiescent differentiated phenotype, to a dedifferentiated, 
proliferative, progenitor-like state. This transition involves the coordinated 
downregulation of myelin-associated genes, such as P0, MBP and periaxin and the 
upregulation of genes associated with the embryonic development such as the 
neurotrophin receptor p75, cell adhesion molecules, and many basement membrane 
components, including, NCAM, GFAP and L1 (Hall et al., 1997; Taniuchi et al., 1986; 
Trapp et al., 1988). In Wlds mutants, the dedifferentiation of SCs is also delayed until 
the onset of axonal degeneration, implicating the requirement of axonal derived 
instructions in the process (Lunn et al., 1989). The exact injury signals remain 
unknown, although there is some evidence that NRG1 may act as one of these early 
signals between damaged axons and SCs, promoting myelin breakdown. Within 
minutes of axonal transection, ErbB2 phosphorylation is observed at the paranodes of 
myelinating SCs. Moreover, rats treated with the pharmacological inhibitor PKI-166, 
which blocks the ErbB2 receptor, exhibit retarded demyelination following nerve 
injury, despite undergoing axonal degeneration (Guertin et al., 2005). However, the 
role of NRG1 has not yet been conclusively demonstrated, as the inhibitor used also 
acts on the epidermal growth factor receptor (EGFR) (which is expressed by SCs upon 
injury (Guertin et al., 2005)), and so a number of ligands (including NRG1) may be 
implicated. In support of the involvement of the NRG/ErbB pathway in driving SC 
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dedifferentiation, addition of high levels of NRG1 Type II to SC-axonal co-cultures 
results in SC demyelination and proliferation (Guertin et al., 2005; Harrisingh et al., 
2004; Zanazzi et al., 2001). Moreover, transgenic mice that overexpress NRG1 Type II 
in myelinating SCs (onset of expression at postnatal day 5) develop hyperplasia and 
demyelination (Huijbregts et al., 2003). Further investigation is needed however to 
obtain experimental evidence supporting a role for NRG1 Type II in Wallerian 
Degeneration. Importantly, at least in vitro, the effect of NRG1 Type II is blocked by 
treatment with MEK inhibitor (but not by a PI3K inhibitor), implicating this branch of 
Ras signalling as the intracellular pathway transducing the dedifferentiation signal 
(Harrisingh et al., 2004).  
 
1.7.3 Schwann cell plasticity is regulated by the Ras/RAF/ERK 
pathway 
Work from our laboratory has provided a major contribution towards the 
establishment of Ras/Raf/ERK as the central pathway driving quiescent, differentiated 
SCs to revert to a proliferative, “progenitor-like” state. Using myelinated SC-axonal 
co-cultures we have shown that sustained activation of Raf/ERK signalling is sufficient 
to trigger SC dedifferentiation. To address whether activation of this pathway also 
regulates SC plasticity in vivo we have recently generated a transgenic mouse model 
expressing a Tamoxifen (Tmx)-inducible Raf-kinase/estrogen receptor fusion protein 
(RafTR) specifically in myelinating Schwann cells (Napoli et al., 2012). We found that 
strong and sustained activation of Raf/ERK signalling in the adult PNS is, indeed, 
sufficient to induce SCs to revert to a “progenitor-like” state, even in the presence of 
intact axons. Moreover, we found that SCs persist in the dedifferentiated state for as 
long as Raf/ERK remains activated. Importantly, this state is reversible as 
dedifferentiated SCs readily redifferentiated and remyelinated axons as soon as the 
RafTR kinase was inactivated by Tmx withdrawal.  
Consistent with Raf/ERK being the pathway controlling the Schwann cell plasticity 
following nerve injury, we and others have shown that as rapidly as within 20 min post-
lesion there is a strong and robust activation of ERK signalling both at the lesion site 
and throughout the entire distal stump of the injured nerve. What is more, ERK is 
activated specifically in Schwann cells and the signal is sustained for several days 
(Harrisingh et al., 2004; Sheu et al., 2000). Strikingly, injured mice treated with the 
MEK inhibitor PD0325901 exhibit a dramatic inhibition in the switch in Schwann cell 
differentiation state (Napoli et al., 2012).  
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As mentioned, the upstream dedifferentiation signal(s) that acts to induce the strong 
and sustained activation of Ras/ERK signalling has yet to be identified. In vitro, NRG1 
stimulation results in a strong, but transient, activation of the Ras/Raf/ERK pathway in 
SCs (Echave et al., 2009). Thus, it seems clear that even if NRG1 acts as an early 
damage signal, other signals must account for the sustained ERK activation that follows 
injury.  
Upon nerve damage, the blood-nerve-barrier (BNB) breaks-down and leaks 
components from the vasculature, hence altering the ECM composition. One of these 
components is fibrinogen that following leakage is converted into fibrin, which can be 
deposited in the matrix (Akassoglou et al., 2000). In a study by Akassoglou and co-
workers, fibrin was found to induce strong phosphorylation of ERK in cultured 
Schwann cells, which correlated with upregulation of the dedifferentiated SC marker 
p75 (Akassoglou et al., 2002). Furthermore, the authors demonstrated that the timing 
of remyelination/regeneration correlates with fibrin clearance, suggesting that its 
presence may prolong the period of ERK activation and therefore be inhibitory for SC 
redifferentiation (Akassoglou et al., 2002). Exactly how Raf/ERK acts on the 
transcriptional machinery to drive dedifferentiation remains under investigation. 
Studies from our lab, however, have shown that ERK activation appears to act by 
coordinating the blockage of Krox-20 dependent activity via repression of myelin gene 
promoters and by inducing the activity of negative regulators of myelination, such as c-
jun and Sox-2 (Rosenberg et al., in preparation). 
It is thus striking that Ras/Raf/ERK induces opposing biological outcomes promoting 
differentiation during development and dedifferentiation following injury. The 
explanation for such context-specific effects may reside in differential levels of activity 
and implies that strict regulatory mechanisms must be in action both in embryogenesis 
and later following an injury to ensure the adequate outcome. Interestingly, the same 
seems to hold true for neuregulin signalling since, in a recent study, a soluble form of 
NRG1 type III was shown to, depending on the concentration present, play a dual 
effect, either promoting or inhibiting myelination (Syed et al., 2010).  
 
1.7.4 The role of Schwann cells in WD: myelin and axonal clearance 
and recruitment of the inflammatory response 
The process of SC dedifferentiation becomes most evident 2 days after injury, when 
myelin sheaths start to disintegrate as a result of Krox-20 and myelin genes 
downregulation. SCs become separated from degenerating myelin and phagocytose 
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myelin debris (myelin ovoids) in a process that is dependent of binding of the 
galactose-specific lectin MAC-2 (expressed by SCs) and sGalcC and GalC in myelin 
debris (Reichert et al., 1994). Besides contributing to myelin clearance, dedifferentiated 
SCs play an important role in the orchestration of an inflammatory response (Napoli 
et al., 2012). Importantly, recent work from our laboratory has shown that activation 
of the Raf/ERK pathway in SCs in sufficient to recapitulate these effects. Strikingly, we 
have shown that dedifferentiated Schwann cells, by means of as yet unknown Raf-
activated signals, induce the BNB breakdown independently of trauma. Furthermore, 
they actively secrete cytokines such as MCP-1 (monocyte chemoattractant protein-1) 
and c-Kit ligand, implicated in attracting inflammatory cells (Napoli et al., 2012). 
Together, these findings have highlighted Schwann cells and Ras/Raf/ERK signalling as 
central mediators of nerve regeneration.  
 
1.7.5 The inflammatory response 
Wallerian degeneration is strictly dependent on the activation of an inflammatory 
response. Shortly following an injury, the endoneurial levels of early inflammatory 
cytokines such as MCP-1, tumour necrosis factor alpha (TNF-α) and interleukin 1α 
(IL-1α) mostly secreted, as mentioned, by ERK-activated-SCs start to increase both at 
the lesion site and distal stump of the damaged nerve. Within days, this network is 
amplified by cytokines, chemokines and other bioactive molecules released by 
recruited inflammatory cells and activated endothelial cells (Be'eri et al., 1998; Shamash 
et al., 2002; Stoll et al., 2002). Different types of inflammatory cells are seen at the 
injury site: 
Neutrophils 
The phagocytic neutrophils (polymorphonuclear granulocytes) are the first 
inflammatory leucocytes to invade the injured tissue, to phagocytose debris and recruit 
other leucocytes during WD (Nathan, 2006). However, their response is very limited 
in time and extent, peaking at 24 hours within an injury and only a few cells infiltrating 
the more distal areas of the distal stump (Perkins and Tracey, 2000). They quickly 
undergo apoptosis after a brief period of phagocytosis, and are normally absent one 
week post-injury (Hall, 2005; Kennedy and DeLeo, 2009; Perry et al., 1987).  
Macrophages 
Macrophages are important effector cells in immune-mediated debris clearance. 
Resident macrophages, which express major MHC molecules and complement 
receptor 3, have a prompt response to injury. They are later joined by chemokine c-c 
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motif receptor 2 (CCR2) positive, bone-marrow derived macrophages (Bruck, 1997; 
Bruck and Friede, 1991; Mueller et al., 2003). The recruitment of macrophages to the 
distal nerve begins 3-4 days following trauma by diapedesis across a temporarily leaky 
BNB and peaks at about 7 days. Monocytes, which differentiate into macrophages in 
the tissue, are attracted by locally produced cytokines and chemokines including 
MCP1, macrophage inflammatory protein1 (MIP-1) TNFα and LIF, expressed by 
dedifferentiating SCs and resident macrophages (Ousman and David, 2001; Toews et 
al., 1998). Macrophages invade the tubes of SCs by passing through the basal lamina 
and degrade and phagocytose the myelin debris (Hall, 2005). At least two mechanisms 
are involved in myelin recognition and uptake. Macrophages express complement 
component receptor 3 (CR3) and the corresponding complement component 3 (C3) 
is expressed at the surface of degenerating myelin, indicating that myelin is opsonized 
by the complement during WD (Bruck and Friede, 1990). In addition, the galactose 
specific lectin MAC-2 is also induced in phagocytosing macrophages, at least partially 
by fibroblast-secreted granulocyte macrophage colony stimulating factor (GM-CSF) and 
contributes to myelin clearance (Stoll and Muller, 1999). Removal of degenerated 
myelin is critical for successful repair since some of the myelin components such as 
MAG, are highly inhibitory to axonal regeneration (McKerracher et al., 1994; 
Mukhopadhyay et al., 1994; Schafer et al., 1996). Myelin clearance begins 3-4 days after 
the injury and is completed approximately 2 weeks following injury. Besides their role 
in myelin clearance, macrophages also produce cytokines that activate SCs, including 
IL-1  (La Fleur et al., 1996), and trophic factors, like NGF that promote axonal 
regeneration (Hikawa and Takenaka, 1996; Perry et al., 1987). Although many 
macrophages remain free in the endoneurium for several weeks, the majority 
eventually disappears either by apoptosis or migration to lymph nodes and spleen 
(Kuhlmann et al., 2001). 
Mast cells 
There is a sustained increase in the number of mast cells within the epineurium and 
endoneurium distal to a traumatic injury. Mast cell-derived vasoactive agents, together 
with metalloproteinases secreted by endothelial cells and TNFα and ILβ secreted by 
macrophages increase the permeability of the BNB (Hall. 2005). However, little is 
known about their contribution to WD and nerve repair.  
T-cells 
T-cells are the last immune cell to arrive at the lesion site, peaking at 14-28 days 
following injury (Moalem et al., 2004). T-cells produce pro- or anti-inflammatory 
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cytokines that support cellular and humoral immunity. Type 1 helper (Th1) T cells 
secrete pro-inflammatory cytokines (e.g. TNFα, INFγ) that activate nearby 
macrophages, neutrophils and NK cells. Anti-inflammatory cytokines (IL4, IL10) 
produced by Th2 T cells inhibit macrophage functions and pro-inflammatory cascades. 
 
1.7.6 Schwann cell proliferation 
As Schwann cell dedifferentiation proceeds, SCs re-enter the cell-cycle. Accordingly, 3 
to 4 days following nerve injury, SCs are found proliferating at the lesion site and 
throughout the entire distal stump (Liu et al., 1995). Given the absolute requirement 
for NRG1 for SC proliferation during development it is not surprising that NRG1 was 
one of the first candidates to be considered to play a similar role in adult SCs following 
injury. Fuelling this idea, elevated expression of NRG1 Type II and ErbB2/3 is observed 
in a time frame consistent with SC proliferation (Carroll et al., 1997; Guertin et al., 
2005). It was hence quite unexpected when analysis of a transgenic mice with targeted 
disruption of ErbB2 revealed that signalling through ErbB2 is not only dispensable for 
the maintenance of myelinated SCs, but is also not required for the SC proliferation 
following an injury (Atanasoski et al., 2006). In spite of ErbB2 disruption, ERK and 
cyclinD1 (that, as will be detailed below, are required for SC proliferation) were still 
activated (although slightly reduced). It therefore seems clear that other mitogenic 
signals, which likely include growth factors and cytokines secreted by inflammatory 
cells, must be involved (Chen et al., 2007; Fawcett and Keynes, 1990; Hirata et al., 
1999). Additional evidence that different mechanisms govern SC proliferation in 
development and in injury came from analysis of the cyclinD1 knockout mice. Schwann 
cell development and proliferation is unimpaired in cyclinD1-/- mice, indicating that 
cyclinD1 is mostly dispensable downstream of the mitogenic actions of NRG1. In sharp 
contrast, SC proliferation following injury was completely absent in cyclinD1 mutants, 
indicating that the proliferative response of adult SCs to damage is strictly dependent 
on this cyclin. Interestingly, Schwann cell dedifferentiation and demyelination were not 
affected in cyclinD1 mutant mice demonstrating that these events can be uncoupled 
(Kim et al., 2000). Despite this apparent independence between proliferation and 
dedifferentiation the same pathway drives the two processes since ERK, besides 
driving dedifferentiation as detailed before, is also required for cyclinD1-dependent 
proliferation of adult SCs (Napoli et al., 2012). Accordingly, MEK treatment completely 
abolished SC proliferation following injury (Napoli et al., 2012).  
Surprisingly, nerve regeneration in cyclinD1 knockout mice was normal, in spite of the 
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blockage in Schwann cell proliferation, suggesting that SC proliferation is not required 
for successful nerve repair. Importantly, these studies were performed in crushed 
nerves (Kim et al., 2000; Yang et al., 2008). It is possible that in this type of injury, the 
maintenance of an intact basal lamina might be sufficient to provide guidance to the 
regrowing axons. In more severe injuries, such as nerve transection, both stumps are 
separated and retract creating a bridge between them. In these cases, proliferating SCs 
form cellular cords that appear to serve as tracks for axonal regrowth across the gap 
formed between both stumps (Parrinello et al., 2010). In support of the critical 
importance of this event, studies have shown that if local mitosis is blocked at the 
bridge, using mitomycin-C, Schwann cells do not migrate from the proximal stump and, 
consequently, axonal regrowth is impaired (Chen et al., 2005; Pellegrino and Spencer, 
1985). Work from our laboratory has provided further insight regarding the molecular 
and cellular events underlying this process. We have shown that following transection, 
at the region of the nerve bridge (see Figure 1-8), fibroblasts interact with Schwann 
cells inducing a switch in SC behaviour from repulsion to attraction. This switch, which 
we have shown to be mediated by the activation of EphB2 receptors on SCs by 
ephrinB on fibroblasts, induces SCs to migrate as cords from the proximal stump, 
through the nerve bridge. Importantly, disruption of such interactions and failure to 
properly form SC cords results in axonal mismigration (Parrinello et al., 2010). 
Together, these results suggest that contrary to crush injuries in which SC 
proliferation appears to be dispensable, likely due to the prominent role played by the 
basal lamina, in nerve transections SC proliferation and subsequent migration as 
cellular cords appears to be required for proper axonal regrowth and nerve repair.  
 
1.7.7 Axonal regrowth 
The success of nerve regeneration depends on the reinnervation of the correct axonal 
targets (Nguyen et al., 2002). As already stated, Schwann cells promote PNS repair by 
providing trophic support and physical guidance to regrowing axons by forming Bands 
of Bungner, which are rail-track-like structures upon which axons can efficiently 
regenerate (Chen et al., 2007; Nguyen et al., 2002). In crush injuries most of axons find 
their original targets, a process that is more difficult in transected nerves. 
Dedifferentiated SCs also produce and present a plethora of neurotrophic factors that 
include NGF, BDNF and NT-3 among others (Funakoshi et al., 1993; Heumann et al., 
1987). Additionally, SCs express a series of adhesion molecules including N-cadherin, 
L1 and NCAM that, at least in vitro, enhance the outgrowth of neurites (Bixby et al., 
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1988; Bixby and Zhang, 1990; Martini and Schachner, 1988; Tacke and Martini, 1990; 
Thornton et al., 2005). Axonal regrowth is also mediated by interaction with ECM 
molecules. Following nerve injury, SCs increase the expression of proteins that are 
integrated in their basal lamina, such as laminins and fibronectin. Interaction between 
these proteins and axonal components facilitates axonal regrowth by providing 
structural and trophic support (Agius and Cochard, 1998; Lefcort et al., 1992; Toyota 
et al., 1990; Vogelezang et al., 2001). Most of the axon sprouts arising from parent 
axons in the proximal stump find and follow Schwann cell columns, whilst a more 
reduced number of axons might also grow at random into the connective tissue of the 
nerve (Geuna et al., 2009). Since an excess number of axons invade the distal SCs 
columns, the initial number of axons present in the distal nerve may considerably 
exceed the original number (Aguayo et al., 1973; Sanders and Young, 1946). Other 
branches that fail to reach the targets are pruned away and disappear. After a few 
months of nerve regeneration there is a reorganization of the nerve trunk into a large 
number of miniature compartments or “minifascicles”, each surrounded by a new 
perineurium (Geuna et al., 2009). This process, known as compartimentalization 
(Morris et al., 1972a, b), also occurs in the end part of the proximal stump and in the 
gap between the two stumps. The process of compartimentalization is likely to be a 
response to the disturbance of the endoneurial environment resulting from a damaged 
perineurium and likely expresses the need for a quick reconstitution of the normal 
endoneurial space by restoring the perineurial barrier (Lundborg, 2004).  
 
1.7.8 Final steps of nerve repair: Schwann cell redifferentiation, 
axonal remyelination and resolution of the inflammatory response 
Unlike proliferation, Schwann cell redifferentiation and remyelination seems to largely 
recapitulate events during development, in both timing and sequence of gene-
expression pattern (Chen et al., 2007; Hall, 2005; Walikonis and Poduslo, 1998; Zang 
et al., 2000). Redifferentiation is triggered when SCs re-establish contact with 
regenerated axons. This induces a transient expression of Oct-6, followed by Krox-20 
upregulation and induction of myelin genes (Scherer et al., 1994; Zorick et al., 1996a).  
Similar signals and signalling pathways seem to be involved in the induction of 
remyelination in both development and regeneration. Of note, NRG1/ErbB2/3 
signalling is likely a key signal for remyelination, as both NRG1-/- and BACE1-null (that 
lack mature NRG1 Type III) are severely hypomyelinated following nerve injury 
(Fricker et al., 2011; Hu et al., 2008). Similar to their functions during development, 
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neurotrophic factors also appear to be involved in the modulation of remyelination 
during repair (Terenghi, 1999; Cosgaya 2002). Following injury, NT3 is downregulated 
whereas BDNF and p75 are upregulated. Consistent with a role in promoting 
redifferentiation, p75 null mice have an abnormal response to injury showing a reduced 
number of myelinated axons and thinner myelin sheaths (Song et al., 2006). 
Extracellular matrix components are also important players in promoting regeneration. 
Accordingly, injured nerves undergo a strong upregulation of laminin, collagens, 
fibronectin and specific integrins (Lefcort et al., 1992) to resemble the specific set of 
ECM component expressed during embryogenesis (Chernousov and Carey, 2000). As 
detailed earlier, laminins and their β1-integrins are required for proper SC 
differentiation during development. Similarly, γ1-laminin mutants show impaired axonal 
regrowth following injury, suggesting that also during redifferentiation laminin/integrin 
signalling may be involved in SC-mediated axonal sorting and in the regulation of SC 
proliferation and survival (Chen and Strickland, 2003). Again, scarce information could 
be found regarding the mechanisms driving redifferentiation into non-myelinating 
Schwann cells. Nevertheless, it is likely that is follows the same molecular and cellular 
events that mediate their differentiation during development. 
In terms of the fate of the inflammatory cells in the regenerating nerve, not much has 
been reported. Likewise, the kinetics and signals underlying the resolution of the 
inflammatory response remain poorly understood. Interestingly, analysis of the RafTR 
transgenic mice in our laboratory has shown that the inflammatory response elicited 
by Raf/ERK activation in SCs could be resolved upon signalling inactivation, suggesting 
the elegant possibility that SCs differentiation status can somehow coordinate both the 
initiation and the later termination of the inflammatory process (Napoli et al., 2012). 
This may have relevant implications as deregulation of the inflammatory response is 
frequently observed in diseases such as neuropathies. 
It should be easy, by this point, to recognize the major role Ras/Raf/ERK signalling plays 
in controlling and coordinating key events in Schwann cell biology. In particular, 
Ras/Raf/ERK is a central regulator of SC plasticity, regulating both differentiation and 
mediating SC dedifferentiation and proliferation following injury. It is therefore not 
surprising that deregulation of the pathway is likely to be involved in several inherited 
and infectious peripheral neuropathies (Fisher et al., 2008; Nadra et al., 2008; Tapinos 
et al., 2008) and in various pathological conditions associated with Neurofibromatosis 
type I. 
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1.8 Neurofibromatosis type I 
1.8.1 Incidence and symptoms 
Neurofibromatosis type 1 (NF1) is one of the most common tumour-predisposition 
syndromes, affecting 1 in 3500 individuals worldwide (Brannan et al., 1994). NF1 is 
inherited as an autosomal dominant disease with the most common phenotypic 
manifestations resulting from abnormalities of neural crest-derived tissues (Riccardi, 
1981). Patients with NF1 develop a wide spectrum of clinical presentations, including 
bony dysplasias, pigmentary lesions of the skin (café-au-lait macules and axillary 
freckling) and iris (Lisch nodules) and learning disabilities. In addition, NF1 patients 
have increased risk for specific kinds of benign and malignant tumours, including optic 
gliomas, astrocytomas, glioblastomas, pheochromocytomas (adrenal medullary 
cancers), juvenile myelomonocytic leukemias and embryonal rhabdomyosarcomas 
(Bader, 1986). However, as the name of the disease implies, the development of 
neurofibromas is the hallmark lesion of NF1. Neurofibromas are benign tumours of 
the peripheral nerve sheath that may develop in different parts of the body (neck, 
head, trunk, limbs) and extend into surrounding structures including skin, bone, muscle 
and internal organs (Williams et al., 2009). Neurofibromas can cause significant 
morbidity - severe disfigurement, pain, functional impairment - and even mortality, due 
to its continuous growth and frequent surgical inaccessibility. A summary of the clinical 
manifestations of the disease and the criteria used for its diagnosis is displayed in Table 
1-1.  
Individuals with NF1 are born with one mutated (non-functional) and one wild-type 
NF1 allele. The NF1 heterozygous condition, although sufficient to cause some of the 
clinical symptoms such as learning disabilities and pigmentary defects, is, by itself 
insufficient for tumourigenesis. Neurofibroma formation, in particular, follows 
Knudson’s “two-hit” model for inactivation of tumour suppressor genes, in that 
tumours only develop upon inactivation of the remaining wild-type NF1 allele and 
consequently complete loss of neurofibromin expression, the protein product of NF1 
(Upadhyaya et al., 1994; Zhu et al., 2002).  
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1.8.2 Neurofibromas: Composition, Genetic and Cellular origins 
Neurofibromas are highly heterogeneous, benign tumours that arise within the 
peripheral nerves. Histologically, neurofibromas resemble a disordered version of the 
normal nerve. In fact, reminiscent of an injured nerve, neurofibromas are composed of 
axonal processes, increased numbers of “perineurial-like” and endothelial cells, 
fibroblasts, mast cells and Schwann cell-like elements (that may represent 40%-80% of 
all cellular components), all of which are embedded in an abundant collagenous matrix 
(Figure 1-9). Clinically, human neurofibromas may be classified as dermal or plexiform 
(Figure 1-10). Dermal neurofibromas are superficial tumours that arise in small nerves 
and are generally well circumscribed. In contrast, plexiform neurofibromas, which arise 
almost exclusively in the context of NF1, arise within large nerves or nerve plexus 
causing diffuse enlargement of the affected nerve. Dermal neurofibromas typically arise 
in patients entering puberty or pregnant women, and increase in number and size with 
age. These are almost invariably benign tumours, rarely progressing into malignancy. In 
contrast, plexiform tumours can be either congenital or appear later in life and are 
prone to undergo malignant progression to Malignant Peripheral Nerve Sheath 
Tumours (MPNSTs), a clinically aggressive and almost invariably lethal cancer, that 
affects approximately 8-13% of individuals with the condition (Evans et al., 2002; Rubin 
and Gutmann, 2005). 
Table 1-1: Clinical features of Neurofibromatosis type I 
Established diagnostic criteria for NF1- patients are diagnosed 
with NF1 if they meet two or more of the following criteria: 
• Multiple dermal neurofibromas or one plexiform neurofibroma 
• Multiple café-au-lait macules 
• Multiple skinfold freckles 
• Iris hamartomas (Lisch nodules) 
• Optic pathway glioma 
• Bony dysplasias 
• First-degree relative with NF1 
Other associated features of NF1 
• Specific learning disabilities 
• Short stature 
• Cardiovascular abnormalities 
• Malignant peripheral nerve sheath tumours 
• Other malignancies; leukaemia, pheochromocytoma, etc. 
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Figure 1-9: Structure of a normal peripheral nerve and a neurofibroma.  
A) Schematic representation of a normal nerve fascicle (see Figure 1-7 for details); B) 
Neurofibromas are heterogeneous tumours composed of hyperproliferative Schwann cells that 
are found abnormally dedifferentiated and devoid of axonal contact. Other cell components 
include perineurial-like cells, macrophages, mast cells and fibroblasts. The perineurium is often 
disrupted. 
 
 
Figure 1-10: Examples of dermal and plexiform neurofibromas. A) Dermal 
neurofibromas growing on the chest and abdomen. B) Magnetic resonance image of plexiform 
neurofibromas growing in the sciatic nerves of an NF1 patient. C) Magnetic resonance image 
of plexiform neurofibromas in the nerve roots, causing compression of the spinal column. 
Photographs from the Children's Tumor Foundation; www.ctf.org. (figures removed due to 
copyright restrictions). 
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Despite the heterogeneity of neurofibromas in terms of location, age of onset and 
cellular composition, it is now well established that Schwann cells are the neoplastic 
element in these lesions and their transformation is known to result from loss of the 
remaining Nf1 allele. Accordingly, in neurofibromas isolated from human patients, 
somatic inactivation of the second Nf1 allele is found specifically in Schwann cells and 
not in other Nf1+/- cellular components (Serra et al., 2000). Importantly, in 
neurofibromas Schwann cells are found abnormally dedifferentiated, dissociated from 
axons and hyperproliferating.  
 
1.8.3 The NF1 gene  
The NF1 gene was identified in 1990 by positional cloning (Viskochil et al., 1990; 
Wallace et al., 1990). The human NF1 gene localizes at chromosome 17q11.2 (in 
chromosome 11 in mice), spans 350 kilobases (Kb) of genomic DNA containing 61 
exons, of which four (9a, 10a-2, 23a and 48a) are alternatively spliced in NF1 
transcripts (Barker et al., 1987; Cawthon et al., 1990b; Marchuk et al., 1991; Viskochil 
et al., 1990; Wallace et al., 1990). These alternatively spliced exons remain poorly 
studied but are thought to reflect tissue-specific or differentiation-regulated RNA 
splicing events. NF1 is highly conserved with regards to its organization and structure 
in both coding and non-coding regions (Bernards et al., 1993; Buchberg et al., 1990). 
It’s promoter region contains a number of perfectly conserved potential transcription 
regulatory elements including multiple AP2 binding sites, an SP1 site, a cAMP response 
element and a serum response element (Hajra et al., 1994). There are 3 small genes 
embedded within exon 27 of NF1 gene, encoded in the opposite strand: EVI2A, EV12B 
and OMGP (Cawthon et al., 1991; Cawthon et al., 1990a). However, there is no clear 
evidence that any of these genes is involved in NF1 pathogenesis. NF1 has one of the 
highest rates of de novo mutations, with already more than 1200 germline and 160 
somatic mutations identified (Thomas et al., 2010). Mutations include whole gene 
deletions (in about 5% of the patients), nonsense, missense, frameshift and mutations 
affecting mRNA splicing (Messiaen et al., 2000; Wimmer et al., 2007; Wimmer et al., 
2006). Although NF1 is completely penetrant, its expressivity is highly variable even 
between individuals with identical mutations, and a well-defined correlation between 
genotype-phenotype is not observed (Carroll, 2011).   
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1.8.4 Neurofibromin 
 The product of the NF1 gene, neurofibromin, is a large 220-250 kDa cytoplasmic 
protein highly expressed in neurons, oligodendrocytes, astrocytes, leukocytes and 
Schwann cells (Daston et al., 1992; DeClue et al., 1991; Gutmann et al., 1991). As 
shown in Figure 1-12, several putative domains have been identified (Aravind et al., 
1999; D'Angelo et al., 2006; Gregory et al., 1993; Izawa et al., 1996; Vandenbroucke et 
al., 2004). However, the most well characterized functional domain of neurofibromin 
corresponds to a GTPase activating protein (GAP)-related domain (GRD) that shares 
strong sequence homology with the GAP family members, such as IRA1 and IRA2 in 
yeast (Tanaka et al., 1990) and GAP1 in Drosophila (Gaul et al., 1992). Accordingly, 
neurofibromin is now recognized as a member of the mammalian family of RasGAPs 
that includes RASA1 (p120GAP), RASA2 (Gap1m), RASA3 (GAP1IP4BP), RASA4 (CAPRI), 
among others (Carroll, 2011). The GAP proteins function as negative regulators of 
Ras-mediated signalling by accelerating the conversion of the active Ras-GTP-bound 
form to the inactive Ras-GDP-bound form (Ballester et al., 1990; Xu et al., 1990). Ras 
are small G proteins encoded by a family of genes that includes H-RAS, N-RAS and K-
RAS (K-RAS encodes two isoforms, K-Ras4A and K-Ras4B) that regulate cellular 
responses by transducing extracellular signals to the nucleus via a series of 
downstream effectors (Figure 1-11).  Ras signalling can be activated by a variety of 
extracellular stimuli including growth factors, hormones, cytokines and 
neurotransmitters via interaction with receptor tyrosine kinases (RTK), G-protein 
coupled receptors, cytokine receptors and ECM receptors. Activation through RTK is 
perhaps the best characterized and is initiated upon binding of a growth factor, which 
causes RTK autophosphorylation. This creates intracellular docking sites for adaptor 
proteins and signal-relay proteins that recruit and activate guanine nucleotide exchange 
factors (GEFs), such as members of the Sos family. GEFs bind Ras and stimulate 
nucleotide dissociation. Nucleotide displacement allows the passive binding to GTP, 
given that the intracellular levels of GTP are much higher than those of GDP. 
Activated Ras-GTP can then interact and activate multiple downstream effector 
pathways, including Raf/MEK/ERK, phosphatidylinositol 3’-kinase (PI3K) and Ral 
guanine-dissociation stimulator (RalGDS), which ultimately communicate with the cell 
nucleus to regulate cell proliferation, survival, migration and differentiation (Schubbert 
et al., 2007). Keeping with the critical role that Ras plays in major cellular processes, it 
is not surprising that constitutively active mutations in Ras are frequently associated 
with human cancers as a result of permanent simulation of the Raf-ERK and/or PI3K 
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pathways that lead to uncontrolled cell proliferation and escape of apoptosis (Weiss et 
al., 1999).  
The Raf/MEK/ERK cascade is the best characterized Ras effector pathway (Repasky et 
al., 2004). Activation of the pathway involves a coordinated multistep process that is 
initiated upon Ras induced activation of Raf. Activated Raf initiates a cascade whereby 
Raf phosphorylates and activates MEK1/2, which in turn phosphorylates ERK1/2. 
Activated ERK can phosphorylate cytosolic substrates and/or be translocated into the 
nucleus where it regulates transcription by phosphorylating a number of targets 
including transcription factors such as JUN and ELK1 (an ETS family member that 
forms part of the serum response that regulates the expression of FOS) (Wasylyk et 
al., 1998). Activation of these transcription factors can lead to the expression of 
proteins involved in the control of cell-cycle progression, such as cyclinD1 (reviewed 
in (Schubbert et al., 2007)). Ras/Raf/ERK can mediate opposing effects in the same cell 
type depending on the intensity and duration of the signal. For example, in the PC12 
cell line NGF addition results in prolonged and sustained ERK activity leading to cell 
cycle exit and differentiation into a neuronal phenotype, while transient activation is 
associated with proliferation (Marshall, 1995). In Schwann cells Ras/ERK signalling also 
mediates multiple and complex effects: whilst signalling through this branch is required 
for proper differentiation during development, its sustained activation in adult SC 
drives dedifferentiation and proliferation, both in vitro and in vivo (Newbern et al., 2011; 
Harrisingh, et al., 2004; Napoli et al., 2012).  
Ras-GTP also binds and activates PI3K. PI3K phosphorylates phosphatidylinositol-4,5-
bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5- triphosphate, which in turn 
activates downstream effectors such as 3-phosphoinositide-dependent protein kinase I 
(PDK1) and AKT (Bader et al., 2005). AKT is a kinase that promotes survival in many 
cell types by inactivating several pro-apoptotic proteins including BAD (Vivanco and 
Sawyers, 2002). AKT can also phosphorylate and inactivate the tuberous sclerosis 
complex 2 (TSC2), which leads to activation of TOR signalling. Importantly, 
constitutive activation of TOR is found in both Nf1-/- Schwann cells and in human 
neurofibromas (Johannessen et al., 2005) and treatment with rapamycin (a TOR 
inhibitor) has been shown to suppress the growth of malignant tumours in a mouse 
model of MPNSTs (Johannessen et al., 2008). However, given that ERK has also been 
found to be capable of phosphorylating TSC2 and consequently, inducing TOR 
activation (Ma et al., 2005), it remains to be clarified if the aberrant TOR signalling 
observed in the absence of Nf1 is a consequence of increased signalling through PI3K, 
   
  60 
ERK or both. 
Inactivation of Ras proteins and termination of the downstream signalling is dependent 
upon GTP hydrolysis by the intrinsic Ras-GTPase activity. However, the intrinsic Ras-
GTP hydrolysis is very inefficient, cleaving GTP at very low rates; GAP proteins, such 
as NF1, facilitate Ras inactivation by binding to Ras and augmenting its GTPase activity 
by several orders of magnitude.  
 
 
Figure 1-11: Ras activation and downstream signals. Ras activation in 
response to growth factors is mediated by RTK activation of adaptor proteins (e.g. Grb2), 
which interact with Ras-GEFs (e.g. Sos). GEFs promote the displacement of GDP, leading to 
binding of GTP and activation of Ras. Activated Ras interacts with a number of effector 
pathways to transduce signals into the cytoplasm and nucleus. Some examples of pathways 
downstream of the best characterized Ras effectors. 
 
NF1, via its GRD domain, inhibits Ras and suppresses Ras-mediated mitogenic signalling 
and is therefore considered a tumour suppressor. In addition to the GRD domain, 
several other domains have been identified and include a tubulin-binding domain 
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(TBD), a cystein/serine rich domain (CSRD), a Sec14 homology domain (Sec14), a 
pleckstrin homology domain (PH) and a nuclear localization sequence (NLS). The TBD 
and CSRD modulate the GAP activity of neurofibromin; binding to tubulin inhibits, 
whereas phosphorylation of CSRD, enhances GAP activity (Bollag et al., 1993; 
Mangoura et al., 2006). Regarding the remaining domains, their function is still unclear. 
Neurofibromin also contains a FAK interacting domain, which may be involved in 
regulating cell adherence (Kweh et al., 2009) (Figure 1-12).  
 
 
Figure 1-12: Schematic representation of the functional domains identified 
in neurofibromin. Several domains have been identified in neurofibromin and include a 
cysteine/serine rich domain (CSRD), a tubulin-binding domain (TBD), a GAP related domain 
(GRD), a Sec14 homology domain (Sec14), a pleckstrin homology domain (PH) and a nuclear 
localization sequence (NLS). The GRD domain is by far the best studied and appears to 
mediate most of neurofibromin’s functions. 
 
 
Neurofibromin also appears to be involved in the regulation of cAMP/PKA pathways. 
Initial work in Drosophila suggested that this effect was independent of Ras activity as 
the phenotypes presented by the Nf1-/- flies, including a growth deficiency, could be 
rescued by increasing signalling through the cAMP-dependent PKA pathway, but not by 
manipulating Ras strength (Guo et al., 1997; Guo et al., 2000; The et al., 1997). 
However, later work by Walker and colleagues has detected aberrant levels of 
activated ERK in Ras2 (paralog of mammalian R-Ras)-expressing larval neurons, 
suggesting that aberrant signalling through Ras was the primary cause of the dNf1-/- 
mutants systemic growth deficiency. Accordingly, the size defects could be rescued by 
expression of a functional NF1-GAP or a Drosophila p120RasGAP ortholog in larval 
neurons (Walker et al., 2006). In agreement with this, a recent report has 
demonstrated that genetic or pharmacological inhibition of the RTK Anaplastic 
Lymphoma Kinase (Alk) (which was found to be located upstream of NF1-regulated 
Ras/ERK signalling) is sufficient to restore normal levels of ERK signalling in neurons of 
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dNf1-/- mutants and, consequently, to rescue the small size phenotype of Nf1-/- flies 
(Gouzi et al., 2011). Together, these studies argued against separable Ras and cAMP-
related functions and, instead, suggested that cAMP/PKA activation occurs 
downstream of Ras signalling. Moreover, the mechanisms through which 
neurofibromin can regulate cAMP dependent signalling seem to be cell-specific, given 
that its loss decreases cAMP levels in astrocytes while increasing them in Schwann cells 
(Dasgupta et al., 2003; Kim et al., 2001). Finally, there is some evidence that 
neurofibromin loss influences calcium signalling (Dang and DeVries, 2005), although the 
domains of the protein involved in this effect are still unknown. Figure 1-13 
summarizes the signalling pathways that have been reported to be affected by 
neurofibromin loss. 
 
Figure 1-13: Pathways deregulated by NF1 loss. Schematic representation of the 
intracellular pathways that seem to be affected by neurofibromin loss and how these may alter 
SC behaviour, ultimately leading to neurofibroma formation. 
 
In terms of the molecular mechanisms regulating neurofibromin expression, only 
limited information is available. In vitro studies have shown neurofibromin is subject to 
rapid and transient proteasomal degradation following growth factor treatment 
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(Cichowski et al., 2003). This prompt degradation of neurofibromin upon activation of 
either G-coupled receptors or receptor tyrosine kinases, appears to be involved in the 
initial activation of the Ras signalling pathway, whereas its rapid-re-expression is 
required for proper attenuation of the pathway. Furthermore, Nf1 deficient cells are 
more sensitive to low concentrations of growth factors, showing Ras activation at 
levels that Nf1wt cells did not respond. Thus, it seems that neurofibromin is required 
for maintaining an appropriate sensitivity to growth factors and for limiting and 
narrowing the period of Ras activation (Cichowski et al., 2003). It is precisely this 
biological function of NF1 that is believed to underlie most clinical presentations of 
NF1 mutations. Importantly, elevated levels of active Ras are detected in NF1-/- 
Schwann cells isolated from neurofibromas (Cichowski and Jacks, 2001; Sherman et al., 
2000) and MPNSTs and have been shown to be critical for the maintenance of a 
transformed phenotype (Basu et al., 1992; DeClue et al., 1992; Kim et al., 1997; Kim et 
al., 1995). Thus, increased Ras activity appears to be important for both the formation 
and maintenance of Schwann cell tumors. 
Although most evidence points to Ras hyperactivation in Schwann cells being the key 
event triggering tumourigenesis in NF1, many questions remain to be answered. These 
include which precise signals are involved in promoting Ras activation during 
neurofibroma formation and which downstream pathways are important in this 
process. Nevertheless, great progress in the understanding of NF1 and neurofibroma 
formation in particular, has been accomplished mostly due to the generation of various 
genetically engineered mouse (GEM) models of NF1. In the next part of this 
introduction I shall review the major existing NF1 models and the key findings that can 
be taken from them also referring, when appropriate, to observations made from the 
analysis of human neurofibromas. 
 
1.9 Mouse models of NF1 
1.9.1 Initial models 
Over the past several years different approaches have been taken to develop models 
for the tumours seem in individuals affected with NF1. The first attempts to directly 
test the role of NF1 in vivo were described independently by the Copeland and 
Weinberg labs in 1994. Both laboratories generated an Nf1 knockout mouse model 
harbouring a targeted mutation in the exon 31 of the Nf1 gene (Brannan et al., 1994; 
Jacks et al., 1994). The heterozygous mice (Nf1+/-) were viable and fertile, but 
disappointingly failed to develop classical features of human NF1 such as neurofibromas 
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or pigmentation defects (Brannan et al., 1994). However, Nf1+/- mice did develop other 
NF1 related symptoms such as learning disabilities. Importantly, these defects were 
later demonstrated to be due to increased ERK activation in inhibitory neurons leading 
to greater GABA release and long-term potentiation (LTP) (Costa et al., 2002; Cui et 
al., 2008; Silva et al., 1997). Critically, genetic or pharmacological inhibition of ERK 
reversed the learning deficits indicating that brain dysfunction in NF1 may be a direct 
consequence of Ras hyperactivation (Costa et al., 2002).  
Furthermore, Nf1+/- mice were prone to tumour development, notably myeloid 
leukaemias and pheochromocytomas, both of which occur with increased frequency in 
NF1 patients (Jacks et al., 1994). Loss of the wild-type allele was commonly found in 
the tumours. Interestingly, the pathogenesis of pheochromocytomas was strain 
specific, as the elevated incidence of these tumours in an Nf1+/- mouse in a mixed 
sv/129xC57BL/6 background disappeared when the mutant allele was bred onto a 
s/129 background (Tischler et al., 1995). 
Otherwise, the heterozygous mice were indistinguishable from wild-type until 12-15 
months of age, when their survival declined sharply due to the development of 
lymphomas, leukemias, lung adenocarcinomas, hepatomas, fibrosarcomas and adrenal 
tumours (Jacks et al., 1994). As these malignancies are also observed in older wild-type 
mice (24 months), this suggested that germline loss of one Nf1 allele accelerated the 
development of tumours for which the mice are already predisposed (Brossier and 
Carroll, 2011).  
The absence of neurofibromas in the Nf1 heterozygous mouse model led to the 
hypothesis that inactivation of the remaining functional Nf1 allele in other cell types, in 
particular Schwann cells, was required for neurofibroma development. However, this 
possibility could not be tested in mice homozygous for the Nf1 null mutation (Nf1-/-) as 
these mice die at day E12.5-E13.5 as the result of cardiac failure (Brannan et al., 1994; 
Jacks et al., 1994). Nevertheless, Nf1-/- mice provided a powerful tool to study the 
effects of neurofibromin loss on Schwann cell function in vitro. 
 
1.9.2 Properties of Nf1 deficient cells 
In accordance with neurofibromin’s role as a Ras-GAP, and similar to human 
neurofibroma-derived Schwann cells, Nf1 null Schwann cells isolated from Nf1-/- mice, 
showed increased Ras activity and refractile morphologies characteristic of Ras 
expressing cells (Kim et al., 1997; Kim et al., 1995). In addition, Nf1 deficient cells 
exhibit functional abnormalities including angiogenic and invasive properties (Muir, 
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1995; Sheela et al., 1990). However, in contrast to the initial expectation that Ras 
hyperactivation would lead to enhanced mitogenesis, Nf1-/- Schwann cells instead 
demonstrated reduced proliferation in response to the mitogenic signal NRG1 or 
axonal contact (Kim et al., 1995). It soon became clear that Nf1 loss leads to 
oncogene-induced senescence (OIS). Similarly, introduction of activated Ras mutants 
into Schwann cells, in the absence of additional insults, induced DNA synthesis 
inhibition and growth arrest, that can only be bypassed through genetic disruption of 
the Rb or p53 pathways (Courtois-Cox et al., 2006; Lloyd et al., 1997; Mathon et al., 
2001; Ridley et al., 1988; Serrano et al., 1997). This, together with the observation that 
human neurofibromas express markers of senescence, may explain the benign nature 
and the growth pattern of these tumours (Courtois-Cox et al., 2006). In humans it has 
been observed that the growth of neurofibromas seems to be self-limited with the 
enlargement periodically stopping and then restarting. In light of these findings one may 
imagine a scenario in which oncogene-induced senescence limits the growth of 
neurofibromas, with periods of growth occurring when tumour cells escape from this 
process via as yet unknown mechanisms (Carroll and Ratner, 2008). Curiously, Nf1 
deficient cells can be induced to hyperproliferate through cAMP-mediated PKA 
activation (Kim et al., 1997), demonstrating how Nf1-/- SC behaviour can be strikingly 
modulated by environmental factors. Importantly, hyperplasia of Nf1-/- mouse Schwann 
cells can be reversed by treatment with inhibitors of Ras farnesylation (a modification 
required for Ras maturation and appropriate localization) (Kim et al., 1997). 
Furthermore, as will be discussed below, progression to malignancy seems to be 
dependent on loss of p53 and/or Rb signalling which underscores the importance of 
OIS in restricting neurofibroma growth. 
 
1.9.3 Nf1 chimeric mice 
In an effort to circumvent the embryonic lethality of Nf1 knockout mice Nf1-/-; Nf1+/- 
chimeras were generated by injecting Nf1-/- embryonic stem cells into Nf1+/- C57BL/6 
blastocysts. Chimeric mice partially composed of Nf1-/- cells survived postnatally and 
developed neurofibromas in spinal nerve roots and peripheral nerves nerve trunks (see 
Figure 1-7, for clarity), reminiscent of human plexiform neurofibromas (Cichowski et 
al., 1999). Importantly the tumours derived exclusively from Nf1-/- cells, indicating that 
complete loss of Nf1 in one or more cell types is rate-limiting and an obligate step in 
neurofibroma formation and explaining the absence of neurofibromas in the 
heterozygous Nf1+/- mice. However, the reasons underlying the fact that inactivation of 
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the second Nf1 allele appears to be a frequent event in humans (NF1 patients are 
heterozygous) and rare in Nf1+/- mice are still unclear, but may involve interspecies 
differences in lifespan, target cell number, proliferative properties or interspecies 
differences in the mutability of the NF1 locus (Cichowski et al., 1999). 
 
1.9.4 Conditional Nf1 knockout mice: the Krox-20 model 
The generation of Nf1-/- chimeras was a major step in our understanding of 
neurofibroma formation. However, given that the chimeras contained multiple cell 
types that were Nf1 null, these experiments were not sufficient to definitively establish 
that loss of neurofibromin in cells of the Schwann cell lineage was sufficient to trigger 
neurofibroma formation. To test if this was the case, the Parada lab generated 
transgenic mice in which floxed Nf1 alleles were conditionally ablated in Schwann cells 
by Cre recombinase under the control of the Krox-20 promoter (a more detailed 
characterization of this technique will be given in chapter 3) (Zhu et al., 2002). 
Surprisingly, Krox-20Cre;Nf1fl/fl mice did not develop any frank tumours, although they 
exhibited microscopic Schwann cell hyperplasia within peripheral nerves. However, 
when Nf1 ablation occurred in an Nf1+/- background (Krox-20Cre;Nf1fl/-) neurofibromas 
developed in peripheral nerve roots with 100% penetrance by one year of age (Zhu et 
al., 2002). These observations, together with the fact that neurofibromas in NF1 
patients are similarly composed of Nf1-/- Schwann cells intermingled with a variety of 
Nf1+/- cells, led to the hypothesis that an Nf1 haploinsufficient tumour 
microenvironment is required to cooperate with neurofibromin loss in Schwann cells 
to drive neurofibroma formation.  
 
1.9.5 Evidence for a role of the microenvironment in neurofibroma 
formation 
The suggestion that Nf1 heterozygous, non-neoplastic cells were required to 
potentiate neurofibroma formation raised the question of which cell types were 
essential for this effect and what were the signalling pathways involved in this 
interaction. As mentioned earlier, neurofibromas are composed not only of neoplastic 
Schwann cells, but of a heterogeneous mixture of other cell types - fibroblasts, 
endothelial cells, mast cells and perineurial-like cells - all of which could be contributing 
to this process. To date, however, the most compelling evidence has come from work 
focusing on mast cells. Initial in vitro experiments have shown that Nf1-/- Schwann cells 
secrete elevated levels of Kit ligand (KitL), a growth factor that activates the c-Kit 
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receptor tyrosine kinase (Yang et al., 2003). In turn, Nf1+/- mast cells show increased c-
Kit receptor expression and enhanced proliferation, migration and survival in response 
to KitL (Chen et al., 2010; Ingram et al., 2000). Additionally, KitL induces mast cell 
secretion of concentrations of the pro-fibrotic transforming growth factor-beta (TGF-
β), a process that is enhanced in Nf1 haploinsufficient mast cells. In response to TGF-β 
both murine Nf1+/- fibroblasts and fibroblasts from human neurofibromas proliferate 
and synthesize excessive collagen, a hallmark of neurofibromas (Yang et al., 2006).  
Recently, Yang and colleagues, in a study using bone marrow transplantation in 
knockout mice, unveiled a crucial role for Nf1+/- mast cells in neurofibroma formation 
in the Krox-20 model. The authors have shown that when Krox-20Cre:Nf1fl/fl mice (that, 
as mentioned earlier do not form tumours) were lethally irradiated and transplanted 
with Nf1+/-  bone marrow they developed multiple neurofibromas that were infiltrated 
by donor mast cells. Furthermore, on the basis that c-Kit receptor activation controls 
the release of mast cells from the bone-marrow (Ingram et al., 2000), the authors 
generated mice harbouring hypoactive Nf1+/- mast cells by intercrossing Nf1+/- mice with 
animals harbouring point mutations in c-Kit receptors (Nf1+/-;cKitW41/W41). When bone 
marrow from these mice was used to replace the lethally irradiated Krox-20Cre:Nf1fl/fl 
no tumours formed, indicating that c-Kit signalling in bone marrow-derived cells is 
critical for neurofibroma development (Yang et al., 2008). Importantly, when Krox-
20Cre:Nf1fl/- mice (that normally form tumours) were transplanted with wild-type bone 
marrow, mast cell recruitment to peripheral nerves was not observed and mice no 
longer developed neurofibromas, pinpointing recruited mast cells as the critical 
haploinsufficient player cooperating with Nf1-/- Schwann cells in this particular mouse 
model (Yang et al., 2008). What remains unclear is exactly what pro-tumourigenic 
effects mast cells perform at the location of the developing tumour and if these effects 
are directed at the Nf1-/- SCs themselves or at any other component of the tumour.  
Furthermore, although it is clear that mast cell recruitment is essential for tumour 
development in the Krox-20 model, it appears that in other neurofibroma models 
other cell components might promote neurofibroma development. In fact, the 
requirement of an Nf1 haploinsufficient tumour microenvironment has been 
subsequently challenged by studies of distinct mouse models of NF1 (discussed below).  
 
1.9.6 The neurofibroma cell of origin  
With the work on the mouse models describe above together with the analysis of  
Nf1-/- Schwann cell properties in vitro, it became evident that the neoplastic cell that 
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gives rise to neurofibromas is derived from the Schwann cell lineage. However, 
precisely which cell type within this lineage undergoes the genetic mutations that 
initiate the tumourigenic process remained unknown. The observation that plexiform 
neurofibromas are often detected at birth, and therefore thought to be congenital had 
raised the possibility that neural crest stem cells or early SC progenitors undergoing 
NF1 loss of heterozygosity (LOH) might be the neurofibroma-initiating cell. Supporting 
this idea, astrocytomas that developed in an NF1-related mouse model 
(NestinCreER;Nf1fl/fl;p53fl/fl ) were shown to originate from neural stem cells (Alcantara 
Llaguno et al., 2009). In contrast, arguments favouring an adult, differentiated SC origin 
also existed. These included the unusual ability of fully differentiated cells to revert to a 
dedifferentiated phenotype with proliferative capabilities, the lack of a known stem cell 
population that can give rise to SCs in the adult organism and the observation that the 
majority of cells within neurofibromas retain a SC phenotype (Parrinello and Lloyd, 
2009). In 2008 three independent groups have addressed whether neurofibromas arise 
from embryonic stem cells or a differentiated population, by generating conditional 
mouse models in which Nf1 ablation in Schwann cells was induced at different stages of 
development (Joseph et al., 2008; Wu et al., 2008; Zheng et al., 2008). 
 
Neural crest cells are not rendered tumourigenic by Nf1 loss 
As noted earlier, NCSCs terminally differentiate by late gestation and cannot be 
detected post-natally in peripheral nerves (Kruger et al., 2002). Nonetheless, Nf1 loss 
during earlier embryogenesis could render NCSCs tumourigenic, leading to a sustained 
expansion of these cells and their postnatal persistence such that they can give rise to 
tumours in the adult. To test this hypothesis Joseph and colleagues analysed the 
frequency of Schwann cell progenitors with stem cell properties in the embryonic and 
postnatal PNS in mice in which Nf1 was inactivated in neural crest cells using 
WntCre;Nf1fl/- mice (Wnt is expressed by E9.5 migrating neural crest cells - (Gitler et 
al., 2003)). Importantly, they found that, although Nf1 loss induced a transient increase 
in the number of NCSCs in most regions of the fetal PNS at E13, their numbers 
decreased progressively in later stages of embryogenesis and could no longer be 
detected post-natally. These findings suggested that Nf1-deficient NCSCs differentiate 
during late gestation in a similar manner as wild-type NCSCs. WntCre;Nf1fl/- mice died 
at birth so it remains to be tested if SCs derived from Nf1-/- NCSCs can give rise to 
tumours. Nevertheless, E13 NCSC/SCPs isolated from Nf1-/- mice could not form 
tumours when engrafted in the sciatic nerves of Nf1+/- mice (Joseph et al., 2008), 
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indicating that NCSCs are not rendered tumourigenic by Nf1 deficiency and thus 
suggesting that more differentiated cells are the targets for tumourigenesis. 
 
Nf1 loss in Schwann cell precursors gives rise to neurofibromas later, in adulthood 
In parallel studies Nf1 deletion in Schwann cell precursors at E12.5 using a P0aCre 
driver (P0 expression begins at E12.5 and is restricted to SCPs) was shown to result in 
the development of neurofibromas in adult nerve trunks by 15-20 months (Joseph et 
al., 2008; Zheng et al., 2008). This was in contrast with the previous Krox20-Nf1fl/- 
model that developed tumours in the nerve roots and never in the nerve trunks (see 
Figure 1-7 to note the differences between nerve trunks and nerve roots). Possible 
reasons for this discrepancy include the different origins of SCs in both regions of the 
peripheral nerves. As noted earlier, whilst Schwann cells in the nerve roots originate 
from boundary cap cells that express Krox-20 at E10.5, SCs in the nerve trunks 
originate from SCPs that express P0 at E12.5 and Krox-20 at E15.5 (immature SCs). 
Therefore the distinct locations of the tumours in both models led to the suggestion 
that Nf1 loss in boundary cap cells at E10.5 induces neurofibromas in nerve roots, 
whereas Nf1 loss in SCPs at E12.5 drives neurofibroma formation in the nerve trunks. 
The observation that Nf1 loss at the stage of immature SCs (E15.5) did not lead to 
tumour formation, raised the possibility that the timing of Nf1 inactivation was the key 
determinant of neurofibroma formation, with Nf1 loss being restricted to a window of 
opportunity (NCSC-SCP) and that more differentiated cells were not susceptible to 
undergo tumourigenesis by Nf1 loss.  
The attempt to isolate Nf1-/- stem cells from adult P0aCre;Nf1fl/- animals that developed 
neurofibromas failed once again, suggesting that the tumours were not the result of 
the presence of Nf1-deficient NCSCs. Instead, analysis of the neurofibromas in this 
mouse model revealed that the majority of proliferating cells within neurofibromas 
lacked markers characteristic of primitive SC progenitors (e.g. BLBP) and, rather, 
expressed markers of adult non-myelinating/dedifferentiated Schwann cells such as p75 
and GFAP. Together, these findings argued against a classical stem cell origin of 
neurofibromas and rather suggested that neurofibromas were being driven by 
proliferation of mature SCs (Joseph et al., 2008).  
Interestingly, analysis of post-natal nerves from P0aCre;Nf1fl/- animals revealed that 
embryonic loss of Nf1, despite giving rise to tumours in the adult animals, did not 
automatically alter the mitogenic or differentiative abilities of SCs (Joseph et al., 2008; 
Zheng et al., 2008). Instead, Schwann cells in P0aCre;Nf1fl/- mice developed normally 
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and were present in the correct numbers in neonatal nerves (Zheng et al., 2008). This 
was particularly surprising given that elevated levels of Ras/ERK, which would be 
expected to result from Nf1 loss, have been consistently shown to induce Schwann cell 
dedifferentiation and proliferation (Harrisingh et al, 2004; Napoli et al., 2012). This led 
us to propose that during SC differentiation other mechanisms are in place, that 
regulate Ras/ERK signalling to ensure that the right levels of ERK are achieved (this will 
be further discussed in chapter 6). 
Thus, based on these studies it seemed that Nf1 deficiency did not directly affect the 
stem/precursor cells that had undergone Nf1 loss, but instead it somehow conferred 
the downstream/differentiated progeny with aberrant properties that ultimately led to 
uncontrolled proliferation and tumour formation. Possible explanations of how 
embryonic Nf1 loss may drive tumourigenesis in the adult will be discussed below.    
In agreement with this window of opportunity for tumour development an 
independent study by Wu and co-workers showed that when Nf1 is ablated at the 
same developmental stage (E12.5) using a Dhh driven Cre recombinase (expressed by 
E12-5 in both SCP and boundary cap cells), it also resulted in rapid and extensive 
neurofibroma formation, causing high morbidity and mortality by 13 months of age 
(Wu et al., 2008). However, tumours developed at the nerve roots, but not in the 
nerve trunks, suggestive of a boundary cap cell of origin rather then an SCP origin. 
Nevertheless, although no full blown tumours developed at nerve trunks, they did 
show hyperplasia and axonal dissociation that, as will be discussed below, were the 
first neoplastic events detected in the P0aCre;Nf1fl/- model (Wu et al., 2008; Zheng et 
al., 2008). It is thus plausible that had the mice not developed tumours in the nerve 
roots and hence survived longer (the tumours developed much more rapidly and 
extensively in this mouse model compared to P0aCre;Nf1fl/- animals) neurofibromas 
would have also eventually developed in the limb nerves.  
Importantly, in contrast to the Krox-20 model in which the development of tumours 
only occurred in the context of an heterozygous (Nf1+/-) background (there is no 
available information on the phenotype of the P0aCre;Nf1fl/fl animals), in the 
DhhCre;Nf1fl/fl mice, neurofibroma development occurred independently of an Nf1 
haploinsufficient microenvironment. This may be particularly relevant in the 
pathogenesis of the sporadic neurofibromas that arise in patients without NF1. 
Analysis of the neurofibromas that developed in this mouse model revealed additional 
differences in comparison with the P0aCre;Nf1fl/fl models. In particular, the molecular 
profile of the tumour cells was distinct - exhibiting immunoreactivity for BLBL, a 
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marker of progenitor cells that was not detected in the tumours of the previous 
models, supporting the idea that the plexiform neurofibromas that developed in both 
mice have different origins (SCPs versus BCCs).  
In summary, these models suggested that although the apparent requirement for 
embryonic loss of Nf1 (NCSC/SCP), Nf1-/- embryonic Schwann cells differentiate 
normally into mature SCs that later in life become the neurofibroma initiating cells. 
Importantly, Nf1 loss at the immature SC stage did not give rise to tumours, suggesting 
that these more differentiated cells are no longer susceptible to become tumourigenic 
by Nf1 depletion. In addition, it also suggested that different neurofibromas, despite 
their similar composition, may derive from distinct cells within the SC lineage of origin. 
This is in agreement with the extreme variability seen in human patients with NF1 and 
raises the tempting speculation that the timing of Nf1 loss may affect the severity of 
the clinical manifestations with Nf1 inactivation in earlier SC precursors leading to the 
most severe phenotypes (Parrinello and Lloyd, 2009). 
 
1.9.7 Mouse model of dermal neurofibromas 
The idea that distinct cells within the SC lineage could give rise to neurofibromas was 
further supported by a study focused on the development of dermal tumours (Le et al., 
2009). In fact, despite the histological similarities shared between dermal and plexiform 
neurofibromas, the distinct location and clinical behaviour of these different 
neurofibromas had already raised the question of whether the cell of origin of dermal 
tumours is distinct from the population that gives rise to plexiform neurofibromas. 
Contributing to this supposition, the P0 and Krox-20 models failed to develop dermal 
neurofibromas, although efficiently developing plexiform tumours.  
With this idea in mind, Le and colleagues proposed that dermal neurofibromas may 
arise from a neural crest-derived adult progenitor cell known as skin-related neural 
precursor cells (SKP) (Fernandes et al., 2008). SKPs can be isolated from the dermis of 
adult mice and humans and in vitro, can be induced to self-renew and differentiate into 
glial, neuronal and melanocytic lineages (Fernandes et al., 2008). To test the idea that 
SKPs can be the source of neoplastic SCs within dermal neurofibromas, the authors 
isolated SKPs from the skin of CMVCreER;Nf1fl/- mice (in this mouse model, Nf1 is 
ubiquitously recombined upon Tamoxifen administration) and then, in vitro, induced 
their recombination. Subsequently, Nf1 recombined SKPs were transplanted back into 
the same heterozygous host. The authors observed that these cells formed tumours 
when transplanted in the dermis of pregnant recipients or when implanted in the 
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proximity of the sciatic nerve (Le et al., 2009). The reasons underlying the fact that 
tumours only formed in these two contexts were not further investigated, but likely 
involve the critical importance of the microenvironment during neurofibroma 
formation. In addition, Le and colleagues applied Tamoxifen topically onto the skin of 
CMVCreER;Nf1fl/- animals to induce Cre recombination in vivo and observed that this led 
to local dermal neurofibroma formation. However, this protocol induces Nf1 
recombination in all the cell types in the skin (including SCs in the peripheral nerves). 
Therefore, until an SKP-specific promoter is generated to allow targeted disruption of 
Nf1 in these cells, it can only be concluded that the cell of origin of dermal 
neurofibromas resides in the skin. Nevertheless, dermal neurofibromas also arose in 
the DhhCre;Nf1fl/fl model and Dhh is also expressed by SKPs (Fernandes et al., 2004; 
Wong et al., 2006), supporting the idea that dermal and plexiform neurofibromas may 
derive from different progenitors. However, attempts to define differences in the 
transcriptomes of dermal and plexiform neurofibromas have thus far been unsuccessful 
(Carroll, 2011; Miller et al., 2009), suggesting that even if the cell of origin is distinct in 
both tumours, they share similar subsequent molecular and cellular events that 
culminate in tumourigenesis. A summary of all the mouse models described, the 
promoters used to drive Nf1 loss and the major phenotypes generated, is depicted in 
Figure 1-14. 
 
Relevance to human disease 
While the models described may be a relatively faithful representation of some of the 
neurofibromas that develop in NF1 patients (particularly those that develop in early 
life), it likely does not cover all the mechanisms of tumourigenesis experienced by 
humans. The hypothesis that neurofibromas might develop from mutations occurring 
in even more differentiated SCs is backed up by the finding that multiple tumours 
within the same patients exhibit different somatic mutations (Thomas et al., 2010). 
Hence, at least in some NF1 patients, it seems that different tumours have resulted 
from independent loss of heterozygosity (LOH) events. If the loss of the second Nf1 
allele had occurred in early SC progenitors one might expect that the same somatic 
mutations was found in different tumours, which does not seem to be the case.  
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Figure 1-14: Susceptible stages for neurofibroma formation. Schematic 
representation of multiple GEM models generated to ablate Nf1 at different stages of SC 
development; the promoters used to direct recombination, the target cells and the main 
phenotypes achieved are represented.  
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1.9.8 Mouse models of malignant peripheral nerve sheath tumours 
Before discussing possible mechanisms that may be involved in triggering the 
development of neurofibromas in the mouse models described, I will briefly review 
available models of MPNSTs. In contrast with the human condition in which the 
frequency of plexiform neurofibromas progressing to MPNSTs is relatively high, in 
mouse models malignant tumours only rarely develop from pre-existing plexiform 
neurofibromas. This probably reflects the fact that mice that develop large plexiform 
neurofibromas have to be sacrificed, thus precluding the study of the natural 
progression of these tumours. Furthermore, the significantly shorter lifespan of a 
mouse may reduce the window of opportunity for acquisition of additional mutations 
in Nf1-/- SCs required to drive MPNST formation. In order to overcome this limitation, 
mice harbouring mutations in different tumour suppressor genes in addition to Nf1 
deficiency were created. As stated earlier, Ras hyperactivation in SCs leads to growth 
arrest that can be overcome by inhibition of the p53 function. With this observation in 
mind the Jacks and Parada laboratories bred mice heterozygous for Nf1 to mice 
heterozygous for p53 (Cichowski et al., 1999; Vogel et al., 1999). As these genes are 
both located on mouse chromosome 11, trans and cis Nf1+/-;p53+/- animals were 
generated, with the latter, as might be predicted, exhibiting a more severe phenotype 
and developing MPNSTs in approximately 30% of the cases. Importantly, LOH at both 
Nf1 and p53 loci was identified in all the MPNSTs developed in these mouse models, 
suggesting that the complete loss of both genes cooperates in the formation of these 
lesions. MPNSTs also formed when Nf1+/- mutants were crossed with p16Ink4a-/-; 
p19Arf -/- animals. However, when Nf1+/- mice were crossed with either p16 null or p19 
null alone no tumours formed, indicating that deregulation of both products encoded 
by CDKN2A (the locus containing both p16INK4a and p19ARF genes) and thus 
deregulation of p53 and Rb pathways, is required to promote MPNSTs in the context 
of Nf1 heterozygosity (Joseph et al., 2008; King et al., 2002). Importantly, mutations in 
p53 and in the CDKN2A genes are commonly found in human MPNSTs (Birindelli et 
al., 2001; Kourea et al., 1999; Menon et al., 1990; Nielsen et al., 1999).  
Malignant peripheral nerve sheath tumours and neurofibromas are histologically 
distinct with the first displaying reduced expression of genes involved in SC 
specification and differentiation, such as Sox10 and S100, whilst presenting elevated 
expression of markers characteristic of migrating neural crest such as Twist1 and 
Sox9. This likely reflects loss or suppression of SC differentiation signals and is 
probably an important step in the progression of neurofibromas into MPNSTs (Joseph 
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et al., 2008; Levy et al., 2004; Miller et al., 2009; Miller et al., 2006).  
 
1.10 Insights into neurofibroma formation 
Early events of tumourigenesis 
As mentioned, embryonic loss of Nf1during embryogenesis leads to tumour formation 
in the adult mice, despite not causing a detectable immediate effect in early Nf1-/- 
Schwann cell behaviour. Instead, at birth, Schwann cells are found in the right numbers 
and without any major differentiation defects. So how can they form tumours later in 
life? A possible explanation came from a closer examination of the P0Cre:Nf1fl/- mutant 
nerves in the early post-natal period. As noticed by Zheng and colleagues, Nf1 
deficiency, although not inducing hyperproliferation or tumourigenesis in early life, did 
result in a subtle defect in the segregation of axons associated with non-myelinating 
Schwann cells, in that Remak bundles displayed an increased number of unsorted 
axons. Over time subsequent degeneration of abnormal Remak bundles occurred, 
leading to the dissociation of nmSC that, once devoid of axonal contact, re-entered the 
cell cycle and hyperproliferated. It is thus plausible that embryonic loss of Nf1 is 
necessary to prime non-myelinating SCs for later tumourigenesis by disrupting the 
normal interactions between axons and SCs. At later stages, probably in response to 
the degeneration of naked axons and dedifferentiated nmSCs, there is the recruitment 
of an inflammatory response with extensive mast cell infiltration and dedifferentiation 
of mSCs, reminiscent of what happens during injury. However, unlike injury that is 
generally a self-limited process, inflammation and SC dedifferentiation in Nf1-/- nerves 
appears to be perpetuated, and in that way contributes to neurofibroma formation 
(Parrinello and Lloyd, 2009). 
 
Ras/Ras/ERK signalling and neurofibroma formation 
How does neurofibromin loss induce the cellular events that culminate in 
neurofibroma formation? Some insight of how this may be happening came from work 
in our laboratory. Using a DRG-SC co-culture system we have shown that the ERK 
activation resulting from Nf1 loss is sufficient to impair SC-axon interactions, via a 
mechanism dependent on the ERK-mediated downregulation of the Schwann cell 
surface molecule Semaphorin4F (Sema4F) (Parrinello et al., 2008). Importantly, we 
have also shown that, in contrast to Nf1 wild-type cells that become quiescent upon 
establishing a more stable interaction with the axons, Sema4F knocked-down cells 
readily proliferated in response to external mitogens, even after establishing long-term 
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contact with axons (Parrinello et al., 2008). This, together with the fact that 
Ras/Raf/ERK activation in Schwann cells drives differentiated cells to revert to a more 
”progenitor-like”, proliferative state, led us to delineate a model of neurofibroma 
formation. In this model we proposed that the increased Ras/Raf/ERK signalling that 
results from Nf1 loss leads to Sema4F downregulation; this may be initially involved in 
the defective nmSC-axon interaction and the later dissociation from axons. 
Dissociated cells, freed from the growth-suppressive signals coming from the axons, 
are able to respond to external growth factor signals (that may be produced by 
inflammatory cells or other components of the nerve microenvironment). Dissociated 
Nf1-/- Schwann cells respond to external signals with an abnormal and sustained 
Ras/ERK activation (due to the lack of neurofibromin), which as shown by Napoli et al., 
is sufficient to induce SC dedifferentiation. Dedifferentiated SCs secrete pro-
inflammatory factors that recruit inflammatory cells (Napoli et al., 2012). These, in 
turn, actively secrete factors that stimulate Ras/ERK in Schwann cells, which may 
contribute to the perpetuation of cycles of SC dedifferentiation/proliferation and 
recruitment of an inflammatory response, which ultimately leads to neurofibroma 
formation (Parrinello and Lloyd, 2009). Figure 1-15 shows a schematic representation 
of the proposed model of neurofibroma formation. 
 
This model hinges on the assumption that adult SCs are strictly dependent on 
neurofibromin to properly regulate Ras/Raf/ERK signalling. This implies that different 
signals inducing Ras activation in Nf1-/- SCs may represent possible triggers to 
tumourigenesis by inducing abnormal SC dedifferentiation and proliferation.  
To test this model we decided to 1) generate a new mouse model in which Nf1 loss 
could be induced in fully differentiated myelinating SCs, testing the susceptibility of fully 
differentiated cells to foster tumour formation; 2) activate Ras/ERK in adult Nf1-/- 
Schwann cells, by means of nerve injury, to test if strong signalling through the pathway 
can modulate the fate of an Nf1-/- Schwann cell (Figure 1-16).  
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Figure 1-15: Model of neurofibroma initiation and progression. Slightly 
elevated levels of Ras resulting from Nf1 loss in SCPs, leads to unstable Remak bundles. Later 
in life, low levels of Sema4F secondary to elevated Ras/ERK may lead to Remak bundle 
disruption and subsequent axonal degeneration. This leads to the recruitment of an 
inflammatory response that in turn induces elevated ERK in myelinating SCs that then 
dedifferentiate and proliferate also contributing to neurofibroma development (adapted from 
Parrinello and Lloyd 2009). 
 
 
1.11 Thesis aims 
Schwann cells are highly plastic cells that retain the ability to self-renew throughout 
adult life. Underlying this remarkable ability there is a Ras/Raf/ERK driven process 
through which fully mature differentiated SCs revert to a dedifferentiated  
“progenitor-like” state that is able to undergo proliferation. This is of great importance 
following nerve injury when dedifferentiated SCs proliferate creating a suitable 
environment for axonal regrowth. Deregulation of this process seems, however, to be 
involved in pathological conditions, as abnormally dedifferentiated SCs are found in 
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neurofibromas, a very common tumour arising in patients with NF1. Importantly, 
neurofibroma formation appears to be somehow driven by Ras hyperactivation as 
tumours only form upon complete loss of neurofibromin, a negative regulator of Ras 
signalling. Important insights into the biology of neurofibromas have already been taken 
from diverse mouse model of NF1. However, many questions remain to be solved. In 
this thesis, I aimed to solve some of the unanswered questions, by addressing the 
effects of Nf1 loss in fully mature SCs and the impact of nerve injury and the associated 
Ras/ERK activation in Nf1-deficient nerves. This thesis describes work with relevant 
implications not only for the understanding of neurofibroma development and the 
signalling pathways involved, but also for possible therapeutic strategies.  
 
 
 
 
Figure 1-16: Main questions addressed in this thesis. A) Testing the effect 
of Nf1 loss in a fully differentiated, myelinating Schwann cell. B) Testing the effect of injury in 
the context of Nf1-/- Schwann cells. 
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Chapter 2: Materials and methods 
2.1 Materials 
Reagents were obtained from Sigma, unless otherwise stated. Al kits were used 
according to manufactures instructions. 
 
2.1.1 Primers for genotyping 
Gene name Sequence (5’-3’) 
Nf flox 
 
(P1) CTT CAG ACT GAT TGT TGT ACC TGA  
(P3) ACC TCT CTA GCC TCA GGA ATGA 
(P4) TGA TTC CCA CTT TCT GGT TCT AAG 
Nf1 +/- 
 
(NF31a) GTA TTG AAT TGA AGC ACC TTT GTT TGG 
(NeoTkp) GC GTG TTC GAA TTC GCC AAT G 
(NF131b) CTG CCC AAG GCT CCC CCA G 
Nf1Δ 
(P1) CTT CAG ACT GAT TGT TGT ACC TGA 
(P2) CAT CTG CTG CTC TTA GAG GAA CA 
P0-CreER 
 
(Pcx) CTG CAC AGA CAT GAG ACC ATA GG 
(Cre)TCG GAT CCG CCG CAT AAC C 
YFP(R26)  
wt 
(PR26-F) AAA GTC GCT CTG AGT TGT TAT 
(PR26-R) GGA GCG GGA GAA ATG GAT ATG 
YFP(R26) 
mutant 
(PR26-F) AAAGTC GCT CTG AGT TGT TAT 
(PR26-Rmut) GCG AAG AGT TTG TCC TCA ACC 
Table 2-1 Primers used for mice genotyping 
2.1.2 siRNA oligos 
Gene Target sequence Cat No. 
NF1 (3) 5’-CAAGCTAGAAGTGGCCTTGTA -3’  SI01919505 
NF1 (5) 5’-TGGCCTAAGATTGACGCTGTA -3’  SI01919512 
Dusp6 (1) 5’- CACGGATATTATGATCACTAA-3’ SI00278271 
Dusp6 (5) 5’-CTCCCTGCAATCTACGTGAAA-3’ SI03089835 
Scram 5’-AATTCTCCGAACGTGTCACGT-3’ S1022563 
Table 2-2 siRNA oligos 
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2.1.3 Primers for qPCR 
Gene name Forward/Reverse Sequence 
B2M 
 
Forward 
Reverse 
TGACCGTGATCTTTCTGGTG 
ATTTGAGGTGGGTGGAACTG 
K20 
 
Forward 
Reverse 
TGACCGTGATCTTTCTGGTG 
ATTTGAGGTGGGTGGAACTG 
P0 
 
Forward 
Reverse 
CTGGTCCAGTGAATGGGTCT 
CATGTGAAAGTGCCGTTGTC 
MBP 
 
Forward 
Reverse 
CACAAGAACTACCCACTACG 
GGGTGTACGAGGTGTCACAA 
Table 2-3 Primers used in qPCRs 
 
 
 
2.1.3 shRNA oligos 
Construct Target sequence 
Top strand/Bottom strand 
shScr TGCGTTGCTAGTACCAACT 
shMKP3-2 GTGCCAAGGACTCTACTAA 
5'-gatccGTGCCAAGGACTCTACTAATTCAAGAGATTAGTAGAGTCCTTGGCACTTTTTTACGCGTg-----3' 
5'-aattcACGCGTAAAAAAGTGCCAAGGACTCTACTAATCTCTTGAATTAGTAGAGTCCTTGGCACg-----3' 
shMKP3-5 AGGGGAGTTCAAGTACAAG 
5'-gatccAGGGGAGTTCAAGTACAAGTTCAAGAGACTTGTACTTGAACTCCCCTTTTTTTACGCGTg-----3' 
5'-aattcACGCGTAAAAAAAGGGGAGTTCAAGTACAAGTCTCTTGAACTTGTACTTGAACTCCCCTg-----3' 
shMKP3-9 CCTCCAACCAGAATGTCTA 
5'-gatccGCCTCCAACCAGAATGTCTATTCAAGAGATAGACATTCTGGTTGGAGGTTTTTTACGCGTg-----3' 
5'-aattcACGCGTAAAAAACCTCCAACCAGAATGTCTATCTCTTGAATAGACATTCTGGTTGGAGGCg-----3' 
Table 2-4 shRNA oligos 
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2.1.4 Antibodies 
Table 2-5 Primary antibodies 
 
 
 
Primary antibody Species Dilution Source 
Immunofluorescence/ Immunohistochemistry 
P0 (myelin protein zero) Mouse 1:1000 Astex Clone 18 
p75NGFR Rabbit 1:500 Millipore 07-476 
Chicken 1:400 Abcam ab13970 
GFP 
Rabbit 1:2000 Abcam ab290-50 
Chicken 1:1000 Abcam ab4680 
Neurofilament 
Rabbit 1:2000 Millipore ab1987 
P-ERK1/2 Rabbit 1:100 Cell signalling 9191S 
S100β Rabbit 1:1000 DAKO Z0311 
Smooth alpha actin (SMA) Mouse 1:100 Sigma A5228 
Iba-1 Rabbit 1:10000 WAKO 019-19741 
CD-117 (c-Kit) Rat 1:300 BDpharmigen 553356 
CD3 Biotin 1:300 BDpharmigen Cl.125-2C11 
NIMP-R14 Rat 1:300 Abcam ab2557 
Collagen I Rabbit 1:1000 Abcam ab292 
Collagen IV Rabbit 1:1000 Abcam ab19808 
Laminin1 Rabbit 1:2000 Abcam ab11575 
Western blotting 
NF1 Rabbit 1:100 Santa Cruz sc-67 
P-ERK1/2 Mouse 1:1000  Sigma M8159 
ERK1/2 Rabbit 1:10000 Sigma M5670 
MKP3 Rabbit 1:500 Cell signalling 3058 
beta-tubulin Mouse 1:2000 Sigma T4026 
Vinculin Mouse 1:1000  Sigma V9131 
DNA dyes       
DAPI  1:100  
Hoechst   1:2000  
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Table 2-6 Secondary antibodies 
 
 
2.2 Animals 
All animal work was performed in accordance with the United Kingdom Home Office 
legislation. Mice were housed in a temperature and humidity controlled vivarium on a 
12-hour light-dark cycle with free access to food and water. 
 
 
2.2.1 Mouse strains 
Nf1flox/flox (Zhu et al., 2001) and Nf1flox/- (Jacks et al., 1994) on a mixed 129/Bl/6 
background were crossed with P0CreER C57Bl/6 mice to generate P0-Nf1fl/fl and P0-
Nf1fl/- mice (Leone et al., 2003). P0-Nf1fl/fl and P0-Nf1fl/- mice were bred to lacZRosa 
(Soriano, 1999) and to  YFPRosa (Srinivas et al., 2001).  
 
 
 
Secondary antibody Species Dilution Source 
Immunofluorescence/ Immunohistochemistry 
Mouse 1:500 
Invitrogen -Molecular Probes 
A11032 Alexa-Fluor 594 
Rabbit 1:500 
Invitrogen -Molecular Probes 
A11012 
Chicken  1:500 
Invitrogen -Molecular Probes 
A11039 
Mouse 1:500 
Invitrogen -Molecular Probes 
A1029 
Rabbit 1:500 
Invitrogen -Molecular Probes 
A11034 
Alexa-Fluor 488 
 
Rat 1:500 
Invitrogen -Molecular Probes 
A11006 
IgY Texas Red Chicken 1:500 Abcam 7116 
Streptavidin-FITC Biotin 1:500 
Invitrogen -Molecular Probes 
S32354 
Western blotting 
Mouse 1:5000 GEhealthcare NA9340 
Anti-HRP 
 Rabbit 1:5000 GEhealthcare NA9310  
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2.3 Cell culture 
2.3.1 Primary Schwann cells 
Primary Schwann cells were isolated from postnatal 7 (P7) Sprague Dawley rat sciatic 
and brachial nerves as previously described (Cheng et al., 1995) and maintained on 
poly-L-lysine (2,4µg/ml) [Sigma P-6282] coated plastic dishes [Nunc]. Cells were 
routinely cultured in DMEM [Lonza 12-707, 1g/l glucose] supplemented with 3% 
charcoal stripped foetal calf serum [Biosera], 4mM L-glutamine [Gibco 25030], 
0,1mg/ml kanamycin [Sigma K1377], 2µg/ml gentamycin [Gibco 15710], 1µg/mL 
forskolin [Calbiochem 344270] and GGF produced in our laboratory. Cell cultures 
were maintained at 37ºC in 10% CO2 and 95% humidity. Medium was changed every 
two days and cells were passaged every three days. Schwann cells were routinely 
plated at a density of 4,8 x105 cells per 10cm dish. 
 
2.3.2 Rat Dorsal Route Ganglion (DRG) explants 
DRG were extracted from P0 or P1 Sprague Dawley rats and stored in ice cold L-15 
[Gibco 11415-064] media. DRG were then plated into the centre of PLL and laminin-
coated [25µg/ml, Sigma] glass-coverslips (13mm) in 200µl of defined basal media 
supplemented with 50ng/ml of NGF [Alomone labs N-245]. The defined basal media 
consisted of DMEM F-12 with glucose [Gibco 21041-025] complemented with SATO 
(100µg/mL BSA [Gibco], 60 ng/ml progesterone, 16µg/ml putrescine, 50 ng/ml 
thyroxine, 50 ng/ml triidothyrine and 40ng/ml selenium), 10µg/ml insulin [Lonza] and 
100µg/ml transferrin [Calbiochem]. Following overnight incubation at 37ºC and 5% 
CO2, DRG were treated with 10
-5M β-D-arabinosylcytosine (AraC), a DNA synthesis 
inhibitor, to eliminate endogenous Schwann cells and fibroblasts. After 48 hours of 
AraC treatment, cultures were medium changed into defined conditions for a further 
72 hours before use.  
 
2.3.3 Phoenix cell culture  
The retroviral packaging line, Phoenix [Nolan lab, Stanford University] was used to 
introduce genetic material into Schwann cells, as described below. Phoenix cells were 
maintained on uncoated plastic dishes, in DMEM+GlutamaxTM [Gibco 31966, 4.5mg/ml 
D-glucose] supplemented with 10% foetal bovine serum (FBS) [Sigma], 0,1mg/ml 
kanamycin [Sigma K1377] and 2µg/ml gentamycin [Gibco 15710]. Before seeding, cells 
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were passaged through an 18G needle, to ensure an even distribution on the plate. 
Cells were incubated at 37ºC in 10% CO2 and 95% humidity.  
 
2.4 Cell culture assays 
2.4.1 Schwann cell differentiation assays 
Primary Schwann cells were cultured to confluence, washed three times with serum 
free defined medium and transferred to defined medium alone or containing 1mM 
dbcAMP [Sigma] to induce differentiation, for the duration of the experiment. Defined 
medium consisted of DMEM with glucose, supplemented with SATO (described 
above), 10µg/ml insulin [Lonza] and 100µg/ml transferrin [Calbiochem]. In some of the 
experiments, shorty before harvesting (see Chapter 6 for details) cultures were 
stimulated with 20ng/ml of human recombinant neuregulin (EGF domain) [R&D 
Systems]. 
 
2.4.2 Myelinating Schwann cell-DRG co-cultures 
Sub-confluent Schwann cells were trypsinised and re-suspended in Schwann cell 
medium (3 % serum) to inhibit trypsin activity. The cells were then centrifuged at 1100 
rpm to pellet and re-suspended in DRG defined basal medium containing NGF 
(detailed above) and 1% of serum. The number of cells was determined using a coulter 
counter [Beckman Coulter]. 60 000 cells/per coverslip (in a final volume of 400µl) 
were plated onto the dissociated DRG. Co-cultures were medium changed every 48 
hours into fresh DRG medium plus 1% serum, for a total period of 7 days. After 7 
days, when Schwann cells reached confluence, co-cultures were medium changed into 
myelination promoting medium (defined DRG medium plus 50µg/ml ascorbic acid, 1% 
serum and 1:300 matrigel [R&D 356231]). Cultures were left to myelinate for up to 3 
weeks and fed every 2-3 days with fresh myelination medium.  
 
2.4.3 Transfection of siRNA into Schwann cells 
Schwann cells were plated on 60mm dishes at a density of 220, 000 in SC medium (3% 
serum). The following day, cells were medium changed with 2,3 ml of fresh SC medium 
and transfected with siRNA duplexes. SiRNA stocks were diluted from 20µM (stock 
solution) to a concentration of 0,2µM (2µL of stock solution plus 198µL of plain 
DMEM). SiRNA/lipid complexes were then prepared by the sequentially adding 88µL 
DMEM + 12µL sRNA working solution (0,2µM) + 6µL Hiperfect solution [Qiagen]. 
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Complexes were allowed to form by incubating the mixture for 10 minutes at room 
temperature. SiRNA/lipid complexes were then added directly to the 60mm dishes and 
incubated overnight (final concentration of approx. 1nM of siRNA). Medium was 
changed 18 hours later, to remove transfection complexes. A second round of 
transfections was performed 48 hours following the first, to achieve an extended 
period of knockdown. 
 
2.4.4 Generation of shRNA expressing SCs by Phoenix infection 
Five million Phoenix cells were seeded on a 10cm plate for each transfection and left 
ON at 37ºC. Five µg of plasmid DNA (pSIREN-RetroQ vector + shRNA- see 2.4.5) 
was mixed with 500µl of serum free medium, followed by 17.5µl of PLUSTM [Invitrogen 
18324-012] and left at room temperature for 15 minutes. A separate tube was 
prepared for each of the constructs. In fresh tubes, 25µL of Lipofectamine reagent 
[Invitrogen 11514-015] was mixed with 500µl of serum free medium and the DNA/ 
PLUSTM mix from the previous step. The transfection mixture was left for further 15 
minutes at room temperature to allow DNA/lipid complexes to form. Medium on 
Phoenix cells was replaced by 4ml of serum-free medium per plate, washing once with 
serum-free medium. The DNA/lipid complexes were then carefully added dropwise to 
the Phoenix plate, gently mixed and incubated at 37ºC, 10% CO2. Four hours later, the 
transfection medium was removed and replaced with normal Phoenix medium. 
Medium was again replaced after 24 hours with 6ml of fresh medium and the cells 
were left ON to produce the virus. Five ml of viral supernatant was then collected 
from each plate, polybrene [Sigma H9268] was added at a final concentration of 8µg/ml 
and the solution was filtered to remove cellular debris before adding to the sub-
confluent SC plates. Phoenix cells were topped up with an extra 5ml of fresh medium 
to continue virus production. Schwann cells (which had been plated at a density of 
6x105 cells per 10 cm dish the previous day) were incubated for 3 hours with the viral 
supernatant, then left to recover ON in normal 3% medium. Twenty-four hours later, 
a second 3-hour infection was carried as just described. Infected cells were left to 
recover for 2 days in normal medium and then cultured for 6 days in medium 
containing puromycin (1µg/ml), to remove non-vector expressing cells. Selective 
medium was replaced every 2-3 days.  
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2.4.5 shRNA oligos design and vector cloning 
ShRNA oligos targeting MKP3 were design using the Clontech RNAi designer 
(http://bioinfo.clontech.com/rnaidesigner/sirnaSequenceDesign.do). Briefly, the online 
program designs shRNA duplexes suitable for cloning into retroviral expression 
vectors by identifying a 19bp sequence targeting the gene of interest, which is then 
incorporated into longer 66bp oligos that contain BamHI and EcoRI overhangs for 
insertion into the pSIREN vector, plus a Mlu1 restriction site for insert identification. 
The target sequences and the shRNA duplexes generated are shown in Table 2-4. 
ShRNA duplexes were purchased from Sigma and cloned into the retroviral expression 
vector RNAi-Ready pSRIEN-RetroQ Vector [Clontech 631526]. Preparation of the 
shRNA expression vectors were carried out according to manufacturer’s instructions: 
1) shRNA duplexes were annealed by mixing 100µM of each shRNA oligo (reverse and 
forward) in a 1:1 ratio and heating to 95ºC for 30 seconds, followed by gradual cooling 
over 6 minutes; 
2) Annealed shRNAs were diluted to 0,5µM concentration (1:100 dilution) in TE buffer 
and then ligated to the linearized vector by incubating the following mixture at room 
temperature for 3 hours: 
- 2µL pSIREN-RetroZ Vector (25ng/µL) 
- 1µL shRNA oligos (0,5µM) 
- 1,5µL T4 DNA ligase buffer (10x) 
- 0,5µL BSA (10 mg/mL) 
- 9,5µL nuclease-free water 
- 0,5µL T4 DNA ligase enzyme (400 U/mL) 
A ligation reaction was set up as above for each of the MKP3 target oligonucleotides, 
control shRNA, plus a vector-only control. 
3) Each ligation reaction was transformed into competent HB101 bacteria by adding 
2µL ligation mixture to 50µL of bacterial cell suspension, incubating on ice for 5 
minutes and then heat shocking at 42ºC for 30 seconds in a water bath before 
replacing on ice. 
4) Transformed bacteria were grown in 250µL of SOC medium, shaking for 1 hour at 
37ºC. 30µL of each transformation was then spread onto agar plates containing the 
selection antibiotic ampicilin and incubated at 37ºC ON. 
5) 3 to 4 well separated colonies were picked from each plate and grown up in small 
starter cultures of LB medium+ampicilin for 8 hours. 
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6) Plasmids were then isolated and purified from the bacteria using the Mini-Prep kit 
[Qiagen] and digested to check the presence of the shRNA insert (see below). 
7) Once the presence of the insert was confirmed by restriction digest, 0,5 mL of the 
starter culture was inoculated into 250mL LB medium+ampicilin and grown up at 37ºC 
ON with vigorous shacking. Plasmids were purified from these bacterial cultures by 
Maxi-Prep [Qiagen] and kept as a stock dissolved in TE and frozen at -20ºC.  
 
Restriction enzyme digests 
Restriction digest to check for the presence of an Mlu1-containing insert were carried 
out on plasmids from 3-4 colonies. All buffers and restriction enzymes were obtained 
from Promega. Restriction digests were performed at 37°C for 1 hour in 20µl 
reactions containing the following: 
µl Reagent  Final 
 DNA   0.5-1.0 µg 
0.5 Enzyme (10u/µl) 5u 
2.0 10x reaction buffer  
0.2 BSA (10mg/ml) 0.1 mg/ml 
 Water   to 20µl 
The MKP3 shRNAs plasmids stocks from the Maxi-prep, having been checked at the 
mini-prep stage for Mlu1 sites by restriction digest, were further verified by 
sequencing.  
 
2.5 DNA/RNA manipulation 
2.5.1 DNA extraction from animal tissue 
Genomic DNA was extracted from ear notches. Animal tissue was lysed ON at 55ºC 
in 400µL of Lysis Buffer (100mM Tris-HCl pH8.5, 5mM EDTA, 0.2% SDS and 200mM 
NaCl) and 4µL of Proteinase K [Roche] (1:100). Following lysis, 50 µL were rapidly 
frozen in dry ice and the SDS pelleted by 15 minutes of centrifugation at 13000 rpm at 
4ºC. Supernatant was used for PCR reactions. 
 
2.5.2 PCR/ Genotyping 
Mice were genotyped by PCR. Reactions were set up using 1μL genomic DNA in a 
final volume of 25 μl. Reactions were set up as described in Table 2-7 using Promega 
Taq polymerase. Primers used for PCR reactions are detailed in Table 2-1. 
   
  88 
 Nf1 flox Nf1 +/- P0 YFP 
Buffer 5X 5 5 5 5 
MgCl2 (50mM) 4.2 2.5 1.5 2 
Primers (10µm) 1 1 2.5 1 
dNTPs (10mM) 0.5 0.5 0.5 0.5 
Taq pol (U) 0.2 0.2 0.2 0.2 
H2O 13.1 14.8 14.3 15.3 
Table 2-7 Genotyping PCR reactions 
 
and the program:  
-  94°C for 3 min;  
-  94°C for 30 sec 
- 55°C for 1 min         X 35    
-  72°C for 2 min 
-  72ºC for 10 min 
-  4ºC 
 
2.5.3 RNA extraction from cultured cells 
Total RNA was isolated using Trizol Reagent (Ambion), according to manufacturer’s 
instructions, and precipitated in isopropanol. Following precipitation, salts and 
contaminants were washed away with 70% ethanol and RNA was eluted in RNAse free 
H20.  
 
2.5.4 cDNA synthesis 
The SuperScriptTM II Reverse First-Strand Synthesis System (Invitrogen) was used with 
random hexamers to reverse transcribe 500ng-1 μg of RNA to produce cDNA for 
quantitative RT-PCR reactions. Reactions containing RNA, 1μl random hexamers and 
1μl of 10mM dNTPs were made up to 12 μl with DEPC treated water, incubated at 
65°C for 5 minutes and placed on ice for > 1 minute. A reaction mix was then 
prepared containing 2μl 10xPCR buffer, 4μl of 25mM MgCl2, 2μl of 0.1M DTT for n x 
reactions and 9μl of this reaction mix was added to each sample and incubated at 25°C 
for 5 minutes. 1μl of RT (200U/μl) was then added to each tube and incubated for 10 
minutes at room temperature and then at 42°C for 50 minutes. The reactions were 
terminated at 70°C for 15 minutes and then chilled on ice. Finally, 1 μl RNase H 
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(2U/μl) was added to each tube and incubated at 37°C for 20 minutes to degrade the 
RNA strands.  
 
2.5.5 qPCR 
Quantitative PCR was performed using the DyNAmo SYBR Green qPCR Kit 
(Finnzymes, NEB) and the Opticon 2 DNA engine (MJ Research). PCR reactions (25μl) 
contained 10μl of PCR Sybr Green mix and 0,5µL of each sense and anti-sense 10mM 
primers. All reactions were performed in duplicate. Intron-spanning gene-specific 
primer pairs were designed using the OligoPerfect™ Designer [Invitrogen]. Cycle 
parameters were as follows: 10 min at 95ºC for Taq activation, followed by 35 cycles 
of 15 sec at 95° C for denaturation, 20 sec at 58ºC for annealing, 20 sec at 72° C and 
1 min at 77ºC for annealing/extension. Relative expression values for each gene of 
interest were normalized to B2M and calculated as follows: 2 -ΔΔCt where ΔΔCt= 
ΔCt(gene interest)- ΔCt(normalizer)  
 
2.6 Protein analysis 
2.6.1 Protein extraction from tissues 
Sciatic nerves were frozen in liquid nitrogen immediately after dissection. Frozen nerve 
samples were homogenised in liquid nitrogen, using and Eppendorf tube micro-pestle. 
Samples were lysed in directly in Laemli buffer, boiled and passaged through an insulin 
syringe.  
 
2.6.2 Protein extraction from cultured cells 
Cells were washed 1x in PBS and scraped off the dish in 1ml PBS with a rubber bung. 
Cell pellets were collected by spinning at 4°C in a cooled microfuge at 13,000 rpm and 
pellets were snap frozen in liquid nitrogen. Harvested cell pellets were lysed in RIPA 
buffer (Table 2-8) and samples vortexed and incubated on ice for 15 minutes, 
vortexing every 5 minutes. Lysates were centrifuged at 13,000 rpm for 15 minutes at 
4°C to remove cell debris and supernatants were transferred to fresh 1.5ml tubes on 
ice. Protein concentrations were measured against standard BSA solutions using the 
BCA microplate assay [Pierce] and RIPA added to normalise protein concentrations in 
all samples. 4x sample buffer was then added and samples boiled for 5 minutes at 95°C 
to denature proteins.  
 
   
  90 
Solutions Components and additional information 
RIPA lysis buffer 1% Triton X-100, 0.5% sodium deoxycholate, 50mM Tris pH7.5, 
100mM NaCL, 1mM EGTA pH8, 20mM NaF, 100µg/ml PMSF, 
15µg/ml aprotonin, 1mM Na3VO4. 
4x Sample buffer 200mM Tris pH 6.8, 8% SDS (BioRad), 40% glycerol, 400mM 
DTT, 0.25% bromophenol blue. 
10x Running buffer 2.5M glycine (BDH), 250mM Tris, 1% SDS. 
10x Transfer buffer 200mM Tris, 1.5M glycine, 20% methanol (BDH) 
Blocking solution 5% milk, 0.05% Tween-20 (BioRad) in PBSA 
Stripping buffer 200mM glycine, pH2.5, 0.4% SDS. 
1x PBSA Tween wash 0.05% Tween-20 in PBSA 
20x TBS Tween 200mM Tris pH8, 3M NaCl, 1% Tween-20 
PBSA 137mM NaCL, 2.7mM KCL, 1.47mM KH2PO4, 8.1mM NA2HPO4 
20X TBS 200mM Tris pH8, 3M NaCl 
Table 2-8: Solutions for protein extraction and Western blotting 
 
2.6.3 SDS-PAGE and Western blotting 
Protein samples were loaded onto polyacrylamide gels and resolved by SDS gel 
electrophoresis (SDS-PAGE). 10% gels were used, except for NF1 in which 5% gels 
were used. Proteins were transferred to PVDF membrane [Millipore] using transfer 
apparatus (see Table 2-6). Membranes were blocked for 1 hour at room temperature 
or overnight at 4°C. Blots for re-probing were washed in stripping buffer for 20 
minutes and blocked in milk. Blocked membranes were incubated overnight in primary 
antibody in block solution in rolling 50ml Falcon tubes. Membranes were then washed 
in TBST and incubated for one hour with horseradish peroxidase-conjugated 
secondary antibody diluted in milk block. Membranes were then washed 4x in TBST 
and once in TBS before chemiluminescent detection using ECL PlusTM reagent [GE 
Healthcare].  
 
2.7 Microscopy 
2.7.1 Tissue processing 
For histological analysis, both paraffin section and frozen sections were used. For 
paraffin sections, mice were sacrificed and sciatic nerves were dissected, post-fixed in 
10% formalin for 24 hours at 4ºC and processed for paraffin embedding (see below). 
Sciatic nerves were cut longitudinally or transversally at 8 µm using a microstat [Leica].  
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For frozen sections, sciatic nerves were dissected and fixed for 2 hours in 4% 
paraformaldehyde (PFA) [TAAB] at room temperature. Fixed nerves were 
cryoprotected in 30% sucrose in PBS overnight at 4ºC, transferred to a 1:1 mixture of 
30% sucrose with O.C.T compound [TissueTek, Sakura] and finally embedded in 
O.C.T and snap-frozen in liquid nitrogen. 8-12 µm thick longitudinal or transversal 
sections were cut using a cryostat [Leica]. 
 
2.7.2 Histology and Tumour Grading 
For hematoxylin and eosin (H&E) histology analysis, sciatic nerves were harvested and 
fixed in 10% formalin ON at 4ºC. Nerves were then rinsed in water and then 
dehydrated through a graded ethanol series: 70%, 80% and 95% ethanol washes (30 
minutes each), followed by 3 washes in 100% ethanol (15, 30 and 45 minutes). Nerves 
were then washed twice in xylene for 15 minutes total and incubated in paraffin at 
60ºC for two hours. A second incubation in fresh paraffin [VWR] was performed for 1 
hour before final inclusion in paraffin. 
8µm thick sections were cut using a microstat, placed onto Superfrost (VWR) slides 
and deparaffinized. For deparaffinization, slides were first incubated at 62ºC for 2-3 
minutes and then placed in xylene for 2 minutes (2X). Next, sections were rehydrated 
through a graded ethanol series to water (2 washed in 100% ethanol for 2 minutes, 
one wash in 95% for 2 minutes, one wash in 70%, ethanol, final rinse in cold tap water). 
 
2.7.3 Hematoxylin/Eosin staining 
Rehydrated sections were overstained with hematoxylin [Sigma] for one 2 minutes. 
Excess stain was removed by washing in tap water for 5 minutes. Sections were then 
destained for a few seconds in acidic ethanol (95ml absolute ethanol and 5ml HCl 10M) 
and washed in ethanol 70% for 3 minutes. Eosin [Sigma] staining was performed for 10 
seconds. Slides were then dehydrated through a series of ethanol and xylene: 3 washes 
in ethanol 95% (5 minutes each); 2 washes in ethanol 100% (2 minutes each) and 2 
washes in xylene (2 minutes each) before mounting in DPX [VWR]. 
 
2.7.4 Alcian blue 
Sections of paraffin-embedded sciatic nerves were rehydrated as described above, 
stained with Alcian blue pH 2,5 for 15 minutes and then rinsed in distilled water. 
Sections were then dehydrated trough a series of ethanol grades and mounted in DPX. 
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2.7.5 X-gal staining 
Sciatic nerves from P0:LacZ mice were dissected, fixed in lacZ fixative (1% 
formaldehyde; 0,2% glutaraldehyde; 2mM MgCl2; 6mM EGTA in PBS) for 1 hour, 
followed by cryoprotection in 20% sucrose/PBS ON at 4ºC. Nerves were then 
embedded in OCT and frozen in liquid nitrogen. 8 µm section were cut and washed 
3X 30 min in LacZ wash buffer (1ml 1M MgCl2; 5ml 1% Sodium deoxycholate; 5 ml 2% 
Nonidet-P40; 489 ml PBS w/o MgCl2 or CaCl2). Following washes, sections were 
incubated in the dark at 37ºC for 3-4 hours with LacZ stain (98ml lacZ wash buffer; 
2ml 5mg/ml X-gal (dissolved in dimethyl-formamide); 0,21 g K-ferrOcyanide and 0,16g 
K-ferrIcyanide). Slides were washes in water, post-fixed in 4% PFA ON at 4ºC and 
then dehydrated in a series of ethanol grades and xylene (see below) before mounting 
in DPX. 
 
2.7.6 Immunohistochemistry  
Immunohistochemistry was performed in paraffin sections. Nerve sections were 
deparaffinized, rehydrated, and subjected to antigen retrieval: slides were submersed in 
a 10mM citrate buffer solution (pH 6,0) and heated in a microwave until boiling. After 
5 minutes at room temperature, slides were transferred to a fresh sodium citrate 
solution and boiled again. A second 20 minutes incubation at RT was performed before 
permeabilization. Section were permeabilized with 0.5% TritonX in PBS for 30 minutes 
and blocked in 10% Goat serum for 1 hour. Before incubation with primary antibodies, 
the endogenous peroxidase activity was quenched by incubating slides with 3% H2O2 
for 10 minutes at RT. The primary antibodies (dilutions used in Table 2-5) (4ºC ON) 
were visualized by treating the sections with HRP secondary antibodies (2 hours RT) 
(Table 2-6), followed by incubation with 3.3’-diaminobenzidine substrate per 
manufacturer’s protocol [Vector Labs]. Sections were then, in most of the 
experiments, stained with H&E (see below), dehydrated and mounted in DPX medium. 
 
2.7.7 Immunofluorescence  
Immunofluorescence was performed in both frozen and paraffin sections. Nerves 
sections were processed as described above, permeabilized in 0.3% Triton in PBS for 
30 min, blocked in 10% goat serum/PBS for ≥1 hour and incubated in primary 
antibodies in blocking buffer overnight at 4°C. Following staining with primary 
antibodies, sections were washed 3 times with PBS and detection was performed using 
the appropriate fluorescent secondary antibodies (Tabe 2-6), for 2 hours at RT. Nuclei 
   
  93 
were counterstained with Hoechst or DAPI in PBS and mounted in FluormountG 
[Southern Biotechnology Associates]. 
For p-ERK immunofluorescence, sciatic nerves were dissected and directly snap frozen 
in OCT and liquid nitrogen. Cryosections (14µm thick) were post-fixed in PFA for 10 
minutes. Following incubation with the primary and the HRP-conjugated secondary 
antibody, the signal was amplified using the tyramide signal amplification kit 
[Invitrogen]. 
Imaging was performed on a Zeiss Axioskop 2 [Zeiss], with OpenLab software [Perkin 
Elmer] (immunohistochemistry). Confocal microscopy was performed using a Leica 
TCS SPE Confocal Microscope, with accompanying Leica LAS AF software 
(immunofluorescence). 
 
2.7.8 Semi-thin and ultra-thin preparation 
Sciatic nerves were dissected and fixed ON at 4ºC with 2% glutaraldehyde in 0.2M 
phosphate buffer. Nerves were then post-fixed in osmium tetroxide for 1.5 hours at 
4º, followed by 45 minutes in 2% uranyl acetate at 4ºC. Nerves were then dehydrated 
in an ethanol series before embeddeding in epoxy resin. Semi-thin sections were cut 
with a glass knife at 0.3 µm and stained with 1% toluidine blue in 2% borax at 75ºC for 
2 minutes, for visualization. Ultra-thin sections were cut with a diamond knife at 70 
nm, collected onto formvar coated slot grids and visualized using transmission electron 
microscope (TEM). 
 
2.8 Administration of substances  
2.8.1 Tamoxifen administration 
Tamoxifen [Sigma] was dissolved in sunflower oil (20mg/mL) and filtered through a 
0.2µm filter. Controls and mutant mice, aged 4-5 weeks old, received intraperitoneal 
injections (i.p.) of 2mg of Tamoxifen (100µL) once a day for 5 consecutive days.  
 
2.8.2 Edu incorporation assay 
Cell proliferation was measured by 5-ethynyl-2’-deoxyuridine (EdU) incorporation 
[Invitrogen]. Mice were pulsed with 2mg of EdU three times; 48h, 24h and 4 hours 
before sacrifice. Sciatic nerves were dissected and processed for immunostaining with 
the appropriate primary and secondary antibodies. Following immunostaining, nerves 
were post-fixed in PFA for 10 min, washed in PBS and permeabilized in 0.3% Triton for 
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15 min. Edu staining was performed using the EdU kit [Invitrogen] according to the 
manufacturer’s instructions.   
 
2.8.3 PD 0325901 administration 
200mg of the MEK inhibitor PD 0325901 [LC labs] were reconstituted in 400 µL of 
DMSO and then dissolved in 0.5% hydroxylpropyl methylcellulose plus 0.2% tween. 
NF1 mutants received i.p. injections of PD 0325901 at a dose of 8mg/Kg, once a day 
for 14 days, beginning 48 hours following surgery. In the control group, NF1 mutants 
received i.p. injections of vehicle only (DMSO in hydroxylpropyl methylcellulose 
solution). 
 
2.9 Sciatic nerve transection 
The right sciatic nerve of anaesthetized 6-7 weeks mice  (Isofluorane), was exposed at 
the sciatic notch. The nerve was partially transected and the wound closed with clips. 
The entire nerve was recovered 7 days or 6-8 months after surgery. Nerves were 
immediately fixed in 4% PFA for immunohistochemistry or frozen in liquid nitrogen for 
protein analysis. Contralateral nerves were used as unlesioned control samples. A 
schematic is shown in Figure 2-1. 
 
Figure 2-1. Schematic representation of the partial transection 
performed in the right sciatic nerve. 
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2.10 Statistical analysis 
The data are represented as mean values plus/minus standard error of the mean (SEM). 
One-way ANOVA with post-hoc Bonferroni tests were used for statistical analysis in 
all experiments, except the one depicted in Figure 6-6 in which data were analysed 
using Repeated Measures ANOVA with post-hoc Newman-Keuls analysis (*p≤0.05; ** 
p≤0.01; *** p≤0.001). All statistical analyses were performed in Prism4 (GraphPad). 
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Chapter 3: Results I 
3.1 Chapter introduction 
A cell to be rendered tumourigenic has to acquire the ability to evade the mechanisms 
that control cell proliferation, growth and survival. It is widely accepted that genetic 
and/or epigenetic lesions are crucial in providing cells with these capabilities. However, 
the outcome of the initial genetic lesion is now known to be strongly dependent on 
the combinatorial action of a variety of cell-intrinsic and cell-extrinsic factors. Thus, 
activation of the same oncogenic pathway in different cellular contexts may have 
profoundly distinct tumourigenic potentials (Visvader, 2011). Similarly, a specific 
genetic lesion occurring at different developmental stages of a cellular target may have 
very different outcomes (Guerra et al., 2007). In addition to cell-intrinsic determinants, 
the interactions between the genetically altered cells and the surrounding 
microenvironment can be critical in determining if the early genetic changes will 
progress to the development of frank tumours.  
It is well established that neurofibromas arise from Schwann cells that undergo LOH at 
the NF1 locus. What has been less clear is the cell type within the Schwann cell lineage 
in which NF1 LOH occurs. The development of conditional mouse models in the past 
few years has allowed this question to be addressed. Using different genetic murine 
models, three different groups have induced loss of Nf1 at different developmental 
stages and demonstrated that neurofibromas can develop from differentiated, non-
myelinating Schwann cells, but only when Nf1 loss occurs during a limited time window 
(E12.5-E13.5) (Joseph et al., 2008; Wu et al., 2008; Zheng et al., 2008). However, it is 
still not clear how these studies translate to the human disease. Moreover, the 
heterogeneity of neurofibroma formation at the level of number, severity and location, 
may be indicative of the existence of different cells of origin. 
To address this possibility, we sought to test if fully differentiated, myelinating Schwann 
cells have tumourigenic potential. Furthermore, we wanted to investigate the 
controversial issue of whether Nf1 haploinsufficiency affects the outcome of Nf1 loss in 
adult Schwann cells. It is relevant to mention that during the course of this study, two 
articles addressing somewhat similar questions to those addressed in this thesis were 
published (Le et al., 2011; Mayes et al., 2011). Their findings, and how they relate to 
this work, will be discussed later, in Chapter 7. 
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3.2 Generation of a mouse model in which Nf1 loss is induced 
specifically in myelinating Schwann cells in adult mice  
To test if Nf1 loss in adult myelinating Schwann cells (mSCs) could elicit tumour 
formation, we needed a system in which Nf1 disruption could be spatially and 
temporally controlled. To do this, we employed the well-documented Cre-lox 
technology. The Cre-lox mechanism requires two components, a) the enzyme Cre 
recombinase that catalyzes recombination between two loxP sites, and b) two loxP sites 
that consist of specific 34-base pair long DNA sequences. By mating mice expressing 
Cre under ubiquitous or specific promoters, with mice carrying genes in which loxP 
sites have been introduced via homologous recombination, genetic modifications can 
be achieved (Nagy, 2000).  
In order to specifically target myelinating Schwann cells, we selected a conditional 
transgenic mouse line expressing the Cre recombinase (Cre-ERT2) under the 
myelinating Schwann cell specific promoter - P0 (Leone et al., 2003) (Figure 3-1Bi).  
The P0-CreERT2 mice express a Tamoxifen-inducible variant of Cre recombinase.  In 
this inducible system Cre is fused to a mutated estrogen receptor ligand-binding 
domain (ER). The CreER fusion protein is not able to bind endogenous estrogen but 
does bind to the synthetic ligand 4-hydroxy-Tamoxifen (4-OHT), produced in the liver 
by Tamoxifen (Tmx) hydroxylation. The CreER fusion protein expressed by these mice 
is incapable of entering the nucleus due to binding to HSP90 and is therefore rendered 
inactive. In the presence of the ligand 4-OHT, HSP90 is released and CreER 
translocates into the nucleus where it exerts its enzymatic activity (Figure 3-1C).  
We initially characterized the ability of P0Cre to ablate genes of interest in the PNS by 
crossing it into the Rosa26 Reporter LacZ (R26R-LacZ) (Figure 3-1A). This reporter 
strain contains a targeted insertion of the LacZ gene, preceded by a loxP-flanked 
transcriptional termination sequence (tpA), into the ubiquitously expressed Rosa26 
locus (Soriano, 1999). Upon Tmx treatment, the termination sequence is removed, 
inducing the expression of the β-galactosidase (β-gal) protein (Figure 3-1B ii).  
Five to six week-old mice were administrated 2mg of Tmx a day over a period of 5 
consecutive days, since this protocol had proven to be the most efficient at inducing 
Cre activity by Leone and colleagues (Leone et al., 2003) (Figure 3-1D). P0Cre-
mediated recombination, revealed by X-gal staining, was detected 15 days following 
the first Tmx injection (d15pTmx) in sciatic nerves of P0:LacZ mice (Figure 3-2A). The 
need to use substrates to visualize β-gal made it difficult to co-label the tissues with 
Schwann cell markers, affecting the accuracy in assessing the efficiency of Cre activity. 
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Figure 3-1: Characterisation of transgenic mice expressing an 
inducible Cre recombinase in the peripheral nervous system. A) P0-
CreER mice were crossed with mouse reporter lines R26R-LacZ and R26R-YFP. B) Schematics 
of: (i) the P0-CreER construct; (ii) the modified Rosa26 locus in the LacZ-R26R and in the YFP-
R26R mice (iii).  Arrows indicate primers used for PCR analysis.  Arrowheads represent loxP 
sites. C) Model of CreER regulation: in the presence of 4-OH Tamoxifen, the CreER fusion 
protein is released from HSP90 and translocates into the nucleus where it mediates 
recombination using the loxP sites. D) Protocol of Tamoxifen administration. 
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Furthermore, the efficiency of Cre recombination is known to vary depending on the 
target gene (for example, the distance between the two loxP sites) (Richardson et al., 
2011). Therefore, we decided to make use of a second reporter mouse – R26-YFP, 
structurally similar to the R26-LacZ, except that it contains the yellow fluorescent 
protein gene in the place of LacZ (Srinivas et al., 2001) (Figure 3-1B iii). P0-CreER mice 
were crossed with R26-YFP and their progeny treated with Tmx. Fifteen days later, 
sciatic nerve cryosections were immunostained for GFP (that labels YFP) and the 
mSchwann cell marker, P0. As shown in Figure 3-2B and quantified in Figure 3-2C, the 
percentage of P0 positive cells that were also positive for Cre activity was variable 
between animals, ranging from a minimum of 15.3% to a maximum of approximately 
50%. The reason for this variability is not known, but may result from batch variations 
of Tmx. 
In the P0-CreER transgenic, Cre recombinase is driven by the well-characterized 1.1kb 
P0 rat promoter fused to the 5’-untranslated region of the human connexin32 gene 
upstream of CreER (Messing et al., 1992; Messing et al., 1994) (Figure 3-1Bi). The 
activity of the P0 promoter has previously been documented as being confined to 
myelinating Schwann cells, whilst being inactive in non-myelinating Schwann cells 
(Messing et al., 1992). Nevertheless, to confirm the specificity of the cells targeted by 
the P0-CreER driver, we co-stained sciatic nerves from Tmx treated animals with GFP 
and the marker of non-myelinating or dedifferentiated Schwann cells, p75. Four-
hundred-eighty p75 positive cells from 6 different animals were counted, and we failed 
to find a single p75+GFP+ cell, confirming the specificity of the promoter to 
myelinating Schwann cells (Figure 3-3A). As mentioned in Chapter I, following injury to 
the PNS, Schwann cells revert to a dedifferentiated, progenitor-like state characterized 
by the expression of the p75 receptor, amongst other markers. Therefore, as a 
positive control, we analysed sciatic nerves from P0:YFP mice seven days following 
nerve transection and confirmed the co-localization of p75 and GFP (Figure 3-3A iv).  
Once characterized, P0-CreER transgenics were mated with mice homozygous for the 
conditional Nf1 allele (Nf1fl/fl), in which loxP sites flank Nf1 exons 31 and 32 (Zhu et al., 
2001) (Figure 3-4A and 3-4B-i). Importantly, exon 31 is frequently found mutated in 
NF1 patients. These are well-characterized animals in which Nf1flox (Nf1fl) has been 
shown to represent a functional conditional allele: Nf1fl behaves as a wild-type allele 
and once floxed, is a phenocopy of the null allele (Zhu et al., 2001). Finally, we also 
crossed P0- CreER to Nf1fl/- mice in which only one Nf1 allele is functional (flox) and the 
second has been rendered null by integration of a knockout (KO) cassette at exon 31 
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Figure 3-2: Cre drives recombination in myelinating Schwann cells 
when expressed under the P0 promoter.  A) X-gal staining demonstrates Cre 
activity in sciatic nerves of 4 different P0:LacZ mice, 15 days following Tamoxifen 
administration.  Vehicle treated mice were used as controls. B) Efficiency of Cre activity 
shows variability between animals. Frozen sections of P0:YFP sciatic nerves were stained for 
the Schwann cell marker P0 (red) and GFP (green). Nuclei were counterstained with DAPI. 
Controls were performed in P0:YFP mice injected with vehicle. Two different mice, 
representative of the variability in Cre activity are shown.  C) Quantification of the percentage 
of P0+GFP+ cells in 7 different animals. Graph shows mean ±SEM. 
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Figure 3-3: P0-CreER mice do not exhibit recombinase activity in 
non-myelinating p75+ Schwann cells.  A) Sciatic nerve cryosections of Tmx-
treated P0:YFP animals were stained for GFP (green) and for the non-
myelinating/dedifferentiated Schwann cell marker p75 (red). No co-localization was found in 
intact nerves. Two mice are shown (ii and iii).  Negative controls were performed in vehicle 
treated P0:YFP mice (i). iv shows injured nerves from Tmx treated mice in which 
dedifferentiating GFP positive cells are found to co-localize with p75, 7 days following nerve 
transection. 480 p75+ cells from 6 different animals were analysed and no p75+GFP+ cells 
were found in uninjured nerves. 
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(Brannan et al., 1994). This strategy yielded P0-Nf1fl/fl and P0-Nf1fl/- mice (referred as 
NF1 mutants). In both mutant mice, activation of Cre produces Nf1-/- Schwann cells, 
however, while in P0-Nf1fl/fl all other cells in the animal are wild-type, P0-Nf1f/- mice have 
a heterozygous background and this more faithfully resembles the human pathogenesis 
(NF1 patients are haploinsufficient for NF1). By using both wild-type (Nf1fl/fl) and 
heterozygous backgrounds (Nf1fl-/), we sought to dissect possible effects of NF1 
haploinsufficiency on tumour development. 
Throughout this thesis most of the studies described were done in P0-NF1fl/fl and P0-
NF1fl/- mice, using Cre negative littermates (NF1fl/fl and Nf1fl/-) as controls. Additionally, in 
some experiments in which selective analysis of the Nf1-/- Schwann cells was pertinent, 
we have used animals resulting from crosses between P0-NF1fl/fl and P0-NF1fl/- and the 
YFP reporter (P0:YFP-Nf1fl/fl and P0:YFP-Nf1fl/- - also designated as NF1 mutants). In these 
cases, P0:YFP-Nf1+/+ and P0:YFP-Nf1+/- were used as controls. Figure 3-5 summarizes all 
the genotypes used in this study.  
Once the correct genotypes were achieved through multiples crosses (Figure 3-4-C i-
iii), we tested the success of P0-CreER-mediated Nf1 recombination. To do this, we 
treated P0-Nf1fl/fl and P0-Nf1fl/- mice with the Tmx protocol detailed above and, 15 days 
later, harvested the sciatic nerves for DNA and protein analysis. A 280 bp product 
corresponding to the deleted Nf1 allele (Nf1Δ - represented schematically in 3-4B-iv) 
appeared exclusively in the PCR analysis of sciatic nerve DNA from Tmx treated 
mutants, but not in DNA from Cre negative controls (Figure 3-4C-iv), thus confirming 
the genomic deletion at the Nf1 locus. Additionally, Western blot analysis using nerve 
lysates revealed that neurofibromin (NF1) levels were reduced in NF1 mutants upon 
Tmx treatment. However, it is relevant to consider that, as I have shown before, the 
efficacy of Cre activity seems to vary between animals (Figure 3-2B and C) and hence it 
is likely that the amount of neurofibromin present in mutant mice may also be variable.  
Interestingly, the levels of neurofibromin do not seem to be significantly affected by 
Nf1 heterozygosity.  
In conclusion, we have generated a mouse model in which Nf1 can be ablated 
specifically in fully differentiated myelinating Schwann cells in adult sciatic nerves.   
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Figure 3-4: Generation of a mouse model to study Nf1 disruption in 
myelinating Schwann cells, in adult peripheral nerves.  A) P0-CreER mice 
were crossed with Nf1fl/fl and Nf1fl/- mice to generate P0-Nf1fl/fl and P0-Nf1fl/- mice.  P0-CreER 
negative littermates were used as controls. B) Schematic representation of (i) the Nf1 flox 
allele with two loxP sites (arrowheads) flanking exons 31 and 32; (ii) the recombined allele 
(Nf1Δ) resulted from Cre-mediated recombination and (iii) the Nf1 null allele (Nf1-) and the 
Nf1+ allele in Nf1fl/- mice. Positions of the primers used are shown (arrows). C) PCRs detecting 
the presence of i) the P0-CreER construct, ii) the Nf1 null and wt allele, iii) the Nf1 floxed 
allele and iv) the recombined Nf1Δ allele in genomic DNA from adult sciatic nerves of Tmx 
treated mice. D) Western blot analysis of NF1 expression in mouse sciatic nerves, 15 days 
following Tamoxifen administration. 
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Figure 3-5: Animals used in this study.  A) NF1 mutants P0-Nf1fl/fl and P0-Nf1fl/- 
were compared with Cre negative Nf1fl/fl and Nf1fl/fl littermates. B) In some experiments, 
P0:YFP-Nf1fl/fl and P0:YFP-Nf1fl/- mutants were  used, instead.  When this was the case, P0:YFP-
Nf1+/+ and P0:YFP-Nf1+/- were used as controls.  All groups of mice were Tmx-treated, unless 
otherwise specified. 
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3.3 Myelinating Schwann cells are not affected by Nf1 
ablation in adult mice 
We started by examining whether the selective loss of Nf1 affects the Schwann cell 
differentiation state two weeks following Tmx administration, as we had previously 
verified that at this time-point neurofibromin levels were already reduced (Figure 3-
6A). Observation of sciatic nerves from NF1 mutants showed no increase in the 
number of p75 positive cells, revealing that myelinating Schwann cells are not induced 
to dedifferentiate by Nf1 loss (Figure 3-6B and C). Moreover, we analysed cell 
proliferation by pulsing the animals with EdU for 48 hours (one daily pulse, during days 
13-15pTmx) and found no mitotically-active Nf1-/- Schwann cells, as shown by co-
labelling with GFP and EdU (Figure 3-6D iii and iv). On the contrary, a few EdU-
positive cells were found in the epineurium, probably reflecting the higher turnover of 
this structure (arrow in Figure 3-6D iv). These rare GFP-/EdU+ cells were equally 
found in NF1 mutants and controls, eliminating a possible non-cell autonomous effect 
of Nf1 mutant Schwann cells.  
 
3.4 Quiescent adult myelinating Schwann cells are 
refractory to tumourigenesis  
In order to investigate the long-term effects of Nf1 disruption in myelinating Schwann 
cells, we characterized sciatic nerves 8 months following Nf1 ablation (Figure 3-7A). 
Gross dissection of NF1 mutants did not reveal any macroscopic alterations (n>10 of 
each genotype). Consistent with this, Nf1-deficient and control sciatic nerves looked 
similar under histological examination of H&E stained sections. In addition, we could 
not detect any differences in the structure or degree of myelination when analysing 
semi-thin sections of NF1 mutants and control mice (Figure 3-7B). Similarly, 
immunolabelling with the myelin marker P0 and the axonal marker neurofilament 
showed no alterations in the myelin sheaths or any signs of axonal degradation in NF1 
mutants, when compared to controls (Figure 3-7C).  
In previous mouse models of NF1, neurofibroma formation was preceded by Remak 
bundle disruption (Zheng et al., 2008). To determine if Nf1-/- mSchwann cell could play 
a non-autonomous effect in these structures, we performed EM analysis in sciatic 
nerve sections. As represented in Figure 3-8, we failed to detect any differences 
between control and mutant mice: Remak bundles remained intact in the presence of 
Nf1 deficient mSCs.  
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Figure 3-6: Nf1 loss in Schwann cells does not induce Schwann cell 
dedifferentiation and proliferation. A) Tmx and EdU protocol. B) Cross-sections 
of sciatic nerves from control and NF1 mice were stained for the non-
myelinating/dedifferentiated Schwann cell marker p75. C) Quantifications of p75+ cells (n=3 
for each group, 8 fields were counted per section; 3 sections per animal, data represents mean 
values ±SEM) D) Controls P0:YFP-Nf1+/+ and P0:YFP-Nf1+/- and mutants P0:YFP-Nf1fl/fl and P0:YFP-
Nf1fl/- were pulsed with EdU (in red). No proliferation was observed in the Schwann cells 
(green).  Arrow points to an epineurial EdU positive cell (3 animals of each genotype were 
analysed). 
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Figure 3-7: Nf1 loss in adult, differentiated Schwann cells does not 
affect nerve structure. A) Sciatic nerves were processed 8 months following Tmx 
injections. B) Representative transverse semi-thin sections of control (i and ii) and mutant 
mice (iii and iv) stained with toluidine blue. D) Immunostaining of cross-sections for P0 - 
marker for myelinating Schwann cells (green) and neurofilament - marker for axons (red). 
Myelinated fibers are not altered despite loss of Nf1 (n=3 for each genotype). 
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Figure 3-8: Remak bundles are maintained in the absence of Nf1. 
Cross-sections were processed for EM analysis and revealed no disruption of Remak bundles, 
8 months after Tmx treatment. Representative images of two controls (i and ii) and two 
mutants (iii and iv) are shown. 4 animals of each genotype were analysed. 
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Mast cells have been implicated as critical mediators of neurofibroma initiation (Yang 
et al., 2008). Given that the infiltration of these cells in peripheral nerves is frequently 
seen well in advance of tumour development (Zhu, 2002), we investigated if mast cells 
were present in sciatic nerves, 8 months following Nf1 disruption (Figure 3-9A). As 
revealed by Alcian blue staining in paraffin sections, no mast cells were found in NF1 
mutant nerves (Figure 3-9B). Likewise, no alterations in the number of macrophages, 
another cell type frequently found in these tumours, were detected (Figure 3-9C and 
D).  
Taken together these observations indicate that mSchwann cells are not rendered 
tumourigenic by loss of Nf1. What is more, disruption of Nf1 in myelinating Schwann 
cells does not impact the maintenance of adult peripheral nerves, in the context of an 
otherwise normal adult nerve,  
 
3.5 The ERK pathway is not activated by Nf1 loss in adult 
myelinating Schwann cells 
As discussed in Chapter 1 of this thesis, NF1 is a Ras-GAP that negatively regulates Ras 
and its downstream pathways, including Ras/Raf/MEK/ERK (Cichowski and Jacks, 2001). 
Work from our lab has shown that Raf/ERK activation is sufficient to drive Schwann 
cell dedifferentiation in vitro (Harrisingh et al., 2004) and in vivo (Napoli et al., 2011). 
Furthermore, we have also shown that in vitro, Nf1 loss via Ras/ERK signalling, induces 
disruption of Schwann cell/axonal interactions rendering Schwann cells more 
susceptible to mitogenic signalling (Parrinello et al., 2008). Thus, it was tempting to 
speculate that loss of Nf1 in vivo would induce activation of Ras/Raf/ERK signalling and, 
consequently, dedifferentiation, axonal dissociation and proliferation of Schwann cells. 
Nevertheless, as just described, Nf1 ablation in adult, myelinating Schwann cells does 
not cause any detectable effect. To understand why this was the case we examined the 
expression levels of activated ERK (p-ERK) by Western blot analysis of sciatic nerve 
lysates and by immunostainings of nerve cryosections (Figure 3-10). In both NF1 
mutants, ERK activation was not detected, revealing that Nf1 loss in fully differentiated 
mSchwann cells is not sufficient to produce a detectable alteration in the signalling 
through Ras/Raf/ERK, providing a plausible explanation for the absence of any 
noticeable phenotype.  
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Figure 3-9: Nf1 loss in adult mSchwann cells does not induce the 
recruitment of an inflammatory response. A) Sciatic nerves from control (i and 
ii) and mutant sciatic nerves (iii and iv) were harvested 8 months following Tamoxifen 
treatment, and processed for analysis. B) Paraffin sections were stained with Alcian Blue and 
the nuclei counterstained with hematoxylin. Three animals of each group were examined; mast 
cell recruitment was not observed in controls (i-ii) and in NF1 mutants (iii-iv); v) an injured 
positive control shows mast cell recruitment 5 days after nerve transection.  C and D) Nerve 
cryosections were immunostained for the macrophage marker Iba-1 (green) and revealed no 
increase in the number of these cells, 8 months after Nf1 loss (n=3 for each group, 8 fields 
were counted per section, 3 sections per animal, data are represented as mean values ±SEM). 
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Figure 3-10: Nf1 loss in adult myelinating Schwann cells does not 
induce activation of ERK signalling. A) 5-6 weeks-old mice were treated with 
Tamoxifen and sciatic nerves were harvested for analysis, 15 days following the first Tmx dose. 
B) Western blot analysis of sciatic nerve extracts shows no alteration of p-ERK levels upon 
Nf1 loss (third and fourth lane). On the right, nerve extracts from control mice 24 hours post 
nerve transection are shown as a control for ERK activation. C) Representative images of 
cross-sections of sciatic nerves immunostained for p-ERK (red) and P0 (green) in the controls 
Nf1fl/fl and Nf1fl/- (i and ii) and in the Nf1-deficient mice P0-Nf1fl/fl and P0-Nf1fl/- (iii and iv) (n=3 
for each group). 
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3.6 Chapter summary and conclusions 
In this chapter I have described the generation of a mouse model to study the selective 
loss of Nf1 in myelinating Schwann cells, in adult mice. Importantly, in this model, p75 
positive, non-myelinating Schwann cells are negative for Cre activity, confirming the 
specificity of Nf1 ablation in mSchwann cells. Characterization of the peripheral nerves 
shortly after Nf1 disruption revealed that the loss of this tumour suppressor does not 
have an automatic impact on Schwann cell differentiation status and proliferation. 
Importantly, long-term analysis of NF1 mutants revealed that Nf1-/- Schwann cells do 
not give rise to tumours in either an Nf1+/+ or Nf1+/- background. Moreover, the overall 
structure of the peripheral nerve is not affected and no inflammatory response is 
induced. Consistently with these findings, we observed that the ERK pathway is not 
detectably activated upon Nf1 loss, suggesting two possibilities: 1) the differentiated, 
myelinated nerve microenvironment is able to suppress Ras activation or 2) in the 
adult homeostatic peripheral nerve, NF1 does not play a relevant role as a Ras 
regulator. 
Altogether, we have shown that Nf1 loss in quiescent, adult mSchwann cells, by itself, 
is not sufficient to drive tumourigenesis.  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Chapter 4: Results II 
4.1 Chapter introduction 
In the previous chapter I have shown that loss of Nf1 in myelinating Schwann cells in 
the context of a normal, adult nerve is not tumourigenic, at least as a result of a 
“single-hit” mechanism. Surprisingly, the levels of ERK signalling were not affected by 
Nf1 loss, suggesting that in an intact nerve, NF1 is mostly dispensable for the 
maintenance of the basal levels of Ras/ERK signalling or that other regulatory 
mechanisms are induced upon Nf1 loss and able to suppress the Ras pathway.  
A link between injury and tumourigenesis was postulated over a century ago (Balkwill 
and Mantovani, 2001). Several lines of evidence, including clinical observations and 
studies in transgenic mice, have demonstrated that wounding and/or inflammation can 
strongly modulate the tumourigenic potential of genetically altered cells (Schuh et al., 
1990; Wong and Reiter, 2011).  
Injury to the PNS results in a sequence of well-defined molecular and cellular events 
known as Wallerian degeneration. Following nerve injury, axons downstream of the 
wound degenerate, Schwann cells dedifferentiate to a proliferative, progenitor-like 
state and a robust inflammatory response is elicited. Upon axonal regrowth, the 
inflammation is resolved and Schwann cells redifferentiate to restore the function of 
the nerve. Importantly, work in our lab has shown that the switch in Schwann cell 
differentiation state to a progenitor-like cell is dependent on strong signalling through 
the Ras/Raf/MEK/ERK pathway (Harrisingh et al., 2004; Napoli et al., 2011). We 
therefore decided to investigate if wounding to the sciatic nerve and its associated 
activation of Ras/Raf/ERK pathway would alter the tumourigenic properties of Nf1-/- 
mSchwann cells.  
 
4.2 Injury induces peripheral nerve tumour formation at 
high frequency 
To test if wounding of the sciatic nerve may cooperate with lack of Nf1 to induce 
tumourigenesis, we performed partial-transections of the right sciatic nerve, 15 days 
following Tmx treatment (Figure 4-1A). Partial-transection was favoured over full-
transection to facilitate the reconnection of the two stumps during regeneration and 
reduce variability among experiments (See Figure 2-1). Six-to-eight months following 
the injury - we would expect that by this time point, the cellular remodelling that takes 
place during the regeneration process should be mostly resolved - mice were 
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sacrificed and gross dissections were performed in control and mutant groups. 
Strikingly, we detected visible tumours at the injury site in approximately 35% of all 
NF1 mutant mice subjected to nerve transection (n=75 of P0-Nf1fl/fl and n=52 of P0-
Nf1fl/-). The frequency of tumour development was not significantly different between 
Nf1+/+ and Nf1+/- backgrounds, ruling out a fundamental role for Nf1 haploinsuficiency in 
tumour formation in this mouse model (Figure 4-1C).  
In sharp contrast to the high frequency of tumour formation observed in NF1 mutants, 
we did not detect abnormal nerve enlargements in the injured nerves from control 
mice (n=78 of Nf1fl/fl and n=61 Nf1fl/-). A single exception was an Nf1fl/- mouse, which 
had a macroscopically enlarged sciatic nerve at the wound site. Given the rarity of this 
event and the fact that it occurred in an animal with a heterozygous background, it is 
tempting to speculate that this tumour may have resulted from LOH at the Nf1 locus. 
In agreement with the results described in the previous chapter, the unwounded 
contra-lateral nerves of the NF1 mutants (in which mSchwann are Nf1-/-) were 
consistently found unaltered. This was true even when sciatic nerves were analysed up 
to 15 months following Nf1 disruption and further confirms that, by itself, Nf1 loss in 
adult mSchwann cells fails to drive tumourigenesis.  
 
4.3 Morphological characterization of sciatic nerves, at the 
site of injury 
Hereafter, NF1 mutants refer to mice with visibly enlarged sciatic nerves only; 
macroscopically normal mutant nerves were not included in any of the following 
analyses.  
The structure and composition of the tumours that developed in Nf1-deficient mice at 
the site of injury were characterized and compared with the equivalent region of 
control animals (roughly 2 mm above the sciatic notch), 8 months following injury. 
Figure 4-2A illustrates the remarkable enlargement of the peripheral nerves in Nf1-
deficient mice, when compared with controls (approximately six fold, as quantified in 
4-2B).  Also, frozen cross-sections were prepared from sciatic nerves, stained with 
Hoechst nuclear staining (Figure 4-2C) and the number of nuclei per field counted 
using epifluorescence microscopy. As shown in Figure 4-2D, NF1 mutants exhibit 
significantly increased cellular density, in addition to increased size.  
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Figure 4-1: NF1 mutant mice form tumours at the site of injury.  
A) Schematic representation of the protocol used to assess the effect of injury. B) Gross 
micrographs show sciatic nerves (uninjured nerve on the left and injured on the right) of age-
matched controls (i and ii) and NF1 mutants (iii and iv) Tmx-treated, 8 months following 
injury.  C) Table shows the frequency of tumour development in all the 4 genotypes studied. 
Tumours form only (*) in mice lacking NF1 in Schwann cells and at a similar frequency in Nf1+/+ 
and Nf1+/- background (*see main text). 
   
  116 
 
 
Figure 4-2: Injured nerves from Nf1-deficient mice are greatly 
enlarged at the site of injury and display increased cellular density.  
A) Transverse semi-thin sections stained with toluidine blue show enlargement of the sciatic 
nerve in NF1 mutant nerves (ii). B) Quantification of the relative area (n=3 of each genotype). 
Note that similar results were obtained for Nf1+/+ and Nf1+/- backgrounds. C) Hoechst staining 
shows nuclei density, 8 months following partial nerve transection. D) Quantification of C 
(n=4 of each genotype). Red dashed lines delineate the unwounded region of the nerves. Data 
represents mean values ±SEM. 
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4.4 Tumours in NF1 mutants can be classified as 
Neurofibromas 
We performed histological analysis on the tumours and used published criteria to 
define grades of mouse peripheral nerve tumours (Stemmer-Rachamimov et al., 2004). 
Paraffin sections from more than 10 tumours were evaluated by H&E and S100 staining 
by our collaborating pathologist. Tumours were classified as GEM Grade I 
neurofibromas, exhibiting the classical characteristics of human neurofibromas, 
including being composed by a heterogeneous cell population containing S100β 
positive and S100β negative cells, abundant ECM deposition and numerous spindle-
shaped cells (Figure 4-3 and 4-4).   
As illustrated in Figure 4-3B, three distinct areas could typically be recognized in the 
tumours: i) the uninjured region of the nerve; ii) an apparently regenerated region and 
iii) the neoplastic lesion itself. These 3 areas were easily recognizable in terms of 
morphological organization, cellular density and S100β expression. The unwounded 
area remained surprisingly unaffected, displaying regular fibre alignment and sparse 
nuclei, comparable to unwounded controls (Figure 4-3Ai and 4-3Bi). The second 
identifiable area appeared similar to the regenerated control (Figure 4-3Aii and 4-3Bi 
and ii); in both cases, despite an increased cellularity when compared to uninjured 
nerves (Figure 4-3Ai), the nerve fibres are aligned in a fairly regular way, resulting in a 
comparatively reorganized structure (note the aligned nuclei in 4-3Aii). Finally, the 
lesion surrounding the nerve displayed evident cellular disorganization, abundant blood 
vessels (black arrows in 4-3Aiii and 4-3B) and numerous inflammatory cells, recognized 
by H&E staining (red arrows in 4-3Biii).  
The distribution of S100β immunoreactive cells - a parameter conventionally used for 
neurofibroma diagnosis - was also markedly divergent between the different areas of 
the tumour. As illustrated by the neurofibroma shown in Figure 4-4B, homogeneous 
S100β positive staining was observed exclusively associated with the unwounded, 
entrapped nerve (i). In the “regenerated area”, S100 expression appeared similar to 
the repaired controls (compare 4-4Bii with 4-4Aii): immunoreactivity was sparsely 
found, mirroring the presence of intermingled S100 positive and S100 negative cells (ii). 
Finally in the lesion itself, only minimal S100 staining was observed (Figure 4-4).  
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Figure 4-3: Histological analysis of control and mutant sciatic nerves. 
A) Control and mutant nerves were sectioned longitudinally and stained for hematoxylin and 
eosin (H&E). i) uncut control; ii) control nerve Nf1fl/fl appears regenerated 8 months following 
injury; note the fairly aligned nuclei in contrast with iii. iii) NF1 mutants developed 
neurofibromas at the site of injury. Note the disordered, convoluted bundles of cells exhibiting 
spindle-cell morphology with ovoid and spindle shaped nuclei, characteristic of these tumours.  
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B) Cross-section of a paraffin embedded sciatic nerve from a P0-Nf1fl/fl mouse displays 
morphologically distinct areas; grey dashed line outlines (i) uninjured and (ii and iii) injured 
regions; green dashed line demarcates the regenerated area from the tumour lesion. Black 
arrows point to blood vessels; red arrows to immune cells. 
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Figure 4-4: Tumours in P0-Nf1flfl and P0-Nf1fl/- mice display variable 
immunoreactividade for the Schwann cell marker S100β. A) Sciatic nerves 
from NF1 mutants were embedded in paraffin, sectioned longitudinally and stained for S100β.  
i) uncut control; ii) control nerve: Nf1fl/fl exhibits a relatively homogeneous staining for S100β 
in contrast to the scarce staining observed in some areas of neurofibromas (iii). B) Cross-
section of a paraffin embedded neurofibroma; i, ii and iii represent distinct areas, where 
S100β is differentially expressed.  Similar results were obtained with P0-Nf1fl/- transgenics (3 
animals of each genotype were analysed). 
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4.5 Ultrastructural analysis confirms the multicellular 
nature of neurofibromas 
Human neurofibromas contain a variety of cell types found in normal peripheral 
nerves, including Schwann cells, fibroblasts, neurons, perineurial cells and mast cells. 
To better define the cellular composition of the tumours that developed in our NF1 
model we prepared semi-thin and ultra-thin sections from control and NF1 mutants, 8 
months following injury (Figure 4-5A illustrates the regions that sections were 
prepared from). The overall ultrastructural appearance of neurofibromas and 
regenerated controls is illustrated in Figure 4-5B.  
Repaired sciatic nerves from control mice, visualized by toluidine blue staining of 
cross-sections, were found tightly packed with myelinated axons, with little intervening 
interstitial space (Figure 4-5Bi). Under EM analysis, they were composed of well-
organized minifascicles or compartments, which are known to form as part of the 
regeneration process (Figure 4-5Biii). The formation of these structures, consisting of 
groups of Schwann cell-axon units delimited by perineurial-like layers, has been 
speculated to represent an attempt by the nerve to preserve some level of protection 
within their immediate microenvironment (Morris et al., 1972).  
Overall, despite the increased cellularity as compared to unwounded controls - that 
can be explained by an increased number of Schwann cells, resulting from the process 
of axonal sprouting, and by the presence of the fascicle-forming cells - control nerves 
appeared reorganized and well regenerated. Importantly, contrary to a study by Atit 
and colleagues in which Nf1 haploinsufficient mice exhibited impaired skin wound 
repair (Atit et al., 1999), here the success of nerve repair was not affected by Nf1 
heterozygosity. 
In contrast, the tumours that formed at the injury site in NF1 mutants were 
significantly enlarged by an expanded interstitial compartment and by increased 
cellularity between myelinated axons  (Figure 4-5Bii). Electron micrographs of these 
tumours revealed the presence of mast cells - confirmed by numerous intracellular 
granules, “perineurial-like” cells - traditionally identified by numerous pinocytic vesicles 
and patchy or continuous basal lamina, and rare myelinated axons, most of which were 
found intact. Schwann cell cytoplasmic processes, as defined by continuous basal 
lamina, were frequently found devoid of axonal association, sometimes wrapping 
abundant collagen pockets (Figure 4-6C). Unsheathed or misegregated axons could 
also be identified (Figure 4-6C and D), which may suggest that, following injury and in 
the context of a Nf1-/- nerve, the redifferentiation process of non-myelinating Schwann  
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Figure 4-5:  Morphological analysis of sciatic nerves at the injury site, 
8 months following transection. A) Sections were prepared from the injured site in 
(i) control and (ii) Nf1-deficient nerves. B) Representative images of semi-thin (i and ii) and 
ultra-thin (iii and iv) sections from control and NF1 mutant peripheral nerves. In control 
animals, sciatic nerves appeared well-organised and regenerated. Mutant mice developed 
macroscopic tumours with disrupted morphology (4 animals of each genotype were processed 
for analysis). 
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Figure 4-6: EM analysis of the tumours that developed in NF1 mutant 
mice, 8 months following peripheral nerve injury. A) Representative image 
of an EM micrograph of a P0-Nf1fl/fl sciatic nerve shows a mixture of intact mSchwann cells 
(arrow), “perineurial-like” cells and mast cells (arrowhead). B) A rare example of 
demyelination found in an NF1 mutant mouse. C) Black arrows point to prominent Schwann 
cell cytoplasmic processes identified by continuous basal lamina. White arrow point to a 
“naked” axon. Abundant collagen deposits are also observed. D) Arrows point to “perineurial-
like” cells identified by patchy basal lamina and intracellular pinocytic vesicles. Note the 
presence of unsegregated axons (3 to 4 tumours of both P0-Nf1flfl and P0-Nf1fl/- were analysed 
by EM, 8 months following injury). 
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cells is impaired. Alternatively, it might reflect disruption of Remak bundles, an event 
frequently witnessed in neurofibromas.  
The data demonstrates a close similarity in the pathology of the lesions developed in 
this novel model of tumourigenesis and previously described human neurofibromas 
(Dickersin, 1987).  
 
4.6 Nf1-/- Schwann cells are a major cellular component of 
the tumours that develop at the site of injury 
The contribution of Nf1-/- Schwann cells to the neurofibromas that developed in this 
murine model was assessed using P0:YFP-Nf1fl/fl and P0:YFP-Nf1fl/-mice. Six months 
following Nf1 loss and sciatic nerve partial-transection, mice were sacrificed and sciatic 
nerves processed for immunofluorescence. Strikingly, near uniform GFP expression 
was observed in the lesions that developed at the site of injury, demonstrating the 
extensive contribution of Nf1-/- Schwann cells. GFP positive cells were mostly found 
deprived of axonal association, enwrapping other cells or forming parallel layers 
(Figure 4-7). Isolated cells invading the adjacent muscle were also observed, suggesting 
that Nf1-/- Schwann cells have the potential to invade surrounding tissues (Figure 4-7iii 
and iv). Importantly, we observed that at the tumour region, the majority of GFP+ 
cells are negative for the mature Schwann cell marker S100β; only the myelinating cells 
appear to express this marker (Figure 4-8). This is consistent with the histological 
analysis represented in Figure 4-4, in which most of the S100β positive cells were 
found in the “regenerated” area and only sparsely detected in the lesion itself. How 
these observations relate with previous described model of NF1 and possible 
implications for the histopathological analysis of these tumours will be addressed later, 
in chapter 7. 
Most of the GFP+ cells were also positive for the p75 marker, providing strong 
evidence that these are dedifferentiated, Nf1-/- Schwann cells (Figure 4-9A). 
Importantly, comparison of EM micrographs and immunofluorescence images, revealed 
a striking resemblance between many of these GFP/p75 expressing cells– which exhibit 
long cytoplasmatic processes enwrapping other cells – and the cells frequently found in 
neurofibromas and traditionally identified as “perineurial-like” (Figure 4-10). This 
suggests that, at least some of these cells, despite their distinct ultrastructural 
morphology, are in fact, mSchwann cells derived. Furthermore, we were able to 
identify some GFP positive/p75 negative cells in these tumours (Figure 4-9B). This 
raises the possibility that neurofibromas contain rare cell populations derived from P0- 
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Figure 4-7: GFP+ positive cells are a major cellular component of the 
tumours that developed in NF1 mutants. Cross-sections of a tumour from a 
P0:YFP-Nf1fl/fl mouse were co-stained for GFP (green) and the axonal marker, neurofilament 
(red). Note that GFP+ cells are devoid of axonal contact. Arrows in iii and iv point to Nf1-/- 
Schwann cells (GFP+), invading the adjacent muscle tissue. 
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Figure 4-8: In the tumour region, the majority of Nf1-/- Schwann cells 
do not express the S100β  marker. Neurofibroma cryosections from a P0:YFP-Nf1fl/fl 
mouse, were immunolabelled for GFP (green) and S100β (red); nuclei were counterstained 
with Hoechst (blue). i and ii show representative images of the neoplastic tissue (note the 
scarce S100β positivity); iii and iv images were taken from the “regenerated” area. The white 
arrow in iii points to a rare GFP+S100β+ cell. 
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Figure 4-9: Most, but not all, Nf1-/- Schwann cells express p75.   
A neurofibroma was dissected from a P0:YFP-Nf1fl/fl animal, 6 months after Tmx treatment and 
nerve injury. Cryosections of the tumour were immunostained for GFP (first panel in A and B) 
and p75 (second panel in A and B); nuclei were stained with Hoechst (blue). A) The majority 
of the GFP+ cells were also positive for the non-myelinating/dedifferentiated Schwann cell 
marker p75. B) Arrowheads identify some GFP positive cells that are negative for p75. 
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Figure 4-10: Striking resemblances between “perineurial-like” cells 
and p75+ Schwann cells or GFP+ SC-derived cells in a neurofibroma. 
A and D) EM micrographs showing representative images of “perineurial-like” cells 
enwrapping minifascicles or forming parallel layers of cytoplasmic processes. B and C) 
Immunofluorescence images showing p75 positive Schwann cells  (green in B) and GFP positive 
(green in C) mSC-derived cells with remarkable morphological similarities to the “perineurial-
like” cells represented in A and D. 
   
  129 
expressing cells that have lost their original identity. It would be interesting to 
investigate this further.  
In contrast to the homogenous distribution of GFP+ cells in neurofibromas, only a few 
positive cells were found at the injury site in controls (Figure 4-11). This might suggest 
that the Schwann cells at the injury site do not derive from P0-expressing cells, but 
instead are mostly derived from the non-myelinating population. A more extensive 
characterization of injured control nerves is needed to investigate if  “perineurial-like” 
mSC-derived are also present in the context of a normal regeneration process. 
Together, these results provide strong evidence that neurofibroma is driven by 
expansion of Nf1 deficient cells, derived from myelinating Schwann cells. 
 
4.7 Increased proliferation in Nf1-deficient tumours, 8 months 
following injury 
We monitored cell proliferation in neurofibromas and control nerves, 8 months after 
nerve transection. By administering EdU 2 days before analysis, we found that cells 
were more likely to be dividing in neurofibromas as compared to normal regenerated 
tissues from controls (Figure 4-12). To address which cells were proliferating within 
the neurofibromas, we stained tumour sections with antibodies for the dedifferentiated 
Schwann cell marker p75. We observed that only 4% of the proliferating cells are 
p75+. Although surprising, this is consistent with the low proliferative index that 
characterises established benign neurofibromas. Interestingly, when we co-stained 
tumours sections with the macrophage marker Iba-1, we found that nearly 50% of the 
proliferating cells were positive for this marker (Figure 4-13). This may suggest that, 
although proliferating slowly at this stage of tumourigenesis, Nf1-/- Schwann cells may 
have a non-autonomous effect on other cellular constituents of the tumour. By 
propagating the inflammatory response, Nf1-/- cells may contribute to the maintenance 
of a pro-tumourigenic microenvironment and, consequently, the tumour itself. 
 
4.8 Characterization of the tumour stroma - inflammatory cells 
and fibroblasts 
A role for inflammation in tumourigenesis is now widely accepted, and it has become 
evident that an inflammatory microenvironment is an essential component of the 
stroma in most tumours (Grivennikov et al., 2010). Histological analysis of H&E stained 
sections of the neurofibromas that developed at the injury-site had already indicated 
the presence of a strong associated inflammatory response.  
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Figure 4-11: Few GFP+ cells are found at the wound site, in control 
animals, 6 months following injury. Cross-sections of sciatic nerves from control 
and Nf1-deficient mice were immunostained for GFP (green). Figure compares the injured 
nerve at the wound site (that corresponds to a neurofibroma in Nf1-deficient nerves) (ii and 
iv) with the respective unwounded contralateral nerve (i and iii). Note that in contrast to the 
neurofibroma where abundant GFP staining is observed, only a few positive cells are found in 
regenerated controls at the injury site. 
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Figure 4-12: Increased proliferation in NF1 mutant nerves.  
A) EdU staining showing that 8 months following transection, Nf1-deficient sciatic nerves 
exhibit increased cell proliferation at the site of injury when compared to the same region of 
control animals. Note that proliferation varies greatly between regions within the same nerves. 
The green dashed line delimits injured regions. B) Quantification of EdU positive cells in all 4 
genotypes (n=3 or 4 of each group, data are mean values, error bars represent ±SEM). 
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Figure 4-13: p75+ Schwann cells and macrophages proliferate in 
tumours formed in Nf1-deficient peripheral nerves after injury.   
A) 8 months after nerve transection, mice were injected with EdU and sciatic nerves were 
harvested and processed for immunostaining. Cross-sections of tumour samples from NF1 
mutants were stained for: EdU (red) and p75 (green) (i and ii); and EdU and Iba-1 (green) (iii); 
B) Quantification of p75+EdU+/EdU+ and Iba1+EdU+/EdU+ (data represent means and ±SEM 
of 3 animals per group). 
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To further characterize the inflammatory component of the tumours, we sectioned 
enlarged Nf1-deficient sciatic nerves and regenerated controls, 8 months following 
injury and performed a series of stainings for a variety of immune cells. Mast cells, a 
component of the innate immune response, were shown to be a critical player in a 
distinct mouse model of neurofibroma development and their presence is one of the 
hallmarks of these tumours. To investigate if this was the case in the neurofibromas 
developed in our NF1 model, we stained paraffin sections with Alcian blue and 
observed that tumours contained an increased number of mast cells when compared 
to regenerated control nerves (Figure 4-14A). Consistent with the Alcian blue staining, 
immunolabelling with the mast cell receptor, c-Kit, also showed an increased number 
of mast cells in the tumours (Figure 4-14B and C). Regenerated nerves, although having 
fewer mast cells than the neurofibromas, still exhibited higher numbers of mast cells 
comparatively to unwounded nerves, which suggests that mast cells persist in the 
nerve long after regeneration. Interestingly, all the animals with an Nf1+/- background 
displayed more mast cells than their Nf1+/+ littermates. This observation, despite being 
found consistently in all the mice analysed, did not reach statistical significance likely 
due to the reduced number of animals used in the experiment (n=4). If proven true, 
this would be in accordance with reports from the Clapp group that showed that 
Nf1+/- mast cells are hypermotile in response to the KitL secreted by Schwann cells and 
that this effect is exacerbated in the presence of Nf1-/- Schwann cells (Yang et al., 
2003). Still, because the frequency of tumour formation did not vary with the Nf1 
background, we can eliminate a determining role for Nf1+/- mast cells in our 
neurofibroma model. Tumour-associated macrophages are a major component of the 
infiltrate of most tumours (Balkwill and Mantovani, 2001). Macrophages derive from 
circulating monocytic precursors and are directed into tumours by chemoattractants. 
In accordance with the high proliferative rate described earlier in Figure 4-11, 
macrophages are present at elevated numbers in these tumours (Figure 4-15). 
Neutrophils are the first immune cell to arrive at site of injury, but are usually cleared 
within few days following wounding. We assessed the presence of these phagocytic 
cells in sciatic nerves of control and NF1 mutants, 8 months following injury. NIMP 
positive cells, although in a reduced number, were only found in the tumours and not 
in the regenerated nerves (Figure 4-16 A and C). Finally, we have analysed the 
presence of T cells, a sub-group of lymphocytes that play a central role in the 
adaptative immune response.  
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Figure 4-14: Increased infiltration of mast cells in P0-Nf1flfl and P0-
Nf1fl/- sciatic nerves. A) Alcian blue and B) c-Kit immunolabelling show increased 
numbers of mast cells in the injured region of NF1 mutants when compared to controls, 8 
months following nerve transection. C) Quantification of mast cells as determined by c-Kit 
staining of sciatic nerve cryosections (n=3 animals for each group; 8 fields per section and 3 
sections per animal were counted, data are represented as mean values ±SEM). 
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Figure 4-15: Macrophages are present at elevated numbers in NF1 
mutant nerves at the tumour region. A) Representative images of sciatic nerve 
cross-sections stained for the macrophage marker Iba-1 and counterstained with DAPI. B) 
Quantification of Iba1+ cells (n=3 animals for each group, 10 fields were counted per section, 
3 sections were analysed for each animal, data are represented as mean values ±SEM). 
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In tumour immunity, T cells are generally more recognized for their antitumour 
activity, however they may also exert tumour-promoting effects under certain 
circumstances (Grivennikov et al., 2010).  CD3 staining revealed the occurrence of a 
few positive cells, exclusively in the tumours (Figure 4-16B and D). To summarize; we 
confirmed the presence of a strong inflammatory component in the neurofibromas 
that formed at the site of injury in Nf1-deficient sciatic nerves. These immune cells 
were differentially distributed throughout the tumours, with most found in clusters in 
the proximity of blood vessels within the tumours (Figure 4-17). In addition to 
inflammatory cells, it is becoming increasingly clear that fibroblasts are also prominent 
modifiers of tumourigenesis (Kalluri and Zeisberg, 2006). Fibroblasts are the principal 
cellular component of connective tissue and are best known for the prominent role 
that they play in wound repair. Activated fibroblasts at the lesion site, proliferate, 
generate large amounts of extracellular matrix and contribute to the contraction of 
the healing wound. Work from our laboratory has discovered an additional and 
important role for these cells in peripheral nerve injury; interactions between 
fibroblasts and Schwann cells, through ephrin-B/EphB2 signalling, result in cell sorting, 
which in turn enables the directional collective cell migration of Schwann cells out of 
the nerve stumps to guide regrowing axons across the wound (Parrinello et al., 2010). 
In normal circumstances, once the wound is repaired, fibroblasts decrease in number 
and revert to a resting phenotype. Instead, at the site of a tumour, they are frequently 
found perpetually activated and play an increasingly acknowledged role in fostering 
tumourigenesis. To investigate if activated fibroblasts were present in neurofibromas 8 
months following injury, we performed immunohistochemistry for Smooth-muscle-
actin (SMA). This marker, although frequently used to identify activated fibroblasts, 
also labels other cell types such as pericytes. Indeed, in all the nerves examined, SMA+ 
cells were found surrounding blood vessels (Figure 4-18iii).  Nevertheless, outside the 
blood vessels, positive cells were detected exclusively in tumours and never in 
regenerated nerves, suggesting that activated fibroblasts are a component of the 
tumour stroma, in some of the neurofibromas. However, as illustrated in Figure 4-18, 
not all tumours were positive for this marker, implying that activated fibroblasts do not 
play a critical role in neurofibroma development in the model described here. This is 
evocative of the pathology of human neurofibromas, in which fibroblast contribution to 
tumour composition is highly variable (Thomas et al., 2011). The presence of these 
different cell types so long after injury is consistent with the presence of a chronically  
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Figure 4-16: Inflammatory cells are recruited into the tumours 
developed by NF1 mutants. Eight months following injury, Tmx-treated mice were 
harvested and cryosections of sciatic nerves were immunostained for A) the neutrophil 
marker NIMP-R14 and for B) the T-cell marker CD3. Representative images of cross-sections 
are shown. C) Quantification of CD3+ and NIMP+ cells (n=3 animals for each group, 10 fields 
were counted per section, 3 sections were analysed for each animal, data are represented as 
mean values ±SEM). 
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Figure 4-17: A strong inflammatory response is observed in the 
neurofibromas. Immunostainings of cryosections of peripheral nerve tumours, 8 months 
after injury show clusters of immune cells, heterogeneously distributed. Examples of regions 
strongly positive for A) the macrophage and mast cell markers (Iba1 and c-Kit, respectively); 
B) the neutrophil marker NIMP and C) the T-cell marker CD3. ii shows higher magnifications 
of i. 
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Figure 4-18: Variable expression of Smooth Muscle Actin in tumours 
from NF1 mutant mice. A) Sciatic nerves were embedded in paraffin and processed 
for SMA staining, 8 months following surgery. Control mice (i and ii) were consistently 
negative for the activated fibroblasts marker SMA. iii shows SMA+ pericytes in an uncut 
control. Tumours developed by P0-Nf1flfl and P0-Nf1fl/- mice (iv-vi) showed variable expression 
of SMA. Shown are three examples representative of this variability (3 animals of each 
genotype were analysed).  
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activated inflammatory response and is strongly reminiscent of Dvorak’s description of 
tumours as “wounds that do not heal” (Dvorak, 1986). 
 
4.9 Distal to the injury site, Nf1-deficient nerves regenerate 
normally 
Up to this point, I have shown that adult Nf1-/- mSchwann are protected from 
tumourigenesis in the context of a normal nerve; yet, when in concert with a nerve 
injury, they give rise to neurofibromas. Thus, it seems that the dedifferentiated, 
progenitor-like state to which mSchwann cells revert upon injury is more susceptible 
to tumourigenesis. Nevertheless, the dedifferentiated state is not, per se, sufficient to 
render Schwann cells tumourigenic. As detailed before, upon wounding to a peripheral 
nerve, all Schwann cells distal to the site of injury dedifferentiate along the length of 
the nerve. However, interestingly, neurofibromas arose exclusively at the site of injury. 
We examined the structure of sciatic nerves downstream of the injury site in both 
controls and NF1 mutants (Figure 4-19A). Figure 4-19Bi shows representative images 
of semi-thin sections stained with toluidine blue and visualized by phase-microscopy. 
Control and Nf1-deficient nerves were indistinguishable; both appeared packed with 
myelinated axons and reduced interstitial space (similar to the site of injury in 
controls- see Figure 4-5i). This was further confirmed at the ultrastructural level using 
electron microscopy; the distal region of controls and mutants were well regenerated 
and, most importantly, comparable in all the 4 genotypes studied (Figure 4-19Bii). 
In agreement with the structural analysis, the inflammatory response in controls and 
mutants was found to be mostly resolved and equivalent between groups. Accordingly, 
the cell density was not significantly different in regenerated controls and mutant distal 
nerves (Figure 4-20). Nevertheless, repaired nerves exhibited slightly higher numbers 
of mast cells and macrophages when compared to unwounded tissue, even when mice 
were analysed up to 12 months after nerve transection, suggesting that a basal 
inflammatory response persists long after wounding (compare Figure 4-20 and 3-9). 
Together, this data suggests that distal to the site of injury, Nf1-/- Schwann cells are 
protected from tumourigenesis. What is more, the nerve region downstream of the 
injury site seemed to regenerate similarly in control and NF1 mutants. Exceptionally, in 
a very small number of tumours (n=3 out of 25 in P0-Nf1flfl and 1 out 18 in P0-Nf1fl/-), 
the distal region was also enlarged, in a manner indicative of the tumours spreading 
along the nerves (Figure 4-21). This is consistent with the human pathogenesis of  
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Figure 4-19:  Distal to the wound site, nerves regenerate normally in 
P0-Nf1fl/fl and P0-Nf1fl/- mice. The distal region of injured sciatic nerves is 
indistinguishable between control (A) and mutant mice (B). i shows representative phase-
microscopy images of semi-thin sections stained with toluidine blue; ii shows electron 
micrograph images. iii represents a semi-thin section from a control uncut  nerve (4 animals of 
each genotype were processed for analysis, similar results were obtained for Nf1+/+ and Nf1+/-  
backgrounds). 
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Figure 4-20:  Analysis of the region distal to the injury site, 8 months 
following wounding. No significant differences were found in the numbers of (A) c-Kit+ 
mast cells, (B) Iba-1+ macrophages and (C) total nuclei in the distal regions of control and 
mutant animals. On the right, a comparison between distal stumps and cut sites is shown. The 
few mutant nerves in which the tumours spread to the distal stumps were not included in this 
analysis; the “cut site” in NF1 tumours refers to tumours only - macroscopically normal nerves 
were not analysed (n=3 animals for each group, 10 fields were counted per section, 3 sections 
were analysed for each animal, data are represented as mean values ±SEM). 
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Figure 4-21: A few tumours spread along the distal stump of the 
nerve. A) Macroscopic appearance of tumours that developed in (i) P0-Nf1fl/fl (ii) and P0-
Nf1fl/- mice. Red boxes indicate the regions cross-sections were prepared from B) Hoechst 
staining of the distal region of the nerve shown in A-i. Dashed lines delineate uninjured (green 
line), regenerated (orange) and tumour (red) areas. Right panel shows zoomed areas. C) Table 
showing the number of tumours that spread along the distal stump. 
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neurofibromas in which tumours can be found growing along large nerve plexus 
(Hrehorovich et al., 2003).  
 
4.10 Distal to the tumour, Nf1-/- Schwann cells 
redifferentiate and remyelinate axons 
The absence of tumours in the distal stump of injured Nf1-deficient nerves could be 
explained by two distinct hypotheses: 1) at this region of the nerve Nf1-/- Schwann cells 
die following dedifferentiation; 2) Nf1-/- Schwann cells persist, but the presence of pro-
differentiative signals (and/or the absence of pro-tumourigenic cues) induce them to 
redifferentiate. 
To discriminate between these possibilities we took advantage of the YFP reporter 
described earlier and traced the fate of Nf1-/- Schwann cells. Six months following 
injury, we harvested Nf1-deficient mice and analysed the nerve region downstream of 
the tumours that had formed at the wound-site (see Figure 4-19A). Remarkably, Nf1-/- 
Schwann cells were found redifferentiated and remyelinating axons, as illustrated in 
Figure 4-22. In contrast to what we encounter at the tumour site, where most GFP 
positive cells are deprived of axonal contact and are S100 negative, at the distal stump 
we found that nearly all GFP positive cells were associated with axons and expressing 
S100 (Figure 4-22). The same was true in the equivalent region of regenerated control 
nerves (Figure 4-23). It is noteworthy that a few GFP+S100-negative cells were also 
identified, some of which were GFP+p75+. Based on this observation, we may 
hypothesize that once dedifferentiated, originally P0-expressing, myelinated Schwann 
cells can re-differentiate into non-myelinating Schwann cells. This needs further analysis 
to be confirmed but, if proven true, provides additional evidence of the remarkable 
plasticity of these cells.  
This data demonstrates that the same genetic insult (Nf1 loss) has opposing outcomes 
depending on the microenvironmental context; dedifferentiated Schwann cells at the 
distal site undergo redifferentiation, whereas at the wound site, unknown signals 
specific for this region induce dedifferentiated Nf1-/- Schwann cells to form 
neurofibromas.  
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Figure 4-22: Distal to the tumour region, Nf1-/- Schwann cells are 
found redifferentiated and remyelinating. Sections were prepared from the 
nerve region distal to the neurofibroma formed in a P0:YFP-Nf1fl/fl mouse (see Figure 4-16) and 
immunolabelled for A) GFP (green) and the mature Schwann cell marker, S100 (red); B) GFP 
(green) and the axonal marker neurofilament (red). Nuclei were stained with DAPI. In contrast 
to what was observed in the tumour itself, at this region of the nerve, Nf1-/- Schwann cells 
redifferentiated and remyelinated normally after injury. 
   
  146 
 
 
Figure 4-23: GFP-expressing cells persist in the regenerated control 
nerves, 6 months following injury. Distal nerves from P0:YFP controls were 
sectioned and stained for A) S100 (red), GFP (green) and DAPI (blue); B) p75 (red), GFP 
(green) and DAPI (blue). Six months after Tmx and nerve transection, most of the Cre 
expressing cells were found remyelinating and expressing the S100 marker. A few GFP+p75+ 
were found, suggesting that mSCs can redifferentiate into non-myelinating Schwann cells, after 
injury. Further confirmation is needed. 
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4.11 Chapter summary and conclusions 
In the previous chapter we had shown that loss of the tumour suppressor 
neurofibromin was unable to perturb myelinating Schwann cell behaviour and induce 
tumour formation in adult mice. Here we tested whether nerve wounding would be 
able to alter the tumourigenic properties of Nf1-/- Schwann cells. To this end, we 
performed nerve transection in Tmx treated control and NF1 mutants and, 6-8 
months later, analysed the nerves. We found that by this time-point, control nerves 
repaired normally and only a basal inflammatory response remained. In contrast, NF1 
mutants developed nerve sheath tumours at the site of injury. Importantly, the 
frequency of tumour formation was independent of the genetic background, eliminating 
a decisive role for Nf1 haploinsufficiency. We characterized the tumours by means of 
histological and ultrastructural analysis and classified them as neurofibromas. Strikingly, 
we traced Nf1-/- cells using P0:YFP-Nf1fl/fl animals and identified them as a major cellular 
component of the tumours. Not all the GFP+ cells were S100 positive, raising the 
exciting possibility that myelinating, P0-expressing Schwann cells may transdifferentiate 
into different cell types, upon injury. In particular, we noticed a remarkable similarity 
between GFP+/S100- cells and a frequent cellular constituent of neurofibromas, usually 
identified as “perineurial-like” cells. Hence it seems likely that these morphological 
distinct cells are, in fact, mSchwann cell derived. Further work will be done to better 
characterize these cells and to test if they also occur in injured control nerves or if this 
phenomenon is specific to an Nf1-/- context.  
We described a strong inflammatory component associated with the neurofibromas 
that develop in Nf1 mutants and confirmed the highly heterogeneous nature of the 
tumours.  
The data described revealed that, unlike their differentiated counterpart, 
dedifferentiated progenitor-like Schwann cells can be rendered tumourigenic by Nf1 
loss. However, the switch in differentiation state is not, by itself, sufficient. Indeed, 
although Schwann cells dedifferentiate along the entire length of the nerve 
downstream of the injury, we found that tumours arose exclusively at the wound-site. 
Remarkably, when we analysed sciatic nerves distally to the wound site, we found that 
Nf1-/- Schwann cells had redifferentiated and remyelinated axons. Consistent with this, 
distal regions of both controls and mutants showed equivalent regeneration.  
Taken together, this data shows that the tumourigenic potential of Nf1-/- mSchwann 
cells can be strongly modulated by microenvironmental cues. Otherwise refractory to 
tumourigenesis, dedifferentiated Schwann cells are susceptible to drive tumour 
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formation, but only when Nf1 loss happens in concert with specific signals present 
exclusively at the site of injury. This new mouse model for neurofibroma formation 
offers excellent opportunities to further dissect microenvironmental components that 
are critical in determining the fate of genetically altered Schwann cells.   
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Chapter 5: Results III 
5.1 Chapter introduction 
In the previous chapter I have shown that wounding cooperates with Nf1 loss to 
induce neurofibroma formation. Unexpectedly, all the tumours developed at the injury 
site, despite the Schwann cells dedifferentiating, with an associated inflammatory 
response, along the length of the nerve. This indicated that reverting to a 
dedifferentiated state is not sufficient to induce Nf1-/- SCs to form tumours. Instead, it 
shows that signals, or a threshold of signals, specific to the site of wounding are 
required to synergize with loss of Nf1 in mSchwann cells to drive tumourigenesis.  To 
start to dissect the microenvironmental cues that may be cooperating with the tumour 
suppressor loss we characterized NF1 mutants and control nerves shortly after injury, 
both at the injury site and distal to the wound. 
 
5.2 The ERK pathway is deregulated in Nf1-deficient mice 
following injury 
In chapter 3 of this thesis, I have shown that, despite its well-established role as a 
negative regulator of Ras signalling, neurofibromin loss in adult mSchwann cells does 
not cause a detectable effect on the relatively low basal levels of Ras/ERK signalling 
(Figure 3-10B). As mentioned, injury to the PNS induces Schwann cell dedifferentiation 
downstream of the site of injury through strong and rapid activation of the 
Ras/Raf/ERK pathway. We therefore wanted to investigate the ability of Nf1-deficient 
nerves to cope with the robust activation of this pathway, following nerve wounding. 
To do this, sciatic nerves of Tmx treated animals were dissected and processed for 
protein analysis, two, five and seven days following nerve transection. As expected, in 
the control mice we observed strong ERK activation, two days following injury. 
However, p-ERK levels markedly decreased by day 5 and 7 days following the surgeries 
were almost back to basal levels. In contrast, in NF1 mutant mice the levels of 
activated ERK were consistently found sustained at day 7. This was found in both 
Nf1+/+ and Nf1+/- backgrounds, once again ruling out an effect of Nf1 heterozygosity 
(Figure 5-1A). These results indicate that the ERK pathway is deregulated upon injury 
in mice with Nf1-/- mSCs.   
Interestingly, when we immunostained sciatic nerve cross-sections prepared from the 
wound site and the distal area of the injured nerve, 7 days following surgery, we found 
a remarkable difference between the regions. Downstream of the injury site, activated  
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Figure 5-1: ERK signalling is deregulated in sciatic nerves of Nf1-
deficient mice, following injury. A) Western blot analysis of nerves from control 
(Nf1fl/fl and Nf1fl/-) and mutant (P0-Nf1fl/fl and P0-Nf1fl/-) mice at indicated time-points after injury. 
Note the ERK signal is sustained at day 7 in mutant mice (blot representative of 4 different 
animals for each genotype) B) 7 days following injury, cryosections of sciatic nerves were 
immunolabelled for the mSC marker P0 (green) and p-ERK (red). Nuclei were counterstained 
with DAPI. Upper panel: site of injury; bottom panel: distal region. ERK pathway is sustained 
only at the site of injury, in NF1 mutants (representative images of 3 animals analysed for each 
group). 
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ERK could no longer be detected in both Nf1-deficient and control nerves. In sharp 
contrast, at the wound site, strong p-ERK staining was still observed, exclusively in 
NF1 mutant nerves (Figure 5-1B). This showed that, despite ERK activation occurring 
throughout the entire length of the distal stump, it is only at the injury site that the 
pathway is deregulated in the absence of NF1. We can envision two possible 
explanations for this: 1) the deregulation of ERK is dependent on a specific signal (or 
on a specific level of a signal) that is present exclusively at the wounding site; 2) at the 
distal region of the nerve, the microenvironment is more pro-differentiative, resulting 
in Ras/ERK suppression and consequently allowing normal redifferentiation of Schwann 
cells.  
These observations are in agreement with our previous findings that downstream of 
the injury site, Nf1-/- Schwann cells were refractory to tumourigenesis and instead were 
found redifferentiated and remyelinating axons, 6-8 months following wounding. 
Furthermore, it strongly suggests a link between the presence of deregulated Ras/ERK 
signalling at the injury site and neurofibroma formation.  
 
 
5.3 Increased proliferation in Nf1-/- Schwann cells 
Upon injury, Schwann cells associated with degenerating axons dedifferentiate to a 
progenitor-like cell and re-enter the cell-cycle. The onset of mitogenesis is 
synchronous and has been described to peak 3-5 days following injury (Triolo et al., 
2006). After this period, Schwann cells interact with the extracellular-matrix (ECM), 
reorganize their basement membrane and rearrange themselves into bands of Bungner. 
Importantly, Schwann cells mitotic activity is dependent on ERK signalling (Newbern et 
al., 2011; Napoli et al., 2012). We therefore tested if the deregulated levels of activated 
ERK detected in NF1 mutants would correlate with an effect on Schwann cell 
proliferation. Proliferation rates were assessed 7 days following injury (the time point 
at which we find that, contrary to controls, Nf1-deficient mice still exhibit elevated 
levels of p-ERK at the wound-site), in P0:YFP-Nf1+/+ and P0:YFP-Nf1+/- controls and in 
P0:YFP-Nf1fl/fl and P0:YFP-Nf1fl/- mutants. Although not statistically significant we found 
that, at this stage, Nf1-/- Schwann cells appeared to proliferate more than Nf1 positive 
or heterozygous cells (Figure 5-2A). Strikingly, this difference was only detected at the 
wound-site and not at the distal region, mirroring the differences in ERK activity and 
suggesting that by maintaining sustained activated levels of ERK, Nf1-/- Schwann cells are 
kept in a more proliferative-state (Figure 5-2B and C). 
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Figure 5-2: Increased proliferation in Nf1-/- Schwann cells 7 days 
following injury. EdU incorporation was assessed 7 days following injury in control (i and 
ii) and mutant mice (iii and iv). A) GFP labels Cre+ Schwann cells, EdU is stained in red. At the 
injury site of mutant mice, Nf1-/- Schwann cells (iii and v) showed increased proliferation when 
compared to GFP+ NF1+ cells in the same region of control mice (green in i and ii). B) 
Quantification of the % of GFP+EdU+ cells in control and mutant groups, at the site of injury. 
C) Similar quantification to B shows that at the distal region, similar rates of proliferation are 
observed in Schwann cells both in controls and mutant animals (n=3 of each animal group, 3 
sections were analysed for each animal, 10 fields were counted per section, data represent 
means ±SEM). 
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5.4 Analysis of the extracellular matrix components 
We next wanted to dissect putative signals differentially expressed at the injury site 
and the distal stump that could be affecting the behaviour of Nf1-/- Schwann cells 
specifically at the site of injury. First, we assessed the expression of ECM components. 
A variety of ECM proteins are upregulated following injury in the PNS and are thought 
to contribute to successful nerve repair by promoting axonal repair and SC 
remyelination (Akassoglou et al., 2002). During regeneration, ECM proteins (that can 
be organized in an interstitial matrix or at cell basement membranes) influence 
Schwann cell behaviour through sequestration and release of growth factors, and, 
through interaction with cell-adhesion receptors (Gardiner, 2011). Importantly, cell-
matrix interactions are known to activate ERK signalling in several cell types (Sanders 
and Basson, 2000).  
To investigate the distribution of ECM components following injury, we harvested 
mice 7 days following injury and compared the expression of the main ECM 
components – laminin 1, fibronectin, collagen I and collagen IV - at the injury site and 
distal stump, in control and Nf1-deficient nerves. As illustrated in Figures 5-3 to 5-6, 
laminin 1, collagen I and collagen IV localized specifically in the basal lamina of Schwann 
cells and epineurial cells (collagen IV was also found surrounding blood vessels), 
whereas fibronectin was abundantly expressed throughout the interstitial matrix 
(Figure 5-7). Overall, despite finding, as previously reported, increased expression of 
these proteins in injured nerves as compared to unwounded nerves, we failed to 
notice any striking difference in their expression levels between the injury site and the 
normal behaving distal region. Given this, we conclude that these components of the 
ECM are not the specific signal altering the behaviour of Nf1-/- Schwann cells.   
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Figure 5-3: Analysis of the extracellular matrix components, 7 days 
following injury- laminin1. A) Sciatic nerves of Tmx-treated mice were partially 
transected and harvested for immunostaining, one week later. Immunolabelling for the ECM 
component laminin1 (green) shows no differences in the expression of this protein between 
controls and mutants and between the injury site and distal regions. B) (in the next page) The 
same as in A, but only the green channel is displayed, for better visualization. C) Amplification 
of A (n=3 for each genotype, shown are representative images). 
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Figure 5-3: Analysis of the extracellular matrix, 7 days following 
injury- laminin1.  B) The same as in A, but only the green channel is displayed, for 
better visualization. Shown are representative images (n=3 for each genotype). 
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Figure 5-3: Analysis of the extracellular matrix, 7 days following 
injury- laminin1. C) Amplification of 5-3A. Note: In the images of the distal stump, 
axons have degenerated, but the structure is maintained, as clearly shown by the tubular 
organization of the ECM. 
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Figure 5-4: Analysis of the ECM, 7 days following injury- collagen 1.  
A) Cross-sections of sciatic nerves from controls P0:YFP-Nf1+/+ and P0:YFP-Nf1+/- and mutants 
P0:YFP-Nf1fl/fl and P0:YFP-Nf1fl/- were stained for the ECM component collagen 1 (red) and GFP 
(green). No differences were observed between genotypes and between the two regions of 
the nerve analysed. B) The red channel alone is shown for easier visualization (next page); C) 
Amplification of A (n=3 for each genotype, shown are representative images). 
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Figure 5-4: Analysis of the ECM, 7 days following injury- collagen 1.  
B) The red channel alone is shown for easier visualization  (n=3 for each animal group, 
shown are representative images). 
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Figure 5-4C: Analysis of the ECM, 7 days following injury- collagen 1 
C) Amplification of 5-4A. 
   
  160 
 
 
 
Figure 5-5: Analysis of the ECM, 7 days following injury – collagen IV.  
A) Cross-sections of sciatic nerves from controls Nf1fl/fl and mutants P0-Nf1fl/fl were stained for 
the ECM component collagen 1V (red), one week following surgery.  Collagen IV is strongly 
expressed at this time point, but in similar levels in all the genotypes and in both injury site and 
distal stump. Dashed line in a and i delineates injured area and unwounded nerve.  Arrow in A 
points to a strongly positive blood vessel. The two lower panels show the red channel alone. 
B) Amplification of j, i, n and p (n=2 for each genotype, shown are representative images). 
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Figure 5-5: Analysis of the ECM, 7 days following injury- collagen 1V.  
B) Amplification of 5-5A. Note: Similarly to Figure 5-3, ECM staining in the distal stump shows 
tubular organization, reflecting a well-preserved structure despite of axonal degeneration. 
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Figure 5-6: Analysis of the ECM, 7 days following injury - fibronectin. 
A) YFP positive control and mutant mice were injected with Tamoxifen and their sciatic 
nerves were transected. One week after, nerves were immunostained for the ECM 
component fibronectin (red) and GFP (green). r and s show unwounded controls. 
Representative fluorescent images of cross-sections are shown. No observable differences 
were detected between genotypes and between the injury site and distal regions of the nerve 
(n=3 for each group). 
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5.5 Enrichment of macrophages at the wound-site 
As mentioned before, injury induces a robust inflammatory response along the nerve. 
The presence of these immune cells at the wound site is known to be key for the 
successful repair of the damaged tissue; in the PNS specifically, they contribute to 
axonal and myelin debris clearance and remodelling of the nerve structure following 
damage. However, besides this well-established role in promoting healing, the 
presence of inflammatory cells has also been shown to play a primordial role in 
tumour-initiation. For example, an early study showed that the development of 
wound-induced tumour in chickens infected with Rous Sarcoma virus was shown to be 
dependent on the action of cytokines released by inflammatory cells at the site of 
wounding (Martins-Green et al., 1994). In order to identify any differential distribution 
of specific immune cells along the nerve, we performed immunostainings for 
inflammatory cells, 7 days following injury. No significant differences were observed in 
the recruitment of inflammatory cells between cells mutants and controls, suggesting 
that at this time point after injury, NF1 deficiency does not detectably affect the 
inflammatory response. Furthermore, analysis of the neutrophil marker NIMP and the 
T-cell marker CD3 revealed very few positive cells in all genotypes (less than 1 
positive cell per section), both at the injury site and distal stump, suggesting that these 
cells do not play a relevant role in promoting tumourigenesis (not shown). However, 
we did observe that increased numbers of macrophages were present at the wound 
site in comparison with the region downstream of the damage (Figure 5-7C). Although 
consistent, this difference was not statistically significant with the number of animals I 
have analysed. In addition, the number of mast cells also tended to be slightly higher at 
the wound site, in both controls and mutant nerves (Figure 5-7B). Again, the same 
results were obtained with Nf1+/+ and Nf1+/- backgrounds, eliminating a contribution of 
Nf1 heterozygosity. It is thus possible that the presence of relatively higher levels of 
mediators secreted by these immune cells may affect the behaviour of Nf1-/- Schwann 
cells, perhaps by providing a continuous stimulus to the Ras/ERK pathway. Further 
work is required to dissect which specific signals are synergizing with Nf1 loss to 
induce neurofibroma formation.  
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Figure 5-7: Enrichment of immune cells at the injury site, compared 
to the distal region of the nerve, 7 days following injury. A) Quantification 
of total nuclei at the site of injury (dark grey) and in the distal region (light grey) of sciatic 
nerves in controls (Nf1fl/fl and Nf1fl/-) and mutant mice (P0-Nf1fl/fl and P0-Nf1fl/-). B) 
Quantification of mast cells as determined by c-Kit staining. C) Quantification of Iba-1+ 
macrophages (for all experiments, data represent means of 3-4 animals; 8 fields were counted 
per section; 3 sections per animal, data represents mean values ±SEM). 
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5.6 Testing the therapeutic potential of MEK inhibitors 
I have shown that shortly following injury, Nf1-deficient mice exhibit deregulated ERK 
signalling in the region that later gives rise to tumours. To investigate the requirement 
of ERK deregulation in neurofibroma formation we are currently testing the effect of 
the highly selective MEK1/2 inhibitor PD 03255901 (Solit et al., 2006) on tumour 
development. We have chosen to use the inhibitor at a relatively low dosage (8 mg/kg) 
to try to reduce but not completely block signalling through the Ras/Raf/ERK pathway, 
because ERK activation is required for Schwann cell dedifferentiation and recruitment 
of inflammatory response (Napoli et al, 2012). To do this, we have developed an 
experimental plan, which is depicted in Figure 5-8A. Briefly, NF1 mutant animals are 
Tmx treated and their right sciatic nerve injured, as detailed before. Two days 
following surgery, the animals are either placed into the control DMSO group or 
treated i.p. with the PD inhibitor. The treatment is administered daily for 14 days in 
order to cover the period of time that corresponds to the most drastic cellular events, 
including the peak of the inflammatory response (Zochodne, 2008). So far, we have 
tested the effect of PD treatment at day 7 of treatment and 1 month following the 
beginning of the protocol and verified that PD treatment is not impairing either SC 
dedifferentiation (Figure 5-8C) or axonal regrowth (Figure 5-8D). However, the levels 
of activated ERK are substantially reduced when compared to untreated or DMSO 
treated animals (Figure 5-8B). We will be examining the longer-term effects of 
MEK/ERK inhibition in 3-4 months; if a reduction in the frequency of tumour 
development is observed, this will unveil MEK inhibitors as useful therapeutics for the 
treatment of neurofibromas, in particular following injuries and surgeries.   
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Figure 5-8: PD treatment efficiently reduces activation of the ERK 
pathway. A) Protocol of PD treatment; 8mg/kg of PD were injected i.p. daily, for 14 days 
starting on day 2 after injury. B) PD or vehicle (DMSO) treated animals were sacrificed 7 days 
following injury; sciatic nerves were harvested and analysed by Western blotting for p-ERK 
activity. C and D) Sciatic nerves from PD and vehicle treated animals were processed for p75 
(green) and neurofilament (red) immunofluorescence; nuclei were stained with Hoechst (blue). 
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     Hoechst      Neurofilament                Hoechst p75 neurofilament 
                             
 
 
 
 
 
 
 
 
 
 
 
 
(continuation from previous page) C shows that 7 days after injury, Schwann cells dedifferentiate 
despite PD treatment (note the strong p75 staining); D) 1 month following injury, axons 
have regrown similarly in control and PD animals. Figures represent region of the nerve 
distal to the site of injury. 
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5.7 Chapter summary and conclusions 
In this chapter I have shown that following injury, the ERK pathway is deregulated and 
sustained in Nf1-deficient nerves. Strikingly, this deregulation is only observed at the 
injury site, despite wounding inducing ERK activation throughout the entire distal 
stump of the damaged peripheral nerve. This correlates with the location of 
neurofibroma formation and suggests a link between deregulation of the Ras/ERK 
signalling and tumourigenesis. In addition, we found that Nf1-/- mSchwann cells exhibit 
slightly higher proliferations rates than control nerves, exclusively at the location of 
the injury. Thus, it appears that microenvironmental cues specific to the wound site 
are able to alter Nf1-/- mSchwann cells early following injury. In contrast, Nf1-/- Schwann 
cells downstream of the wound seem protected from these signals; the regulation of 
the ERK pathway does not seem impaired and Nf1-/- Schwann cell proliferate similarly 
to control nerves. This is in striking accordance with the longer-term studies that 
showed that at this region of the nerve, Nf1-/- Schwann cells behave normally and do 
not form tumours.  
Next, we compared nerve sections prepared from both the site of injury and the distal 
stump. We started by analyzing the expression of the ECM components laminin 1, 
fibronectin, collagen I and collagen IV. However, despite finding that all components 
were highly expressed following injury, we failed to detect any differences between the 
injury site and the distal stump, eliminating a role for these ECM components in 
promoting Nf1-/- Schwann cell tumourigenesis. We have also analysed the distribution 
of the inflammatory response along the injured nerves. Although we have detected, as 
expected, recruitment of immune cells throughout the entire length of the nerve, we 
found that at the injury site there was a small, but consistent, enrichment of mast cells 
and, more pronouncedly, macrophages. This may suggest that at the site of injury, a 
threshold of specific signals released by these cells is present and is necessary for the 
transformation of Nf1-/- Schwann cells.  
Finally, I have described current work that aims to test if ERK inhibition has 
therapeutic potential for the treatment of neurofibromas. 
In conclusion, I have shown that neurofibroma formation correlates with an early 
deregulation of Ras/ERK pathway. The signal(s) behind this is still unknown, but it may 
be related to increased numbers of inflammatory cells, present at the injury site. 
Importantly, as a result of the data described in this thesis, we are currently testing the 
potential therapeutic impact of MEK inhibitors in wound-induced neurofibromas.  
   
  169 
Chapter 6: Results IV 
6.1 Chapter introduction 
Ras/Raf/ERK signalling regulates major cellular processes as diverse as apoptosis, 
survival, proliferation and differentiation (Downward, 1998). This pivotal regulation is 
mainly achieved through modulation of signal amplitude and duration, which is afforded 
through manipulation of multiple regulatory controls; subcellular 
compartmentalization, crosstalk with other pathways and protein interactions between 
components of the pathway and scaffolds, phosphatases and adaptor proteins that 
enhance, inhibit or redirect the signal flux. 
The plethora of biological effects controlled by this pathway is well illustrated in 
Schwann cells in which Ras/ERK signalling has been implicated in mutually exclusive 
biological functions such as proliferation (Echave et al., 2009), differentiation (Newbern 
et al., 2011) and dedifferentiation (Harrisingh et al., 2004; Napoli et al., 2012). Given 
this central role, it is not surprising that aberrant Ras signalling is found in a range of 
syndromes affecting the nervous system and, importantly, in Schwann cells isolated 
from neurofibromas. It is therefore clear that this pathway must be under tight 
regulatory mechanisms in the PNS.  Consistent with this idea, I have shown in chapter 
3 that Nf1 loss in adult mice does not automatically alter ERK signalling, suggesting that 
other mechanisms of control must be in place. Similarly, studies in transgenic mice 
engineered to lose Nf1 during development showed that Schwann cells differentiated 
normally, indicating that ERK is not deregulated and suggesting that also during 
development Ras/ERK is subjected to additional regulatory mechanisms besides NF1 
(Joseph et al., 2008; Wu et al., 2008; Zheng et al., 2008). Nevertheless, these mice still 
developed tumours later in adulthood, perhaps suggesting that a trigger acts to perturb 
the flux of Ras/ERK and this may initiate tumourigenesis. In line with this, I have shown 
in the previous chapters that ERK deregulation precedes neurofibroma development, 
indicating that in this mouse model the Ras/ERK pathway might be involved in the early 
steps of tumour formation. In contrast, in the nerve regions where Nf1-/- Schwann cells 
exhibited normal ERK regulation, no tumours formed and Schwann cells 
redifferentitated normally. Collectively, these observations suggest that the flux of 
signalling through the ERK pathway is crucial in determining the fate of Nf1-/- SC. 
Understanding the normal mechanisms of ERK regulation in Schwann cells may provide 
insights into how ERK signalling contributes to tumourigenesis in the context of NF1 
and identify potential therapeutic strategies. 
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Given this, we employed a simple in vitro system that would allow us to investigate 
mechanisms by which ERK is regulated during Schwann cell differentiation. We have 
used rat primary Schwann cells that can be dissociated from rat peripheral nerves and 
expanded indefinitely in vitro in their undifferentiated, more “progenitor-like” state 
(Mathon et al., 2001). Importantly, these cells can be induced to express myelination-
associated markers by activation of cAMP signalling (Monuki et al., 1989; Shuman et al., 
1988; Sobue and Pleasure, 1984; Zorick et al., 1996b), which is implicated in Schwann 
cell development in vivo (Monk et al., 2009; Monk et al., 2011). This system has been 
extensively used to study mechanisms involved in Schwann cell differentiation and is 
amenable to efficient silencing with siRNA and shRNA. 
 
6.2 cAMP-differentiated Schwann cells show a dampened 
ERK signalling 
One of the best-studied pathways that crosstalks with and regulates Ras/Raf/ERK to 
control proliferation and differentiation is cAMP (Stork and Schmitt, 2002). Depending 
on the cell type, cAMP can either activate or inhibit ERK signalling. For example, in 
adipocytes and hepatocytes cAMP inhibits proliferation through ERK inhibition 
(Sevetson et al., 1993; Thoresen et al., 1999). In primary Schwann cells, cAMP signalling 
has different outcomes depending on the cellular context; at low concentrations and in 
the presence of mitogens cAMP promotes proliferation, whilst at elevated 
concentrations and in the absence of mitogenic signalling, it induces differentiation 
(Arthur-Farraj et al., 2011). Given its role in promoting SC differentiation and its 
known ability to regulate ERK signalling in different systems, we asked if the cAMP 
pathway is involved in ERK regulation in Schwann cells. To test this, primary Schwann 
cells cultured in defined medium without serum were treated with the cell-permeable 
cAMP analogue dibutyryl-cAMP (db-cAMP) for 2 hours, followed by stimulation with 
the mitogen NRG1 (specifically, the EGF domain of human recombinant NRG1 - see 
Figure 1-3) to activate ERK signalling, 10 minutes before lysis. Activation of the 
Ras/ERK pathway was measured using an antibody against pERK. NRG1 elicited strong 
phosphorylation of ERK in both untreated and cAMP treated cells, indicating that in 
these experimental conditions, cAMP does not detectably affect ERK signalling (Figure 
6-1A). This data suggests that cAMP does not have a direct effect on the Ras/ERK 
pathway in primary Schwann cells. Next, we tested if longer-exposure to cAMP (the 
upregulation of differentiation markers by cAMP is more evident at 24 to 48 hours of 
treatment), would unveil an indirect effect of cAMP on ERK regulation. To do this, 
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Schwann cells were kept in db-cAMP for 48 hours and then stimulated with NRG1. 
Remarkably, we found that the pronounced ERK activation evoked by NRG1 was 
severely blunted in db-cAMP treated cells (Figure 6-1B), indicating that the pro-
differentiative effect of cAMP dampens the flux of signalling downstream of Ras/ERK.  
 
 
6.3 Pro-differentiating conditions quench ERK activation in 
Nf1-deficient Schwann cells  
As mentioned, studies in mouse models of NF1 have shown that Nf1-/- Schwann cells 
are able to differentiate normally and give rise to the right numbers of myelinating and 
non-myelinating Schwann cells. We hypothesized that this is made possible by the 
existence of additional regulatory mechanisms that maintain ERK signalling quenched 
during development. As we found that cAMP signalling regulates ERK, we tested its 
effects on Nf1-/- Schwann cells using siRNA knockdowns (kd).  
To do this, we optimized the siRNA-mediated silencing protocol by using two 
transfections separated by 48 hours in order to maintain the suppression of NF1 levels 
for the duration of the experiment (Figure 6-2A-C). Using this system we tested the 
effects of Nf1 loss on ERK signalling. NF1 kd cells were induced to differentiate for 48 
hours in the presence of db-cAMP and then harvested 10 minutes after NRG1 
stimulation. As shown in Figure 6-2D, in unstimulated conditions we failed to detect 
any differences in ERK expression between scrambled control and NF1 kd cells, likely 
due to the low basal levels of ERK. In contrast, 10 minutes following NRG1 
stimulation, Nf1 deficient cells displayed slightly increased levels of activated ERK, 
consistent with the role of NF1 as a negative regulator of the pathway. Importantly, we 
observed that in the presence of cAMP, Nf1-deficient cells, similarly to controls cells, 
showed a marked dampening of ERK indicating that even in the absence of Nf1, cAMP 
signalling results in a dampened flux through the ERK pathway. These data may help to 
elucidate how Nf1 loss during development does not impair Schwann cell 
differentiation. 
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Figure 6-1: NRG1 stimulation elicits dampened ERK activation in 
Schwann cells induced to differentiate in the presence of db-cAMP. 
A) Short exposure to cAMP does not affect ERK signalling. Primary cultures of Schwann cells 
were grown to confluence and then incubated with either defined medium (SATO) or defined 
medium plus 1mM of db-cAMP. 2 hours later, cells were stimulated with NRG1 for 10 minutes 
and processed for Western blot analysis of p-ERK. B) Schwann cells were induced to 
differentiate by treatment with db-cAMP for 48 hours, and then stimulated with NRG1 for the 
indicated time-points. Western blot for p-ERK show that differentiated Schwann cells display 
quenched ERK activation when compared to undifferentiated cells (blot is representative of 4 
independent experiments). 
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Figure 6-2: NF1 knockdown cells exhibit a marked quenching of ERK 
activation upon NRG1 stimulation. A) Protocol of siRNA transfection. B) 
Western blot analysis shows that NF1 is efficiently knocked-down using siRNA and that 
protein levels remain low up to 80 hours following the first transfection. C) Schwann cells 
transfected with scrambled control appeared more rounded and flattened, while the NF1 
knocked-down cells showed the refractile morphology characteristic of Ras hyperactivation. 
D) Scrambled control and NF1 knocked-down cells were kept in db-cAMP for 2 days and 
stimulated with NRG1 for 10 minutes. Blot shows levels of p-ERK. 
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6.4 MKP3 is strongly induced by cAMP exposure 
In many systems cAMP inhibits ERK activation by uncoupling Raf from Ras activation 
(Cook and McCormick, 1993; Wu, 1993). To test if a similar mechanism operated in 
our system, Schwann cells were allowed to differentiate in the presence of cAMP and 
stimulated with NRG1 shortly before processing for Western blot analysis. As 
illustrated in Figure 6-3, cAMP did not significantly affect the levels of the activated 
upstream kinases Raf and MEK (Figure 6-3iii and iv). In addition, we analysed the levels 
of AKT activation, another Ras effector downstream of ErbB2, and detected no 
significant changes (Figure 6-3i). Together, these results suggest that cAMP specifically 
quenches ERK signalling downstream of MEK. 
The regulated dephosphorylation of the essential threonine and tyrosine residues in 
the ERK activation loop plays a key role in determining the magnitude and duration of 
the kinase activation and, hence, the physiological outcome of signalling (Owens and 
Keyse, 2007). The major players involved in this type of regulation belong to the family 
of dual specificity MAP kinase phosphatases (MKPs also known as DUSPs). 
Interestingly, it has been suggested that these phosphatases may be involved in 
regulating the extent of ERK activation to control the decision between differentiation 
and proliferation (Camps et al., 1998; Misra-Press et al., 1995). Moreover, cAMP 
signalling has been shown to transcriptionally activate MKPs (Burgun et al., 2000). To 
test whether these proteins play a role in the regulation of ERK signalling in Schwann 
cells, we cultured the cells for two days in db-cAMP and stimulated them with NRG1. 
Shortly before harvesting, cells were treated with a cocktail of phosphatase inhibitors 
(1mM NaF, 1mM NaO3 and phosphatase cocktail from Sigma). As shown in Figure 6-
4A, in the presence of phosphatase inhibitors, the ERK pathway was similarly induced 
in both differentiated and undifferentiated cells. This suggested that phosphatases are 
indeed contributing to the regulation of ERK signalling under differentiating conditions.  
A previous study reported that the ERK-specific phosphatase MKP3 is strongly 
upregulated at the mRNA level upon Schwann cell differentiation in vitro, in response 
to forskolin (an activator of adenylyl cyclase) (Bermingham et al., 2001). We therefore 
decided to determine the role of this phosphatase in ERK regulation in response to 
cAMP. To do this, Schwann cells were maintained in the presence of db-cAMP for 
different periods of time and then processed for Western blot analysis. As illustrated 
in Figure 6-4B, we detected a strong induction of MKP3 expression 24 hours after 
cAMP treatment, which was sustained for at least 48 hours. In contrast, we did not 
find any induction of the serine/threonine protein phosphatase 1 (PP1) (Figure 6-4C).  
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Figure 6-3: Dampening of ERK signalling occurs downstream of MEK. 
Schwann cells were differentiated in db-cAMP for 2 days before NRG1 stimulation. Ten 
minutes after NRG treatment, cells were harvested and analysed by Western blotting with the 
specified antibodies. ERK is the only kinase quenched in the presence of db-cAMP (blots are 
representative of 2-4 experiments). 
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Figure 6-4: The ERK-specific phosphatase MKP3 is strongly induced 
by cAMP signalling. A) Cells were differentiated in the presence of cAMP and 
stimulated with NRG1 for 10 minutes. After stimulation, cells were treated with a cocktail of 
phosphatase inhibitors or left untreated. Cells were harvested and processed for p-ERK 
analysis. Blot shows that in the presence of the phoshatase inhibitors, the ERK pathway is 
activated similarly in differentiated and undifferentiated SCs (blot is representative of two 
independent experiments). B) Cells were exposed to db-cAMP and harvested at 12, 24 and 48 
hours. Shown are levels of the phosphatase MKP3 (blot is representative of 3 independent 
experiments). C) Cells treated with db-cAMP for 48 hours were processed for 
phosphoprotein phosphatase 1 (PP1) analysis. 
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This data suggested that cAMP might exert its pro-differentiating effects, at least in 
part, by quenching ERK signalling through MKP3 induction. To test this more directly, 
we used the double transfection protocol described above to efficiently knockdown 
MKP3 (Figure 6-5A). MKP3 knockdown cells were either kept in defined medium or 
exposed to 1mM db-cAMP for two days and then stimulated with NRG1 and 
processed for Western blot analysis. Surprisingly, we found that in the absence of this 
phosphatase, db-cAMP still induced a strong dampening of ERK signalling, indicating 
that either MKP3 is not involved in ERK quenching or that MKP3 might act in 
conjunction with other phosphatases (Figure 6-5B). To discriminate between the two 
possibilities we compared the kinetics of ERK activation in response to NRG1 in 
control and MKP3 kd cells. As shown in Figure 6-5C, in the absence of MKP3, cAMP 
treated cells showed a stronger and more rapid activation of ERK following NRG1 
stimulation, suggesting that indeed MKP3 plays a role in regulating signalling through 
the ERK pathway. 
 
6.5 MKP3 loss impairs Schwann cell cAMP-induced 
differentiation in vitro, but not in SC-DRG co-cultures 
We next tested if MKP3, through regulation of ERK signalling, had an effect on 
Schwann cell cAMP-induced differentiation. To assess this, we transiently knocked-
down MKP3 in Schwann cells and then induced them to differentiate in the presence of 
high levels of cAMP. Forty-eight hours later, cells were harvested and RNA was 
extracted for analysis by quantitative RT-PCR. As shown in Figure 6-6, in the absence 
of the phosphatase, the mRNA expression of the myelin-protein P0 and the 
transcription factor Krox-20 (considered the master regulator of SC differentiation) 
were significantly impaired. This data suggests that MKP3 might regulate the outcome 
of cAMP signalling by setting the appropriate level of activated ERK. We then assessed 
the effect of MKP3 kd in a more physiological system. In vivo, Schwann cell 
differentiation is strictly dependent on axoglial signalling (Jessen and Mirsky, 2005). This 
can be mimicked in vitro by co-culturing Schwann cells with dorsal root ganglia (DRG) 
explants extracted from P0 (postanatal day 0) rats. In these cultures, Schwann cells are 
induced to differentiate and myelinate by axonal cues. In order to test the role of 
MKP3 in Schwann cell differentiation in these cultures we needed a more long-lasting 
knockdown (it takes 3-4 weeks to achieve significant myelination). To achieve this we  
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Figure 6-5: MKP3 knockdown does not prevent cAMP-mediated ERK 
dampening, but affects the kinetics of ERK activation following NRG 
stimulation. A) MKP3 is efficiently knocked-down using siRNA. B) MKP3 knockdown 
cells still show dampened ERK signalling in the presence of cAMP.  Scrambled control and 
MKP3 kd cells were either left untreated or exposed to db-cAMP for two days. Cells were 
stimulated with NRG1 for 10 min before lysis. C) In MKP3 kd cells, ERK activation occurs 
faster than in control cells, implicating this phosphatase in ERK regulation in differentiating 
conditions. Cells were kept in db-cAMP, stimulated with NRG1 for 5 and 10 min and then 
processed for Western blot analysis of activated ERK (all the blots are representative of 2-3 
independent experiments). 
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Figure 6-6: MKP3 knockdown impairs db-cAMP induced Schwann cell 
differentiation. Control and MKP3 knocked-down Schwann cells were cultured in 
defined medium alone (undifferentiated) or with db-cAMP for 48 hours. A) Krox-20 and B) P0 
expression levels were then analysed using RT-PCR. B2M was used as loading control. The 
results are expressed as fold induction ±SEM of 3-5 independent experiments (*p≤0.05, 
significant difference, Repeated Measures ANOVA with post-hoc Newman-Keuls analyses). 
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cloned short hairpin RNA constructs (shRNAs) targeting the MKP3 sequence into the 
pSiren-RetroQ vector (see Chapter 2). This retroviral vector plasmid allows 
constitutive expression of the shRNA constructs and selection of the infected cells by 
puromycin treatment. We successfully obtained Schwann cells expressing 3 different 
shRNAs for MKP3, all of them leading to reduced levels of the phosphatase (Figure 6-
7A). Nevertheless, it is worth noting that the depletion of MKP3 achieved by this 
method was not as dramatic as the one obtained using siRNA. MKP3-shRNA 
expressing Schwann cells were seeded onto the DRG cultures, as described in 
Materials and Methods, and myelination efficiency was assessed 3 weeks later by 
quantification of fibres positive for the myelin protein zero (P0).  As depicted in Figure 
6-7B and C, we did not find MKP3 knockdown caused any consistent effect on 
myelination efficiency. This may suggest that in SC-DRG co-cultures other 
mechanisms, including other phosphatases, might compensate for MKP3 reduction, or, 
that the remaining levels of the phosphatase, although low, are sufficient to regulate 
ERK therefore allowing efficient differentiation. 
 
 
6.6 MKP3 is expressed in vivo at the onset of myelination 
and re-expressed following injury in the PNS 
Finally, we analysed the expression of the protein in vivo. As shown in Figure 6-8A, 
MKP3 is expressed in rat at postnatal day zero (P0) and its expression gradually 
decreases after that, consistent with a role in controlling ERK signalling during 
Schwann cell myelination. Interestingly, we also observed that the phosphatase is re-
expressed following injury, which may suggest that upon the ERK activation that 
rapidly follows injury, MKP3 again plays a role in setting the appropriate levels of ERK 
signalling. However, a more systematic analysis, including characterization of 
MKP3/pERK expression during embryogenesis, is still required.  
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Figure 6-7: MKP3 knockdown does not impair Schwann cell 
differentiation in SC-DRG co-cultures. Schwann cells were infected with 
pRetroSiren vector expressing 3 different shRNAs against MKP3. A) Blot shows reduced 
levels of MKP3 in MKP3-shRNA cells compared to scr-shRNA control. B) MKP3-shRNA 
Schwann cells were co-cultured with DRG and induced to differentiate for 3 weeks, by the 
addition of ascorbic acid and matrigel. Shown are representative images of immunostainings for 
the myelin protein P0. C) Quantification of B. Graph represents mean results from 4-5 
coverslips; 20 fields were counted in each coverslip. Error bars indicate ±SEM. n.s, not 
significantly different (one-way ANOVA, Bonferroni post-test). 
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Figure 6-8: MKP3 is expressed at P0 and re-expressed following 
injury to the PNS, in rats. A) Sciatic nerves from P0, P7, P16 and P32 rats were 
harvested and processed for Western blot analysis of MKP3. B) 4 weeks-old rats were injured 
in the right sciatic nerve. Blot shows MKP3 levels at the indicated time points following injury, 
in the proximal and distal stumps and in the uncut contralateral nerve (n=3 for each time-
point).  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6.7 Chapter summary and conclusions 
In this chapter we have used an in vitro system of primary Schwann cells to show that 
the flux of signalling through Ras/ERK in response to NRG1 is dampened in db-cAMP-
differentiated Schwann cells, as compared to undifferentiated cells. Importantly, we 
observed that this effect was still in place in NF1 depleted Schwann cells, suggesting a 
possible mechanism by which Nf1-/- Schwann cells differentiate during development. 
Also, we have shown that cAMP signalling induces the strong expression of an ERK-
specific phosphatase, MKP3, indicating a potential role for this mechanism in the 
regulatory control of the Ras/ERK pathway. However, we showed that MK3P depleted 
cells still exhibited ERK quenching, implicating other phosphatases/mechanisms in the 
regulation of this pathway. Nevertheless, the induction of the differentiation markers 
P0 and Krox-20 was impaired in MKP3 deficient cells, indicating that cAMP signalling 
likely exerts part of its pro-differentiating effects by setting ERK at appropriate levels, 
through induction of the phosphatase MKP3. The presence of other phosphatases or 
mechanisms was further suggested by the observation that SCs infected with shRNA 
for MKP3 myelinated to a similar extent as control cells. Alternatively, it is possible 
that the low levels of MKP3 that remained in shRNA-infected cells were enough to 
regulate ERK and allow differentiation to proceed. 
Importantly, we have detected expression of MKP3 at the onset of myelination in P0 
rats (earlier expression was not assessed yet) and later, in adult animals following 
nerve injury, suggesting that this protein plays a role in regulating ERK signalling in vivo. 
In the future it would be interesting to pursue further studies to investigate how this 
phosphatase (and others) may be involved in pathologies affecting the Ras/ERK 
pathway in the PNS, including neurofibroma formation. 
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Chapter 7: Discussion 
Although NF1 is widely expressed, NF1 patients are predisposed to a unique and 
restricted set of tumours, suggesting that certain cell types are particularly sensitive to 
loss of this specific tumour suppressor. The most common tumourigenic manifestation 
in these patients is the development of neurofibromas, benign tumours of Schwann cell 
origin that arise in peripheral nerves. Schwann cells, or cells within the Schwann cell 
lineage are therefore, highly sensitive to loss of Nf1. Neurofibromin loss is thought to 
induce tumourigenesis by leading to Ras hyperactivation. However, the mechanisms by 
which Ras becomes activated in the peripheral nerves and through which precise 
downstream effectors it exerts its tumourigenic effects remain elusive.  
Previous work in mouse models showed that disruption of the Nf1 gene in early stages 
of SC development (NCSC-SCP) resulted in neurofibroma formation. Surprisingly, 
analysis of post-natal nerves demonstrated that embryonic loss of Nf1 did not 
automatically impact SC differentiation in that Nf1-/- SCs appeared to have developed 
normally and were present in the right numbers in post-natal nerves. Instead, the 
embryonic loss of Nf1 had “primed” the downstream/differentiated progeny with 
aberrant properties that ultimately led to tumour formation in adult life. The lack of a 
detectable effect of Nf1 loss on SC differentiation was particularly intriguing in light of 
the findings in our laboratory that sustained activation of Ras/Raf/ERK signalling in 
Schwann cells induces dedifferentiation and proliferation. To explain these apparently 
contradictory observations, we hypothesized that during development, the normal 
nerve microenvironment (perhaps through axonal signals), acts to quench the Ras 
pathway thereby enabling normal differentiation. However, when later in life, as yet 
unknown signals activate Ras, Schwann cells that in the adult life rely on NF1 for the 
proper regulation of Ras signalling, fail to dampen the signal in the absence of 
neurofibromin and, probably in concert with additional microenvironmental/epigenetic 
factors, culminate in uncontrolled proliferation and tumour formation. In this thesis, I 
presented worked aimed at testing these hypotheses.  
 
7.1 Adult, quiescent myelinating Schwann cells are not 
susceptible to Nf1 loss 
Contrary to other cell types that rely on a population of self-renewing stem cells to 
generate new cells, there does not seem to be a pool of stem cells capable of 
generating new Schwann cells in an adult individual. Instead, the demand for new cells 
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is met by the ability of fully differentiated SCs to dedifferentiate to a “progenitor-like” 
state with proliferative capabilities. This feature is particularly obvious and relevant 
following an injury to the peripheral nervous system, upon which SCs revert to a 
dedifferentiated state, proliferate and create a microenvironment conducive for nerve 
regeneration. Keeping in mind the remarkable plasticity that SCs retain throughout 
their life, I tested the susceptibility of adult myelinating Schwann cells to give rise to 
tumours upon loss of Nf1. However, I found that the specific disruption of the Nf1 
gene in adult, myelinating Schwann cells did not alter SC differentiation status and 
accordingly, did not result in neurofibroma formation. The resistance of adult mSCs to 
Nf1-induced neurofibromas is likely a consequence of the limited proliferation of adult 
myelinating Schwann cells. To test this possibility we have investigated the homeostatic 
dynamics of the SC population in the adult intact nerve. We have assessed SC 
proliferation in the adult sciatic nerve by continual administration of EdU over periods 
up to 70 days. Interestingly, we have found that whilst non-myelinating SCs do 
proliferate, albeit in a slow rate (approximately 4% per month), myelinating SCs appear 
to be remarkably quiescent in the adult peripheral nerve (we have failed to identify a 
single EdU positive nuclei in more than 14,000 cells counted) (Nihouarn et al., 
unpublished data). It is therefore likely that very low levels of Ras signalling are 
required to maintain SCs in this highly quiescent state. In this scenario, the Ras 
pathway in myelinating Schwann cells may not get sufficiently activated to require the 
activity of NF1. This is consistent with the very low levels of basal ERK detected in the 
adult peripheral nerve and with the lack of any detectable change in ERK activation, 
following Nf1 loss. Furthermore, if myelinating SCs in an intact nerve do not normally 
proliferate (or at least exhibit an extraordinarily slow turnover rate), it would not be 
expected that in human patients, under these circumstances, the inactivation of the 
second Nf1 allele is a frequent event. 
During the course of this thesis, two independent studies from the Parada and Ratner 
laboratories have addressed if Nf1 loss in late stages of SC development (immature 
stage) or in adult SCs had tumourigenic potential (Le et al., 2011; Mayes et al., 2011). 
For this purpose, they have used a Tamoxifen-inducible Cre recombinase under the 
control of two distinct Plp drivers. Importantly, the results in both studies argued 
against the idea that there is a limited window of opportunity for neurofibroma 
formation (discussed in chapter 1), because when Tmx was administered to 
pregnant/lactating females or adult mice, inducing Nf1 loss at the immature stage and 
beyond, it resulted in the development of neurofibromas. Both studies found that loss 
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of Nf1 at the SCP and immature stage resulted in tumourigenesis with high penetrance. 
However, the studies diverged when they considered loss of Nf1 in mature SCs (2-4 
months old mice). Whereas Mayes and colleagues reported that Nf1-/- adult SCs gave 
rise to neurofibromas with 100% penetrance, beginning 5 months post-injection, Le 
and colleagues found that adult loss of Nf1 resulted in neurofibromas only in rare cases 
(2 out 19) and late in life, suggesting that only a very special set of circumstances can 
render an Nf1-/- mature SC capable of developing into a tumour. The reasons behind 
these discrepancies were not further investigated by the authors. Importantly, in the 
mouse model used by Mayes, PlpCre-mediated recombination was found in a broad 
range of cells: in addition to glial cells (satellite and SCs), spleen and thymus, 
recombination was also found in the heart, lung, thyroid, skin, fat and bone (mice 
developed hematopoietic-containing tumours in a variety of locations: liver, spleen, 
lung, kidney, lymph nodes). Given this ubiquitous expression, the study of the specific 
effect of Nf1 loss in mature SCs is hard to interpret. On the other hand, in the mouse 
model used by Le and co-workers, Nf1 recombination appeared to be more restricted 
and no other types of tumours developed, besides neurofibromas. Importantly, Plp is 
expressed in both myelinating and non-myelinating Schwann cells. In fact, Mayes 
performed an ultrastructural analysis of the nerve following Nf1 loss and, similarly to 
what has been described for some of the previous NF1 mouse models (P0aCre:Nf1fl/- 
discussed in chapter 1), observed that myelinating SCs seemed unaffected by Nf1 
ablation whilst Remak bundles appeared disrupted. This is in accordance with our 
observations that Nf1 loss in adult myelinating SCs does not seem to alter SC 
differentiation state. Furthermore, it is also in agreement with our findings, that unlike 
mSCs that appear completely quiescent, non-myelinating SCs proliferate in the adult 
nerve, even if at a slow rate, which may make them more susceptible to Ras 
deregulation in an Nf1-/- context. In conclusion, myelinating SCs appear to be a 
remarkable stable entity under normal homeostatic conditions and are not altered by 
Nf1 loss. Non-myelinating SCs, on the other hand, do proliferate in the adult sciatic 
nerve (although slowly), and for this reason are likely more sensitive to deregulation 
through Ras signalling upon Nf1 loss. Non-myelinating Schwann cells may therefore, be 
the cell of origin in the mouse models described by Mayes and Le.  
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7.2 Adult Nf1-/- myelinating SCs form tumours, following 
injury 
Human tumours frequently develop at sites of chronic injury. This was recognized 
more than a century ago by Rudolf Virchow, who postulated that previous injuries and 
chronic inflammation are a precondition for tumourigenesis (Virchow, 1863). Indeed, 
the relationship between chronic inflammation and the development of cancer has 
been well established in cases such as the Helicobacter pylori-induced gastritis/gastric 
cancer and chronic viral hepatitis/hepatic cancer, among others (Schafer and Werner, 
2008). Experimental studies in animal models have also supported this concept. In the 
pancreas for instance, expression of an endogenous K-RasG12V oncogene in adult acinar 
cells has no detectable consequences in the context of a healthy tissue. However, 
when these mice are challenged with chronic pancreatitis, they develop pancreatic 
tumours and cancer (Guerra et al., 2007). Therefore injury/inflammation can 
dramatically alter the potential of a genetically mutated cell to become a tumour-
initiating cell. Injury or infection-associated inflammation may promote tumourigenesis 
in a variety of ways. First, inflammatory cells may produce cytokines that promote cell 
division. Secondly, inflammation is associated with increased formation of reactive 
species (ROS) and genomic stress that can directly promote oncogenic mutations (Lin 
and Karin, 2007). Furthermore, it is becoming increasingly acknowledged that 
wounding may also promote tumourigenesis through mechanisms that are independent 
of inflammation. An example of how this may happen came from a recent study on a 
model of basal cell carcinoma (BCC). The conditional expression of an oncogenic allele 
of Smo - a central mediator of the Hedgehog (Hh) pathway- in follicular stem cells of 
an adult mouse model does not automatically result in hyperactivation of the pathway 
and does not induce tumour formation. However, upon cutaneous injury, these 
oncogene-expressing cells gave rise to BCC-like tumours (Wong and Reiter, 2011). 
Following injury, both wild-type and oncogene-expressing follicular stem cells leave 
their original location - the follicular bulge - and migrate to the wound site where Smo-
expressing cells (and not wild-type cells) exhibit strong activation of Hh signalling. This 
suggested that in the bulge, the presence of negative regulators of HH act to inhibit 
Smo-mediated oncogenesis. However, when cells leave the bulge to migrate to the 
wound site, stem cells escape from this growth-restrictive niche and the downstream 
HH signal transduction is derepressed, giving rise to BCC-like tumours. Hence, 
extrinsic factors that may be independent of inflammation, such as mobilization to 
distinct locations, may alter the tumourigenic potential of genetically altered cells.  
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In this thesis I presented experimental work establishing a relationship between 
wounding and neurofibroma development. I have found that whilst otherwise 
refractory to tumourigenesis, adult Nf1-/- myelinating SCs can form tumours in the 
context of a nerve injury. Importantly, besides creating the pro-tumourigenic 
microenvironment required by the Nf1 deficient cells to induce tumourigenesis, injury 
may also play an additional and critical role. As stated before, NF1 patients are born 
heterozygous and the loss of the second Nf1 allele is the bottleneck event for 
neurofibroma formation. This raises the question of under which circumstances 
inactivation of the second allele is made possible. Critically, unlike the highly quiescent 
intact nerve, following injury SCs exhibit elevated proliferation (Kim et al., 2000), 
which may create opportunities for somatic mutations to occur. Indeed, the 
observation that one of the Nf1+/- mice developed a tumour at a wound site may 
support this possibility. Identification of somatic mutations inactivating the second 
allele would nevertheless be required to confirm this.  
We have tracked Nf1-/- SCs by crossing our P0Cre-Nf1 models with a YFP reporter. 
We observed that Nf1-/- mSchwann cell-derived cells are a major component of the 
tumours that developed at the injury site. Surprisingly, we observed that contrary to 
the YFP-negative Nf1 positive-Schwann cells that exhibit immunoreactivity for the 
marker S100, the majority of the YFP-positive Nf1-/- mSC-derived cells within the 
tumour region, were negative for this marker. A similar phenomenon has been 
described by Cichowski and colleagues in the neurofibromas that developed in the 
Nf1+/-;Nf1-/- chimeric mouse model (Cichowski et al., 1999). In this mouse model, S100 
staining was only observed at the areas of normal nerve, whereas at the neoplastic 
lesion itself, only minimal staining was present. Interestingly, experiments in our 
laboratory have shown that Ras-expressing SCs exhibit a marked reduction in S100 
expression (Quereda, unpublished data). It is thus plausible that the lack of S100 
expression in Nf1-/- SCs is related to the presence of higher levels of Ras signalling. 
However, direct evidence for this is still lacking. I will address this in the future by 
performing in vitro knockdown of Nf1 and determining if and how the resulting 
elevated levels of Ras signalling may affect S100 expression. These findings are relevant, 
as they may have implications for the pathological classification of human 
neurofibromas. The presence of S100 positive cells is frequently used as a diagnostic 
criteria for neurofibromas. However, if S100 positive cells are specifically marking Nf1-
positive Schwann cells and not the neoplastic Nf1-/- SCs, it would be appropriate to 
consider alternative SC markers when assessing for the presence of neurofibromas. 
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Interestingly, analysis of immunofluorescence images of GFP+/S100-/p75+cells revealed 
that a great number of these cells, that are derived from mSCs and express the p75 
marker, therefore were presumably dedifferentiated SCs, appeared morphologically 
distinct from SCs. Indeed, their characteristic morphology - exhibiting long cytoplasmic 
processes either displayed in parallel arrays or enwrapping other cells - more 
resembled the one of “perineurial-like” cells, a frequent cellular component of 
neurofibromas. Perineurial-like cells although ultrastructurally similar to the fibroblast-
like cells that compose the perineurium, frequently lack markers expressed by 
perineurial cells such as the epithelial membrane antigen (EMA) (Perentes et al., 1987; 
Theaker and Fletcher, 1989; Theaker et al., 1988). It is therefore unclear if the 
“perineurial-like” cells present in neurofibromas derive from perineurial cells or other 
cellular components. Furthermore, as discussed in chapter 1, the origin of perineurial 
cells also remains unclear. Interestingly, it has been previously reported, that 
neurofibromas contain intermediate/transitional cells that share characteristics with 
both SCs and perineurial cells, which had led to the suggestion that SCs and 
“perineurial-like” cells are functional variants of the same cell type (Hirose et al., 
1986). These cells were characterized by presence of pinocytic vesicles (characteristic 
of perineurial cells) and continuous basal lamina (characteristic of SCs) (Erlandson, 
1991; Hirose et al., 1986). Based on our observations, it appears that in fact, 
“perineurial-like” cells, or at least some of them, derive from Nf1-/- myelinating 
Schwann cells.  It is, nonetheless, important to mention that a definitive confirmation 
that “perineurial-like” cells derive from Nf1-deficient Schwann cells can only be 
achieved by performing gold-labelling staining for GFP in neurofibroma EM sections of 
P0:YFP-Nf1fl/fl mice. Curiously, it has been reported that gpr126-null mice, that lack 
differentiated SCs cells due to the absence of signalling through cAMP, exhibit an 
elevated number of fascicle-forming “perineurial-like” cells (Monk et al., 2011). It is 
therefore tempting to speculate that also in this case, “perineurial-like” cells derive 
from Schwann cell progenitors, that lacking signals required to differentiate into 
mature SCs, abnormally differentiate into “perineurial-like” cells.  
In addition, we also identified a population of mSC-derived GFP positive cells that 
lacked the expression of the SC markers S100 and p75, raising the possibility that 
dedifferentiated SCs can also give rise to a distinct, as yet unidentified cellular 
component. An extensive molecular profiling of these cells is required to draw further 
conclusions. Importantly, a more exhaustive analysis of injured controls is still needed 
to test if this apparent potential of dedifferentiated SCs to give rise to different cells is 
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restricted to the Nf1-/- genotype or if it is a general characteristic of normal 
dedifferentiated SCs. The P0:YFP mice will be, in this sense, a valuable tool to further 
study the plastic behaviour of SCs following injury.  
The initial extensive characterization of the P0-Cre-mediated recombination revealed 
that, at least in the sciatic nerve, Cre recombinase appears to be specifically expressed 
by myelinating Schwann cells, arguing against the possibility that an as yet unidentified 
population of progenitors may be the neurofibroma-initiating cell in adult peripheral 
nerves. Nevertheless, although unlikely, the existence of a P0-expressing progenitor 
cell, which may reside in a distinct location and migrate to the injury site upon 
wounding, cannot be excluded. 
Our results indicate that mature myelinating Schwann cells can indeed be the cell of 
origin for neurofibromas, but only when they leave their quiescent state and are 
induced to dedifferentiate. 
 
7.3 Following injury, tumours form independently of the 
Nf1 background  
Tumour cells do not grow in isolation. Indeed, the tumour microenvironment controls 
the behaviour of genetically altered cells, either suppressing their tumourigenic 
properties or supporting and promoting their survival, proliferation and 
transformation. Neurofibromas - highly heterogeneous tumours composed of a 
mixture of cells that besides the neoplastic SCs, includes and a variety of non-
neoplastic elements including “perineurial-like” cells, fibroblasts, axons and mast cells - 
are a good example of the complexity of cellular interactions within tumours. In 
particular, in the Krox-20Cre-Nflflox mouse model, the ability of Nf1-/- SCs to drive 
tumours was shown to be dependent on the presence of an Nf1 haploinsufficient 
stroma (Zhu et al., 2002). As discussed in chapter 1, later studies in Krox-20Cre-Nflflox 
animals have narrowed the requirement of Nf1 heterozygosity to the presence of 
Nf1+/- mast cells. Accordingly, transplantation of Nf1+/- bone marrow into Krox-20Cre-
Nflflox animals (that normally do not develop tumours) was sufficient to allow Nf1-/- 
Schwann cells to form neurofibromas in an Nf1+/+ background. Importantly, this effect 
could be reverted by the inhibition of Kit signalling (required for mast cell migration 
and maturation), which pinpointed mast cells as the critical Nf1+/- player (Yang et al., 
2008). However, these studies did not clarify exactly how mast cell Nf1 heterozygosity 
promotes tumourigenesis. Importantly, Nf1 haploinsufficient mast cells are 
hypersensitive to KitL, a migratory stimuli secreted in elevated levels by Nf1-/-  Schwann 
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cells. Thus, it is possible that rather than conferring specific pro-tumourigenic effects at 
the site of the developing tumour (e.g secretion of growth factors that Nf1wt cells do 
not), Nf1 haploinsufficiency may act by attributing mast cells enhanced migration and 
recruitment to the mutant nerve.  
Importantly, in our mouse model, Nf1-/- Schwann cells developed tumours following 
injury in both Nf1+/+ and Nf1+/- backgrounds and at similar frequencies, indicating that 
Nf1 heterozygosity is not required for neurofibroma development.  
The requirement for Nf1 haploinsufficiency had been previously been challenged by the 
work in the Ratner lab with the Dhh;Nf1fl/fl and PlpCreER;Nf1fl/fl mouse models which also 
developed neurofibromas in a wild-type background (Mayes et al., 2011; Wu et al., 
2008). Nevertheless, it is important to take into consideration that both mouse 
models presented important differences in comparison with the model described in 
this thesis. Most critically, in both mouse models, Cre recombination was not targeted 
exclusively to Schwann cells, which brings additional hurdles in the interpretation of 
the results. In the Dhh model in particular, neurofibromas developed rapidly and 
extensively at the nerve roots, which was more consistent with a boundary cap rather 
than a SC origin (see chapter 1 for more details). Furthermore, Dhh is also expressed 
by additional embryonic cells such as SKPs. On the other hand, in the PlpCreER model 
Cre activity was also observed on a variety of cells in addition to Schwann cells. In 
contrast, in the P0-Nf1flox model here described, P0Cre appears to target exclusively 
myelinating Schwann cells. Hence, our mouse model provides a “cleaner” system to 
show that given the right microenvironmental conditions, Nf1-/- Schwann cells may 
form tumours even in the context of an Nf1+/+ background. However, this does not 
mean that the nerve microenvironment does not play a critical role in controlling the 
fate of Nf1-/- SCs. Indeed, in our mouse model, a variety of inflammatory cells including 
mast cells are recruited to the peripheral nerve in response to the injury in both Nf1+/+ 
and Nf1+/- backgrounds. Hence, it is possible that once at the Nf1-deficient nerve, 
immune cells may critically alter the behaviour of Nf1-/- SCs. Mast cells in particular, 
may also in this mouse model, exert essential pro-tumourigenic effects. This would be 
consistent with the hypothesis that in the specific case of the Krox-20 model, 
haploinsufficiency is required to attribute an increased migration of mast cells to the 
nerve. If this is overcome (in our case, by eliciting an inflammatory response), Nf1 
heterozygosity is no longer compulsory. The requirement, in our mouse model, for 
the presence of mast cells at the sciatic nerve may be tested by treating the injured 
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animals with c-Kit inhibitors (e.g Imatibib mesylate), as c-Kit activity in mast cells is key 
in governing mast cell behaviour (Ingram et al., 2001; Yang et al., 2003). 
 
7.4 The nerve is tumour-suppressive 
We have shown that adult, mature mSC can induce tumour formation, but only after 
reverting to a dedifferentiated state in response to injury. Nevertheless, we observed 
that reverting to a “progenitor-like” state is not, per se, sufficient for tumourigenesis. 
Following injury, strong and sustained activation of Ras/Raf/ERK signalling induces SCs 
at the injury site and downstream of the lesion to dedifferentiate. The damage 
response is also associated with a robust inflammatory response, involving the influx of 
mast cells, macrophages, neutrophils, T-cells and fibroblasts throughout the entire 
length of the nerve, distal to the wound-site. However, despite this remarkable 
remodelling of the nerve downstream of the injury, we observed that dedifferentiated 
Nf1-/- cells formed tumours exclusively at the injury site. Strikingly, the nerve stump 
distal to the lesion site was indistinguishable between controls and NF1 mutants and 
remarkably, Nf1-/- Schwann cell at this region of the nerve, redifferentiated normally 
and remyelinated axons. Accordingly, the kinetics of Ras/ERK signalling did not seem 
to be altered in Nf1-/- SCs at the distal stump since, 7 days following injury, ERK was 
dampened in both wild-type and NF1 mutant nerves. These observations strongly 
suggest that the nerve microenvironment is highly tumour-suppressive, because even 
in the presence of strong activation of Ras signalling and in the presence of an 
inflammatory environment, is able to suppress Ras/ERK in the absence of NF1 thereby 
allowing normal redifferentiation. This is somehow reminiscent of what seems to 
happen during SC development in NF1 mutants. As mentioned before Nf1-/- Schwann 
cells differentiate normally, although Ras/Raf/ERK signalling is activated during the initial 
stages of differentiation (Newbern et al., 2011). Bringing together the observation that 
strong activation of Ras/ERK drives SCs dedifferentiation with the fact that in fully 
differentiated SCs the basal levels of activated ERK are very low, we may speculate 
that following the initial requirement for Ras/ERK during embryogenesis, ERK signalling 
has to be dampened to allow the completion of SC differentiation. This speculation is 
backed up by two main findings. First, ERK appears to be required for Krox-20 
induction, which places its effects in early differentiation (Newbern et al., 2011; 
Rosenberg et al., in prep.). Second, experiments in our laboratory using SC-DRG co-
cultures have shown that ERK is found strongly activated in SCs that are aligned with 
axons – and are therefore in preparation for myelination, whilst is no longer activated 
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when SCs are fully differentiated (Napoli et al., unpublished data). Collectively, these 
findings suggest that the nerve microenvironment (probably pro-differentiative axonal 
signals) is strongly suppressive for Ras/ERK signalling. Our work suggests that only 
when Nf1-/- SCs escape from this suppressive environment they have the capacity to 
form tumours.  
 
7.5 The microenvironment at the injury site is tumour-
promoting 
We found that only at the location of the injury, Nf1-/- SCs find the conditions required 
to drive tumour formation. In accordance with the differential behaviour of SCs at the 
wound site and SCs at the distal stump, the ERK activation that seems normal in Nf1-/- 
SCs distal to the cut, appears sustained and deregulated in NF1 mutants at the injury 
site. The connection between deregulated Ras/ERK signalling and tumour development 
is currently being tested in experiments using the MEK inhibitor PD 0325901. 
Importantly, if an effect on preventing tumour development is observed, this may 
unveil a possible therapeutic strategy to treat NF1 patients. 
How can we explain that genotypically identical cells behave so differently depending 
on the location in the injured nerve? The answer seems to involve cell-exogenous 
factors. As discussed in Chapter 1, upon nerve transection both stumps on each side 
of the injured nerve retract, leaving a gap between them. This gap - the nerve bridge - 
consists of a unique microenvironment that includes elevated amounts of ECM and a 
variety of cells such as immune cells and fibroblasts. We may therefore speculate that 
some specific component of the bridge microenvironment that we have not yet 
identified, is responsible for the different behaviour.  
Another critical difference between the injury site and the distal stumps is the stability 
of the Schwann cell basal lamina. Importantly, whilst the basal lamina is physically 
disrupted at the lesion site, in the distal stump of the nerves SC basal lamina remains 
well-organized and fairly intact, despite Schwann cells dedifferentiating within the 
tubes. We may therefore speculate that the lack of a tightly associated and organized 
basal membrane in the SCs at the injury site, might make SCs at this location more 
freely accessible to various proteins, including growth factors and cytokines which may 
influence proliferation of Nf1-/- Schwann cells. In contrast, in the distal stump, SCs are 
kept more protected and their access to extracellular factors may be more restricted, 
hence reducing the upstream signals feeding Ras signalling. In other words, at the injury 
site, disruption of the basal lamina may leave Schwann cells more susceptible to the 
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pro-tumourigenic microenvironment of the wound. Importantly, this hypothesis may 
be tested by studying the effects of less severe injuries such as nerve crush. 
Importantly, crush does not disrupt the structure of the basal lamina. Thus, by 
comparing the consequences of nerve transection to the ones of nerve crush, one 
could address the importance of the preservation of the basal lamina.   
The importance of the severity of the injury has been also implicated in a rather 
distinct mouse model. Specifically, in a transgenic mouse model expressing the jun 
oncogene it was shown that the development of tumours of the connective tissue, 
termed dermal fibrosarcomas, only arise upon complete transection of the skin. When 
a more superficial injury is performed tumours do not develop, suggesting that a more 
dramatic disruption of the tissue architecture is required for oncogene expressing cells 
to develop into tumours (Schuh et al., 1990). 
 
7.6 Possible signals upstream of the Ras pathway 
Neurofibromin is a Ras-GAP meaning that its effects on Ras signalling are dependent 
on external activation of the pathway. For example, Nf1-/- hematopoietic progenitors 
exhibit Ras hyperactivation and increased proliferation only in response to specific 
growth factors and/or cytokines such as GM-CSF (granulocyte-macrophage colony 
stimulating factor), SCF (stem cell factor) and IL-3 (Largaespada et al., 1996; Zhang et 
al., 1998). 
Which pro-tumourigenic factors may one expect to find at the wound site? Early work 
on the tumourigenic effects of the Rous sarcoma virus showed that chickens infected 
with the virus only developed tumours at the site of wounding (Dolberg et al., 1985). 
Interestingly, the effect of wounding on the development of the tumours was later 
demonstrated to be mimicked by local application of pro-inflammatory growth factors, 
such as transforming growth factor-β (TGF-β) and acidic and basic fibroblast growth 
factor (aFGF and bFGF) (Martins-Green et al., 1994). This led to the conclusion that 
tumour development in this animal model was accomplished through the cytokines 
released by the inflammatory cells at the wound site. 
Importantly, we found that following injury macrophages are enriched at the site of 
injury compared to the distal areas of the nerve (in both controls and NF1 mutants). 
Activated macrophages have been shown to produce and secrete both TGF-β (Assoian 
et al., 1987) and FGF (Baird et al., 1985; Schulze-Osthoff et al., 1990). Additional 
growth factors are also produced by macrophages including platelet-derived growth 
factor BB (Watabe et al., 1994), which is a known mitogenic signal to Schwann cells 
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(when in the presence of cAMP) (Kim et al., 2001). It is thus plausible that the wound 
microenvironment provides a variety of signals or specific thresholds of signals that 
may promote tumourigenesis by activating Ras and thus stimulating the proliferation, 
migration and/or survival of Schwann cells. Consistent with a role for growth factors in 
promoting deregulated signalling through Ras, PDGF and TGF-β are found at increased 
levels in neurofibromas in vivo (Carroll and Stonecypher, 2005; Kadono et al., 2000; 
Watanabe et al., 2001). The effect of specific growth factors or cytokines could also be 
tested in our mouse model, by locally administrating putative factors in the distal 
stump of injured NF1 mutant nerves. 
 
7.7 Penetrance 
In our model, neurofibroma development occurred in approximately 30% of the 
injured animals. We may only speculate on the reasons underlying this incomplete 
penetrance. One possible explanation is related to the remarkable variability in Cre-
recombinase efficiency (that ranged between 15 and 50%). A more careful analysis, 
comparing Cre recombination and the presence/absence of tumours can now be done 
using P0:YFP-Nf1flox mutants. Another possibility is that slight biological differences in 
the wounding process varying from animal to animal may dictate the behaviour of Nf1-/- 
SCs. We did not observe any differences between females and males, excluding a 
prominent role for hormonal components. Still, slight inter-individual differences in the 
inflammatory response may result in different thresholds of specific factors present at 
the wound site, which may be critical for the outcome of Nf1 loss. Furthermore, 
differences in the regeneration process, such as the speed of repair, may also influence 
the likelihood of tumour formation. Lastly, it is also possible that additional genetic 
and/or epigenetic changes are required for Nf1-/- to exhibit abnormal proliferation and 
culminate in tumour development, and thus it may involve stochastic changes. 
 
7.8 Ras/Raf/ERK regulation in differentiating Schwann cells 
As discussed in section 7.4, both during developmental differentiation and re-
differentiation (in the distal stump) following injury, the nerve microenvironment 
appears to be able to regulate and suppress Ras/ERK signalling even in the absence of 
neurofibromin. These observations imply that additional regulatory mechanisms are in 
place during SC differentiation and may override Nf1 loss. In this regard, we have 
studied possible mechanisms of ERK regulation in differentiating SCs. Importantly, we 
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found that the ERK1/2 phosphatase MKP3 (Dusp6) is strongly induced in SCs by the 
pro-differentiative signal cAMP. Consistent with a role for MKP3 in regulating ERK 
levels during differentiation, MKP3 depleted cells exhibited an impaired differentiation 
in SC monocultures. In Drosophila, MKP3 null mutation results in embryonic lethality 
and severe defects in oogenesis (Maillet et al., 2008). In sharp contrast, MKP3 
knockout mice are viable and exhibit no major developmental defects, except an 
increased basal ERK1/2 phosphorylation in the heart, which results in cardiac 
hypercellularity (Maillet et al., 2008). The most likely explanation for the lack of a more 
striking phenotype is that other phosphatases compensate for the embryonic loss of 
MKP3. Indeed, the closely related DUSP7 (MKP-X) and DUSP9 (MKP4) also 
dephosphorylate ERK1/2, suggesting that these phosphatases could play a 
compensatory effect in the absence of MKP3 (Dickinson and Keyse, 2006). To 
overcome this possible effect, one could test the effects of MKP3 loss in a situation of 
acute activation of ERK signalling, such as the one experienced by Schwann cells 
following an injury. Importantly we observed that MKP3 is re-expressed in peripheral 
nerves after wounding. If MKP3 is indeed important in the regulation of Ras/ERK levels 
during differentiation/re-differentiation one could expect that following injury, 
redifferentiation may be impaired in the MKP3 null mice. In any case, it seems clear 
that the right balance of Ras/ERK signalling is critical for SC development and 
behaviour in the adult life, in particular following injury. Importantly, deregulation of 
this pathway seems to play a critical role in neurofibroma formation.  
 
7.9 Conclusions and therapeutic relevance 
The peripheral nerve is a remarkably regenerative structure, owing much to the 
plasticity of Schwann cells. Following an injury, fully differentiated Schwann cells via a 
Ras/Raf/ERK-mediated mechanism dedifferentiate to a progenitor-like state, which 
proliferate and aid in the nerve repair process. Once axons have regrown, SCs re-
associate with axons and redifferentiate. The molecular switch that allows SCs to 
change differentiation status has to be tightly regulated.  
We have generated a new mouse model of neurofibroma formation. In this thesis, I 
have shown that adult, highly quiescent myelinating Schwann cells are not made 
tumourigenic by Nf1 loss. However, upon injury, Nf1-/- Schwann cells residing at the 
wound site, probably in response to a variety of growth factors and cytokines 
produced by cells involved in the wounding process (and made accessible by the 
physical disruption of the basal lamina), exhibit deregulated Ras/ERK signalling. 
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Abnormal Ras/Raf/ERK signalling, probably in cooperation with other 
genetic/epigenetic changes, may ultimately lead to neurofibroma formation. A 
schematic representation of this model is shown in Figure 7-1. 
During this thesis I have started to test the therapeutic effect of the treatment with 
MEK inhibitors in wound-induced neurofibromas. If this proves successful, it may have 
important implications in the treatment of human patients.  
Crucially, there is anecdotal evidence linking mechanical trauma and the development 
of neurofibromas. Patients have reported that neurofibromas frequently arise in sites 
of trauma (e.g. after bites, scratches, cuts) (Riccardi, 1992). Importantly, it has been 
suggested that given the high quality of peripheral nerve repair, it is likely that many 
cases of nerve injury may go entirely unnoticed and subclinical injury may be more 
common than it is presently though to be (Nguyen et al., 2002). Therefore is even 
possible that neurofibromas may develop from unnoticed nerve injuries. Furthermore, 
it may be the case that Ras/ERK signalling deregulation may also be involved in 
neurofibroma formation in cases with no apparent connection with trauma, which may 
imply a wider impact for treatments with MEK inhibitors. 
 
7.10 Further work 
Future studies should aim at dissecting the signals involved in promoting the distinct 
behaviour of Nf1-/- Schwann cells at the injury site and distal stump of the peripheral 
nerve. As discussed before, several factors may be involved including TGF-β and 
PDGF, amongst others. Systematic approaches, such as microarray analysis comparing 
upregulation of genes at the cut versus distal sites in mutant mice, should be taken. A 
more simple in vitro system could also be used to test the susceptibility of Nf1-/- 
Schwann cells to engage in deregulated Ras signalling upon stimulation with a variety of 
factors, including the ones mentioned above and others, also associated with wounding 
such as ATP, H2O2 and VEGF. Furthermore, if the MEK inhibitor treatment does not 
yield promising results, others therapeutic approaches may be tested. In particular, 
given the role that inflammatory-derived factors may play in neurofibroma 
development, anti-inflammatory drugs may be an alternative strategy to consider. 
We have generated a powerful system to study the early events of tumourigenesis. In 
particular, this novel mouse model has the great advantage of developing frequent 
tumours in specific locations. This, together with the ability to track genetically altered 
cells (YFP+), provides great opportunities to investigate the, as yet fairly obscure, very 
early steps of tumour development. 
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Figure 7-1: Model for neurofibroma formation. Following a nerve injury, at 
the wound site and distally to the injury site, axons (red) degenerate and Schwann cells (blue) 
dedifferentiate. A robust inflammatory response (orange and purple) and fibroblasts (green) 
are also recruited (i and ii). In wild-type animals, axons regrow, the inflammatory response is 
attenuated and Schwann cells redifferentiate (iii and iv). In this thesis, I have shown that if Nf1 
is deleted specifically in mSchwann cells in the adult mouse, neurofibroma-like tumours arise at 
the injury site (v). In contrast, in the distal stump of NF1 nerves, regeneration was 
indistinguishable from controls, suggesting that the nerve microenvironment is tumour 
suppressive. 
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